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Abstract 
Regio- and stereoselective hydroxylation represents a major challenge for synthetic chemistry. 
The cytochrome P450 subfamily CYP106A efficiently catalyzes such reactions in steroids, di-, and 
triterpenes. The well-studied CYP106A2, from B. megaterium ATCC 13368, is a promising candidate 
for the pharmaceutical industry. It shares 63% amino acid sequence identity with CYP106A1 from            
B. megaterium DSM 319 which was recently identified. The global objective of the work was the in depth 
characterization of the CYP106A subfamily concerning the bioconversion of steroids, to explore their 
potential application as industrial biocatalysts. 
A focused steroid library was screened with the CYP106A subfamily. Binding studies, in vitro 
and in vivo reactions allowed the comparison of enzyme activity, product pattern and product structures. 
13 new substrates were identified for CYP106A1 and 7 for CYP106A2. The hydroxylase activity was 
confirmed at positons 6β, 7β, 9α and 15β, in addition to an unprecedented 11-oxidase activity. 
The 11-oxidase activity of CYP106A1 was further studied, identifying 3 11β-hydroxysteroids as 
novel substrates for 11-oxidation. The reaction mechanism was also investigated, resulting in a large 
inverse kinetic isotope effect (~0.44) suggesting the ferric peroxoanion as the reactive intermediate. 
The CYP106A2 based B. megaterium whole-cell system has shown effective                                  
15β-hydroxycyproterone acetate production. The conversion was scaled up from shake flask to bench-
top bioreactor, the reaction-bottlenecks were identified and addressed, demonstrating a successful process 
development with a product formation of 0.43 g/L, approaching industrial process requirements and a 
future large-scale application. 
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Zusammenfassung 
Regio- und stereoselektive Hydroxylierung stellt für die synthetische Chemie eine ernste 
Herausforderung dar. Die CYP106A-Subfamilie der Cytochrome P450 katalysiert diesen Reaktionstyp 
auf effiziente Weise für Steroide, Di- und Triterpene. Das intensiv untersuchte CYP106A2 aus                     
B. megaterium ATCC 13368 teilt 63% Sequenzidentität mit CYP106A1 aus B. megaterium DSM 319, 
das erst kürzlich identifiziert wurde. Das Ziel der Arbeit war, beide Enzyme in Bezug auf den Umsatz 
von Steroiden zu charakterisieren und ihre potenzielle Anwendung als industrielle Biokatalysatoren zu 
erkunden. 
Ein Steroidbibliothek-Screening wurde mit den CYP106A-Enzymen vorgenommen. 
Bindungsstudien, in vitro- und in vivo-Reaktionen ermöglichen den Vergleich der Enzymaktivität, der 
Produktmuster und der Produktstrukturen. 13 neue Substrate wurden für CYP106A1 und 7 für 
CYP106A2 identifiziert. Die Hydroxylaseaktivität wurde für die Positonen 6β, 7β, 9α und 15β, zusätzlich 
zu einer 11-Oxidaseaktivität bestätigt. 
Die 11-Oxidaseaktivität von CYP106A1 wurde untersucht und 3 11β-Hydroxysteroide als neue 
Substrate für die 11-Oxidation identifiziert. Der in mechanistischen Studien große inverse kinetische 
Isotopeneffekt (~ 0,44) deutet auf ein Eisen(III)-peroxoanion als reaktives Zwischenprodukt hin. 
Das CYP106A2-B. megaterium-Ganzzellsystem hat sich als effizienter Katalysator für die 
Herstellung von 15β-Hydroxycyproteronacetat erwiesen. Die Reaktion wurde von Schüttelkolben auf 
einen Tischbioreaktor hochskaliert, die Hauptengpässe der Reaktion beseitigt und somit ein Prozess 
erfolgreich etabliert. Die Produktausbeute von 0.43 g/L, bietet eine Basis für eine zukünftige Anwendung 
im industriellen Maßstab.  
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1. Introduction 
1.1. Cytochromes P450 
1.1.1. General aspects 
Cytochrome P450 enzymes (P450s) are heme-containing monooxygenases, constituting one of 
the largest and oldest enzyme families, found in almost every life form, from prokaryotes to eukaryotes 
[1]. They are involved in various biological processes such as carbon-source degradation, secondary 
metabolite formation in prokaryotes, lower eukaryotes and plants, as well as in steroid hormone 
biosynthesis and xenobiotic metabolism in humans [2-4]. Their first experimental evidence dates to 1955, 
when the oxidation of xenobiotic compounds was detected in rabbit liver microsomes [5, 6]. This was 
followed by the independent discovery of a carbon monoxide binding pigment in rat and pig livers by 
Klingenberg and Garfinkel in 1958, respectively, showing an absorption maximum at 450 nm [7, 8]. In 
1962, this microsomal carbon monoxide binding pigment was named cytochrome P450 by Omura and 
Sato [9], who demonstrated the presence of iron-bound protoporphyrin IX in the enzyme. The 
cytochrome denotes the hemoprotein nature, while P stands for “pigment” and 450 refers to the 
characteristic absorption maximum observed at 450 nm during complex formation with CO (Soret peak). 
This characteristic absorption is induced by the thiolate group of a conserved cysteine, forming the fifth 
ligand of the heme iron [10], thus assigning these enzymes as heme thiolate proteins [11]. Their unusual 
spectral property is still in use for the quantitative determination of the P450 content of a protein probe 
[4]. 
Today the P450 database (http://drnelson.uthsc.edu/CytochromeP450.html) lists more than 
21000 representatives. The amount of P450 genes varies enormously in different species. For instance, 
7446 P450 genes are found in plants, 6313 in animals, 1254 in bacteria, 27 in archaea and only 2 are 
discovered in viruses. They are classified according to the guidelines of a systematic nomenclature, 
introduced by Nebert et al. in 1989 [12]. The enzymes are divided into families based on their amino acid 
sequence identity (> 40 %) and are given the CYP designation for Cytochrome P450 followed by a 
number (Figure 1). The letter behind the family number represents the subfamily, which requires a 
similarity of more than 55 % in their amino acid sequences. The last number is unique for each P450, 
indicating the individual isoenzyme. 
 
Figure 1 - Nomenclature of P450s exemplified by CYP106A1 
Categorized as external monooxygenases, P450s are able to activate molecular oxygen with the 
support of one or more redox-partners, which transfer electrons from the cofactor, usually nicotinamide 
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adenine dinucleotide phosphate (NAD(P)H), to the P450 heme [4]. The general P450-catalyzed reaction 
is performed by inserting a single oxygen atom, delivered from molecular oxygen, into the aliphatic or 
aromatic substrate, while the remaining oxygen atom is reduced to water (Figure 2): 
 
Figure 2 - General reaction mechanism catalyzed by P450s 
Based on the electron transport system, and their cellular localization, P450s can be assigned to 
different classes. In 2007, their classification was elaborated by Hannemann et al. resulting in 10 classes 
[13]. Class I involves mostly bacterial P450 systems along with the mitochondrial ones from eukaryotes, 
in which the electrons are transferred from NAD(P)H via a flavin adenine dinucleotide (FAD)-containing 
reductase to a soluble iron-sulfur protein, which then eventually reduces the P450 system itself. In the 
bacterial system, all proteins are present in a soluble form, whereas in the mitochondrial system only the 
ferredoxin is soluble, the reductase is associated and the P450 is embedded in the inner membrane [4, 13-
16]. The second category (class II) comprises the microsomal system, in which all the protein components 
are embedded in the membrane. Here, the electron is transferred from NAD(P)H via cytochrome P450 
reductase (CPR), which contains the prosthetic groups FAD and a flavin mononucleotide (FMN). The 
FAD acts as an electron acceptor for NAD(P)H and the FMN domain transfers the electrons to the P450 
[17] (Figure 3). 
 
Figure 3 - Schematic organisation of the Class I, bacterial (A), mitochondrial (B) and the Class II, 
microsomal P450 systems. (Scheme adapted from Hannemann et al., 2007 [13]) 
In addition to the main categories, there are many fascinating other systems, such as P450BM-3 
(CYP102A1) from Bacillus megaterium from class VIII in which the P450 is fused to its eukaryotic-like 
diflavin reductase partner in a single polypeptide chain and is, therefore, catalytically self-sufficient [13].  
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1.1.2. Structural features 
Although P450s from different gene families often demonstrate less than 20 % sequence identity, 
their structural organization shows similar folding and conserved topography (Figure 4), indicating a 
common mechanism of oxygen activation [18]. They consist of two domains, the first one being the α 
domain, rich in helices, including the highly conserved core formed by a four-helix bundle (D, L and I 
and the antiparallel E-helix) besides two other helices (J and K) [19]. The second one is the β domain 
with two beta-sheets (β1 and β2) in addition to another highly preserved structural motif, the meander 
loop at the C-terminal end of the K-helix, stabilized by the conserved sequence ExxR [20]. The heme is 
located between the distal I-helix and the proximal L-helix bound via a cysteine thiolate, including the 
signature heme-binding motive FxxGx(H/R)xCxG. The long I-helix forms a wall for the substrate-
binding pocket and contains the conserved consensus sequence (A/G)GxS(E/D)T. The well preserved 
threonine in the active center is believed to be involved in the activation of molecular oxygen throughout 
the catalytic cycle [21]. 
 
Figure 4 - Topographic map showing the secondary structural elements of cytochromes P450, 
exemplified by P450 BM3. The blue cylinders represent α-helices, the orange arrows the β-strands. The 
random coil structures are shown as black lines, linking the individual secondary structure elements. The 
elements are grouped in two domains, as first described by Poulos et al., 1987 [22] (Figure modified after 
Peterson and Graham, 1998 [23]). 
There are six regions identified by Gotoh named substrate recognition sites (SRS) having 
particular importance in the recognition and binding of substrates: the B'-helix region (SRS1), parts of 
helices F and G (SRS2 and SRS3), a portion of the I-helix (SRS4), the β4 hairpin structure (SRS5) and 
the area between K-helix and β2 (SRS6) [24]. The SRSs are considered to be the most variable regions, 
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showing structural rearrangement of the protein upon substrate binding in favor of the catalytic reaction, 
according to the proposed model of induced fit by Koshland [21, 25, 26]. 
1.1.3. Catalytic cycle of cytochromes P450 
P450s were shown to catalyze a vast number of reactions with abundant substrate diversity. The 
ability to perform these different reactions using the same catalytic cycle lies in the changing oxidation 
states of the iron atom. Seven intermediates including three oxidation states form the complex catalytic 
reaction mechanism of P450s, identified for CYP101 [21]. An overview of the reaction cycle is shown 
in Figure 5. 
 
Figure 5 - Catalytic cycle of cytochrome P450 monooxygenases. The numbers (1-7) represent the 
actual state of the enzyme: 1 – Low-spin substrate-free state. 2 – High-spin enzyme-substrate complex. 
3 - High-spin ferrous state. 4 – Oxy-ferrous state. 5a - Ferric peroxo intermediate. 5b – Ferric 
hydroperoxo intermediate/compound 0. 6 – High-valent iron-oxo state/compound I. 7 - Product oxidation 
and release. RH and ROH illustrate the substrate and the product, respectively. The three unproductive 
shunt-pathways are marked with dashed grey arrows and the reduced oxygen products are shown as 
outlets. (Figure adapted from Makris et al., 2002 [27] and Denisov et al., 2005 [21]) 
The cycle starts with the substrate-free, inactive ferric state (Fe (III)) of the heme iron, where the 
sixth coordination center is occupied by a water molecule (1). Upon substrate binding, the water at the 
distal site of the heme is partially or completely displaced, resulting in an increase of the redox potential 
(by 100-130 mV) and a transition from the low spin to the five-times coordinated high spin Fe (III) 
complex (2). This triggers the first electron transfer from NAD(P)H to the heme iron, producing a high 
spin ferrous iron (Fe II) (3). The subsequent binding of molecular oxygen, generates the oxy-ferrous 
intermediate, one of the key intermediates of the cycle (4). The following step is a second electron 
transfer, yielding the highly reactive peroxoanion state (5a), which is then protonated at the distal oxygen 
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atom to form the hydroperoxo intermediate, Compound 0 (Cpd 0) (5b). The next protonation step of the 
distal oxygen atom and the subsequent cleavage of the O-O bond leads to the release of a water molecule 
and the formation of the so-called Compound I (Cpd I) (6), a high-valent iron-oxo complex. This Fe(IV)O 
porphyrin cation radical initiates the oxygen atom transfer to the substrate (7) and the initial state is 
restored.  
However, the depicted cycle is not always complete, there are three “uncoupling” pathways 
which can abort the catalytic cycle, being unproductive regarding substrate oxidation, yet still consuming 
NAD(P)H. The first one is the auto-oxidation of the oxy-ferrous complex (4) while forming the 
superoxide radical. The second one is known as the peroxide shunt, in which hydrogen peroxide is 
released from the hydroperoxo intermediate (5b) resulting in the substrate-bound high spin complex (2). 
Some P450s utilize the peroxide shunt in reverse, as a short cut for their reactions, introducing the oxygen 
to the substrate directly from the hydrogen peroxide [28]. The third possibility is the so-called oxidase 
shunt, where the activated oxygen atom of Cpd I (6) is protonated and reduced to form water rather than 
being inserted into the substrate. 
1.1.4. Biotechnological application of cytochromes P450 
Throughout their long evolution, P450s became versatile biocatalysts, performing a large variety 
of reactions, such as: hydroxylations, dehydrogenations, epoxidations, sulfoxidations, deaminations, N-, 
O-, S-dealkylations and many more [4, 29] (Figure 6). In addition to their diverse reaction spectrum they 
convert a broad range of substrates, from fatty acids, terpenes and steroids to drugs, organic solvents and 
even toxins. Nevertheless, what makes these enzymes particularly interesting for industrial biocatalysis 
is the ability to incorporate molecular oxygen into non-activated carbons in a regio- and/or stereoselective 
fashion at neutral pH and moderate temperatures [30-33]. Such selective hydroxylation of aromatic or 
aliphatic C-H bonds is hard to achieve by classical chemical synthesis, which often requires functional 
group protection, suffers from side reactions and high temperature operation [34-36]. 
 
 
Figure 6 - Examples of the diverse oxidation reactions catalyzed by P450s. 
X: -C, -N, -S. (Figure adapted from Bornschauer and Buchholz, 2005 [37]) 
In the last few years, significant progress has been made to reduce limitations and expand the 
application of P450s for synthetic processes [29, 38]. By means of protein engineering, such as site-
directed mutagenesis or by directed (molecular) evolution techniques, the enzyme activity, stability, 
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substrate specificity and solvent tolerance has been successfully improved [39]. Yet, despite their 
impressive synthetic potential, it was also recognized that isolated P450s are challenging to implement 
in industry. Their constant need for the expensive cofactor supply and for the corresponding redox 
partners along with their instability and low activity under process conditions all raise limitations for such 
an approach [31, 40]. To circumvent this, the focus was shifted to the whole-cell system application of 
P450s. The application of a microbial host has proven to be a promising strategy by providing endogenous 
cofactor regeneration, potential co-expression of homologous or heterologous redox partners and 
protected environment for the biocatalyst [41]. In addition, the P450 stability was shown to be enhanced 
in the cellular milieu, since the H2O2 formed during uncoupling reactions is rendered harmless by the 
cellular catalase [42]. In spite of its many advantages, whole-cell catalysis also faces some important 
limitations, such as the transcellular transport limitation, low solubility/inhibition/toxicity of both 
substrate and product, inadequate NAD(P)H supply and unwanted side-reactions [40, 43]. 
Since cytochrome P450 substrates are mostly hydrophobic organic compounds, their transport in 
proximity of the whole-cell catalyst, present in the aqueous phase, as well as through the cell membrane, 
is a major challenge. To enable the substrate uptake, different membrane permeabilization methods 
(physical, chemical, and molecular engineering approaches) can be applied, depending on the 
microorganism. These methods may include the disintegration of the membrane by ultrasonication, 
freeze-thawing, using surface active substances such as Triton X, Tween, saponins or chelating agents 
such as ethylenediaminetetraacetic acid (EDTA) and even the co-expression of membrane transport 
proteins [44-48]. The faster transport of the substrate to the catalyst can be facilitated by using immiscible 
or miscible organic solvents. Two-phase systems with immiscible solvents are of particular interest, in 
which the organic phase serves as a substrate reservoir and facilitates the product removal, while the 
aqueous phase protects the biocatalyst from degradation [49, 50]. Another option is to apply an organic 
co-solvent such as ethanol, methanol or dimethyl sulfoxide (DMSO) in higher concentrations to increase 
substrate solubility. However, in these cases the solvent tolerance of the biocatalyst has to be considered. 
A further possibility, which circumvents the use of damaging organic solvents, yet still increases 
both membrane permeability and substrate solubility, is the use of cyclodextrins (CD). CDs are 
oligosaccharides, consisting of cyclically arranged (α-1,4)-linked α-D-glucopyranose units, forming a 
lipophilic central cavity and a hydrophilic outer surface. Depending on the number of units they are called 
α-, β- and γ-CDs containing six, seven or eight glucopyranose units, respectively. These basic CDs can 
be further improved by chemical modifications resulting in derivatives with improved solubility and 
stability such as 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) [51, 52]. Due to their hydrophobic cone-
like cavity, CDs are able to form inclusion complexes with a variety of organic molecules. Based on this 
outstanding property, they have been widely used in medicine and healthcare for improved solubility, 
chemical stability and bioavailability of drugs [53]. Since CDs are inert to microorganisms and were 
shown to be beneficial to respiratory-chain activity [54] their use in microbial transformations of 
hydrophobic substrates has also been exemplified [55-57]. Besides improving substrate solubility, they 
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have also been used to avoid substrate/product toxicity and/or inhibition during the biocatalytic process 
by complexation of the corresponding molecule in the hydrophobic central cavity, thus removing it from 
the aqueous environment present in the cell [58]. 
At present, the practical application of P450s is limited mostly to the production of fine chemicals 
such as pharmaceuticals, flavors, fragrances and (human) drug metabolites [42]. Among the remarkable 
examples of biotechnological P450 applications is the artificial multi-enzyme cascade for the production 
of the anti-malarial drug artemisinic acid in Saccharomyces cerevisiae (S. cerevisiae) [59], the synthesis 
of a taxol precursor in Escherichia coli (E. coli) [60] and the production of pregnenolone, progesterone 
and finally hydrocortisone using S. cerevisiae [61, 62]. Several further developments have also 
contributed to raise attention to the commercial potential of P450s, such as the 11β-hydroxlation of 
cortexolone to hydrocortisone by Curvularia sp. [43, 63], the 6β-hydroxylation of compactin to 
pravastatin [64, 65], the biotransformation of Vitamin D3 to 1α,25-dihydroxyvitamin D3 [66, 67], or their 
role in anthocyanin biosynthesis in blue or violet flowers [68, 69]. The production of human drug 
metabolites is also a significant aspect of P450 applications due to their importance in diagnostics and 
drug development, for the assessment of drug-induced side effects, toxicity and possible drug-drug 
interactions. Their production by classical chemistry or using liver homogenates faces limitations, yet, 
the recombinant expression of human drug-metabolizing P450s turned out to be a promising alternative. 
This was successfully demonstrated by Novartis Pharma AG (Basel, Switzerland), who established an  
E. coli host co-expressing human P450s with human CPR [70]. Nonetheless, these mammalian systems 
might be limited due to the insufficient expression of the membrane-associated enzymes, hence bacterial, 
soluble P450s could be considered as suitable alternatives. 
1.2. Cytochromes P450 from Bacillus megaterium 
Bacillus megaterium (B. megaterium) is a gram-positive, rod shaped soil-bacterium which has 
been proven to be an ideal expression host for industrial biotechnology, mainly applied to protein 
production [71, 72]. It is used as a production strain for industrial enzymes such as, penicillin G acylase 
or different amylases, polyhydroxybutirate and vitamin B12 [73]. Beyond these applications, in the past 
decade B. megaterium has gained interest as host for novel recombinant enzymes and therapeutic proteins 
due to its many advantageous properties: it has a stable plasmid replication system, is not a pathogen, 
lacks alkaline proteases, does not form endotoxins, has a high protein secretion capacity directly into the 
medium and it is able to grow on a variety of carbon sources, which allows for low cost cultivation [74-
77]. 
Amongst the most interesting proteins present in B. megaterium are P450s [78] such as: 
CYP102A1 (P450 BM3), a self-sufficient and so far one of the most thoroughly studied bacterial P450 
[79]; CYP106A1 (P450 BM1) [80], recently functionally characterized by Brill et al. (2014) [81] and 
Lee et al. (2014) [82]; and finally CYP106A2 from B. megaterium ATCC 13368 [83, 84], which was 
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extensively investigated in the past four decades and its biotechnological relevance has been 
demonstrated in the conversion of steroids, di- and triterpenes [48, 85-89]. 
1.2.1. CYP106A1 from Bacillus megaterium DSM 319 
CYP106A1 from B. megaterium ATCC 14581 is a soluble ~47.7 kDa protein consisting of 410 
amino acids. It was first identified by He et al. in 1989, and has been investigated at the level of gene 
regulation and gene expression in the following years [90, 91]. In 2011, the genome of B. megaterium 
DSM 319 was sequenced [92], which led to the identification of several P450 genes, including the one 
encoding CYP106A1. The enzyme was purified and characterized by Brill et al., who demonstrated its 
successful application in a whole-cell system for the hydroxylation of the triterpene, 11-keto-β-boswellic 
acid, at 7β and 15α positions [81]. Recently, CYP106A1 was also isolated from the B. megaterium strain 
ATCC 14581 by Lee et al., showing successful in vitro steroid transformations, however, the product 
structures were left unidentified [82]. Its closest homologue is the well-studied CYP106A2 from                
B. megaterium ATCC 13368, with whom it shares 63 % amino acid sequence identity and 76 % similarity. 
Based on the high sequence identity between the two subfamily members, CYP106A1 was proposed to 
be an equally or even more promising catalyst in terms of steroidal drug or drug metabolite production, 
leading to a possible transition of the pharmaceutical industry towards greener processes. 
1.2.2. CYP106A2 from Bacillus megaterium ATCC 13368 
CYP106A2 from B. megaterium ATCC 13368 is a soluble ~47 kDa protein consisting of 410 
amino acids. It is one of the few cloned bacterial steroid hydroxylases, also known as 15β-hydroxylase, 
which originates from its favored hydroxylation position on 3-oxo-Δ4 steroids. The discovery of                 
B. megaterium ATCC 13368-mediated steroid oxidation goes back to 1958, when the 15β-hydroxylation 
of progesterone was described by McAleer et al. (1958) [93]. Only later, in 1975 was the role of the 
cytochrome P450 as steroid hydroxylase recognized by Berg et al., who also identified the potential 
components of the steroid hydroxylase system [83] followed by the isolation, purification and functional 
characterization of the enzyme [84, 94, 95]. Finally in 1993, the cloning, sequencing and heterologous 
expression of CYP106A2 took place in E.coli and B. subtilis [96]. Although its natural electron transfer 
partners are not known, its activity was successfully reconstituted using bovine adrenal redox partners, 
as well as by putidaredoxin and putidaredoxin reductase [48, 97-99]. 
In the past two decades, CYP106A2 was profoundly investigated as a potential industrial 
biocatalyst, applying the enzyme in whole-cell systems using both E. coli [48, 86, 98] and B. megaterium 
as expression hosts [87-89, 100]. Using E.coli, the transport of hydrophobic substrates across the outer 
membrane was found to be limited [101], thus further approaches were focused on using the gram-
positive B. megaterium as host. The substrate spectrum of CYP106A2 was originally thought to be 
limited to 3-oxo-Δ4-steroids [83], yet recent studies have shown that the hydroxylation of                                
3-hydroxy-Δ5-steroids, di- and triterpenes is also feasible [87-89, 100]. The native substrate of 
CYP106A2 and its biological function are still unidentified. However, as a consequence of on-going 
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natural substrate library screenings, the list of its substrates is steadily growing. An overview of the so 
far identified CYP106A2 substrates is shown in Table 1. 
Table 1 - Overview of the formerly identified substrates of CYP106A2 
(Table adapted from Janocha, 2013 [102]) 
CYP106A2 substrates References 
Testosterone Berg et al. 1976, Berg et al. 1979a 
Progesterone  Berg et al. 1976, Berg et al. 1979a 
17α-Hydroxyprogesteron  Berg et al. 1976, Berg et al. 1979a 
20α-Dihydroprogesterone Berg et al. 1976, Berg et al. 1979a 
Deoxycorticosterone (DOC)  Berg et al. 1976, Berg et al. 1979a 
Corticosterone  Berg et al. 1976, Berg et al. 1979a 
Androstendione Berg et al. 1976, Berg et al. 1979a 
Anilin  Berg und Rafter 1981 
6-Fluor-16-Methyl-DOC Rauschenbach et al. 1993 
Betulinic acid Chatterjee et al. 2000 
6β-Hydroxyprogesterone  Lisurek 2004 
15β-Hydroxyprogesterone  Lisurek 2004 
Cholestenone  Lisurek 2004 
Spironolactone  Lisurek 2004 
11-Deoxycortisol  Virus 2006 
4-Pregnen-20β-ol-3-one  Bleif 2007 
11-Keto-β-boswellic acid  Bleif 2007 
Dihydrochinopimaric acid  Bleif 2007 
Ethisterone  Bleif 2007 
17α-Methyltestosterone  Bleif 2007 
4-Pregnen-17α,20α,21-triol-3-one  Bleif 2007 
Abietic acid  Bleif 2012 
Oleanolic acid Bleif 2012 
Ursolic acid Bleif 2012 
Glycyrrhetinic acid Bleif 2012 
Digitoxigenin  Schmitz 2013 
Prednisone  Schmitz 2013 
Dexamethasone  Schmitz 2013 
Dehydroepiandrosterone Schmitz 2013 
Pregnenolone  Schmitz 2013 
Dipterocarpol  Schmitz 2013 
Betulin Schmitz 2013 
Though its original name, 15β-hydroxylase, suggests hydroxylation at the 15β position, the long-
thought strict regioselectivity was contradicted by the identification of 6β, 7α/β, 9α, 11α and 15α-hydroxy 
derivatives [85, 103, 104]. This by-product formation has been extensively studied for progesterone, 
where the 6β, 9α and 11α derivatives are of pharmaceutical interest (contraceptives, hormone replacement 
therapy) [103]. To enhance the previously observed C11-hydroxylation, a combinatory strategy was 
applied, joining directed evolution and rational protein design to change the selectivity of the enzyme 
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from 15β to 11α in the hydroxylation of progesterone [85]. An impressive increase in regioselectivity 
towards C11 was achieved forming a particularly interesting reaction product due to its inhibitory effect 
on 11β-hydroxysteroid dehydrogenase [105].  
1.3. Steroid hormones and steroidal drugs  
Steroids are terpenoid lipids with a characteristic gonane skeleton comprising seventeen carbon 
atoms in a four-ring structure, forming three cyclohexane rings (rings A, B, and C) and one cyclopentane 
ring (ring D) (Figure 7). Various derivatives exist, which principally differ in the oxidation state of the 
rings and in the functional groups attached to the four-ring system. 
 
Figure 7 - Sterane, the parent ring structure of steroid compounds. 
The four-ring structure (A-D) and the numbering of the carbon atoms (1-17) are shown. 
Steroids play an important role as biological and chemical compounds in many living systems 
and have been identified in animals (e.g.: cholesterol, corticosteroids, sex hormones, bile acids, vitamin 
D, neurosteroids), plants (e.g.: phytosterols, diosgenin) and lower eukaryotes such as yeast and fungi 
(e.g.: ergosterol, ergosteroids) [106, 107]. In humans, steroidal hormones are synthesized in steroidogenic 
tissues such as gonads and adrenal glands from cholesterol. Their natural roles include the regulation of 
electrolyte and water homeostasis, cholesterol levels, control of sexual differentiation and reproduction, 
as well as cardiovascular and neuroprotective functions [108-111]. Steroid hormones are also known to 
control cell proliferation and tissue differentiation, to regulate signal transduction pathways and cell-to-
cell communication processes [112-114].  
Drugs based on the steroid structure are of great pharmaceutical importance being widely used 
in almost all fields of healthcare, from anti-microbial, anti-viral, anti-fungal agents to the treatment of 
hormone-dependent cancer forms, autoimmune and allergic disorders [106]. To date, steroids represent 
one of the largest sectors in the pharmaceutical industry with more than 300 approved drugs known [115, 
116]. Steroid analogues with altered functional groups are favored over their natural counterparts, due to 
their improved therapeutic features such as, reduced side effects, higher potency and better 
pharmacokinetics [117]. Moreover, steroid hydroxylation is considered to be one of the most important 
reactions in steroid functionalization, since the derivatives can have enhanced biological activity and/or 
be further modified in drug development [118-120]. The synthesis of these functionalized derivatives is 
a real challenge for synthetic steroid chemistry, suffering from low predictability and specificity, yet, the 
combination of classical chemistry and biocatalysis was found to be successful to produce these steroids 
13 
 
for the pharmaceutical industry [107]. Microbial steroid hydroxylation using heterologously expressed 
P450s is considered to be a promising tool to produce such hydroxysteroids. Unfortunately, the 
biotechnological application of eukaryotic P450s is restricted due to their membrane-associated assembly 
leading to limitations in their expression and catalytic activities [13, 29]. In contrast, bacterial P450s are 
soluble proteins, which can be overexpressed to very high amounts allowing higher productivities in 
biotransformation and representing a promising alternative for industrial applications [48, 99]. 
1.4. Aim and outline of the work 
The global objective of this work was the in-depth characterization of the bacterial CYP106A 
subfamily in the bioconversion of steroid compounds to explore and expand their potential application as 
biocatalysts in industrial-scale steroid hydroxylations (Figure 8). CYP106A2 from B. megaterium ATCC 
13368 was extensively studied since the late 1970s and shown to hydroxylate steroids, di- and triterpenes 
in a regio- and stereoselective manner. Its lesser known counterpart, CYP106A1 from B. megaterium 
DSM 319, sharing high sequence identity, was also recognized as a terpene- and steroid-hydroxylase, 
however, its potential as a biocatalyst was not fully investigated. 
 
Figure 8 - Summary of the motivation, previous work and contents of this thesis. The orange box 
represents the global aim of the work, the yellow contains the state of the art. The blue and the grey 
rectangles symbolize the published and unpublished results, respectively, with the corresponding chapter 
number. 
For a detailed analysis of the CYP106A subfamily members and a comparison of their steroid 
hydroxylating capacity, a focused steroid library was screened. The initial substrate-screening was based 
on their high-spin shift induction via difference spectroscopy, also allowing the determination of 
dissociation constants (KD). Since type I shift-induction is a good indication but not a prerequisite for 
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successful conversion, all steroids were subjected to further in vitro assays and subsequent analysis of 
product formation by high performance liquid chromatography (HPLC). Out of the 19 converted steroids, 
6 were chosen for further investigation. Since functionalized steroids could be of pharmaceutical 
importance as drugs or drug metabolites, the emphasis was placed on the analysis of enzyme activity and 
product identification for the evaluation of potential biotechnological applications.  Substrate conversions 
were performed using formerly established B. megaterium MS941 whole-cell systems, overexpressing 
each CYP106 enzyme. The conversion products were isolated by preparative HPLC and their structural 
determination was achieved by NMR spectroscopy. The obtained results are summarized in Chapter 2.1 
of this thesis. 
In Chapter 2.2, the newly identified CYP106A1 11-oxidase activity, obtained as a result in 
Chapter 2.1, was further investigated. Three 11β-hydroxysteroid-analogues (prednisolone, 
dexamethasone and 11β-hydroxyandrostenedione) were screened with CYP106A1. The 11-oxidation of 
the substrates was confirmed by NMR in all cases, however, single 11-keto product formation was only 
obtained for 11β-hydroxyandrostenedione. The latter reaction was chosen to investigate the mechanism 
of the reaction using kinetic solvent isotope effect. 
 The final section (Chapter 2.3) describes the results obtained in a collaborative project with the 
Technical University of Denmark, where the bioconversion of the pharmaceutically relevant 
antiandrogen, cyproterone acetate, was investigated using a CYP106A2-based B. megaterium whole-cell 
system. Since the product, 15β-hydroxycyproterone acetate, is of pharmaceutical interest, the aim was to 
scale-up the reaction from shake flasks to bioreactors to model an efficient, yet greener and cost-effective 
production. To improve the yield and product titers for a future large-scale application, the main 
bottlenecks of the reaction were identified and addressed.  
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2. Scientific articles 
The obtained results presented in this work are published in the articles listed below:  
2.1. Kiss et al. (2015) 
Comparison of CYP106A1 and CYP106A2 from Bacillus megaterium - identification of a novel 
11-oxidase activity 
Flora Marta Kiss, Daniela Schmitz, Josef Zapp, Tobias K. F. Dier, Dietrich A. Volmer, Rita 
Bernhardt 
Applied Microbiology and Biotechnology 2015 Apr 24 doi: 10.1007/s00253-015-6563-8 
Reprinted with the permission of Springer Science and Business Media. 
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Comparison of CYP106A1 and CYP106A2 from Bacillus 
megaterium - identification of a novel 11-oxidase activity 
Flora Marta Kiss1, Daniela Schmitz1, Josef Zapp2, Tobias K. F. Dier3, Dietrich A. Volmer3, 
Rita Bernhardt1* 
Abstract 
The CYP106A subfamily hydroxylates steroids, di- and triterpenes in a regio- and stereoselective manner, 
which is a challenging task for synthetic chemistry. The well-studied CYP106A2 enzyme, from the 
Bacillus megaterium strain ATCC 13368, is a highly promising candidate for the pharmaceutical 
industry. It shares 63 % amino acid sequence identity with CYP106A1 from B. megaterium DSM319, 
which was recently characterized. A focused steroid library was screened with both, CYP106A1 and 
CYP106A2. Nineteen out of the 23 tested steroids were successfully converted by both enzymes during 
in vitro and in vivo reactions. Thirteen new substrates were identified for CYP106A1, while the substrate 
spectrum of CYP106A2 was extended by 7 new members. Finally, 6 chosen steroids were further studied 
on a preparative scale employing a recombinant B. megaterium MS941 whole-cell system, yielding 
sufficient amounts of product for structure characterization by nuclear magnetic resonance. The 
hydroxylase activity was confirmed at positons 6β, 7β, 9α and 15β. In addition, the CYP106A subfamily 
showed unprecedented 11-oxidase activity, converting 11β-hydroxysteroids to their 11-keto derivatives. 
This novel reaction and the diverse hydroxylation positions on pharmaceutically relevant compounds 
underline the role of the CYP106A subfamily in drug development and production. 
Keywords: CYP106A1, CYP106A2, cortisol, cortisone, 11β-hydroxysteroid dehydrogenation 
Introduction  
For the past decade cytochrome P450 enzymes 
(P450s) have been studied as candidates for 
pharmaceutical drug and drug precursor 
development. This large superfamily of             
heme cofactor-containing monooxygenases 
(http://drnelson.uthsc.edu/CytochromeP450.html) 
is involved in the catalysis of a wide range of 
reactions from hydroxylations, epoxidations and 
deaminations to dealkylations and C-C bond 
cleavage. Not only do they perform versatile 
reactions, they also convert a broad range of 
substrates. P450s participate in the biosynthesis of 
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endogenous steroids, fatty acids and vitamins as 
well as in the elimination of exogenous 
compounds, xenobiotics and drugs (Bernhardt, 
2006; Urlacher et al., 2004). They are thus suitable 
for the production of pharmaceutical compounds 
and provide a more economically and ecologically 
sustainable alternative to chemical synthesis, even 
more so, where the latter has failed to produce 
sufficient amounts of product (Bernhardt and 
Urlacher, 2014; Urlacher and Girhard, 2012). The 
chemical synthesis of steroids is very complex and 
costly, particularly when performing                 
regio- and stereo-selective hydroxylations. 
Microbial/enzymatic transformations are, 
therefore, favored by the industry as a straight-
forward, greener and more cost-effective solution 
(Donova and Egorova, 2012; Tong and Dong, 
2009). 
The heterologous expression of bacterial P450 
enzymes was shown to be successful in several 
host organisms, making the Class I bacterial P450 
systems preferable over their membrane-bound 
mammalian counterparts, due to their solubility 
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and easy handling (Bernhardt, 2006; Hannemann 
et al., 2007; Venkataraman et al., 2014). Although 
their expression and purification is possible at an 
analytical scale, the use of isolated P450s in 
industrial applications is not feasible, mainly due 
to their instability under process conditions and 
the need for a constant supply of the rather 
expensive cofactor NADP(H) (Bernhardt and 
Urlacher, 2014; O'Reilly et al., 2011; Urlacher and 
Eiben, 2006). The latter has been addressed by 
both enzymatic and chemical methods (Chefson 
and Auclair, 2006; Hollmann et al., 2006), along 
with the progress towards improved 
thermostability (Li et al., 2007) and solvent 
tolerance (Seng Wong et al., 2004). A different 
possible workaround is the construction of whole-
cell systems, where the P450 is expressed by a 
microbial host organism. These constructs have 
the advantage of stabilizing the P450 integrity and 
electron transfer and provide cofactor regeneration 
by the cellular metabolism. Numerous organisms 
have been described to realize the heterologous 
expression of P450s, including the most widely 
used, Escherichia coli (Agematu et al., 2006; 
Bracco et al., 2013; Makino et al., 2014). 
Nevertheless, there are cases when using E. coli 
can lead to limitations, such as the restricted 
transport of large hydrophobic molecules across 
the cell membrane (Janocha and Bernhardt, 2013; 
Zehentgruber et al., 2010). Another candidate, 
Bacillus megaterium, has recently aroused greater 
interest as a genetically modified host organism 
for biotechnological/industrial approaches, 
especially for the expression of heterologous 
proteins. On account of having its own P450 
expression system, it does not require the addition 
of the heme-precursor (δ-aminolevulinic acid) in 
contrast to E.coli which lacks natural P450 genes 
and heme proteins. Its attractive characteristics 
also include: growth on various carbon sources, 
high plasmid stability and no alkaline protease or 
endotoxin production (Bleif et al., 2012; Korneli 
et al., 2013; Vary et al., 2007). 
From a biotechnological standpoint, 
CYP106A2 from the B. megaterium strain ATCC 
13368 (Berg et al., 1976; Berg et al., 1979) and its 
unique hydroxylating properties raised interest in 
the past years (Hannemann et al., 2006; Virus and 
Bernhardt, 2008). CYP106A2 being extensively 
studied since the late 1970s, is a highly active 
steroid hydroxylase, catalyzing mainly the        
15β-hydroxylation of 3-oxo-Δ4-steroids (Berg et 
al., 1976; Berg et al., 1979). Furthermore, the 
enzyme was shown to hydroxylate di- and 
triterpenes (Bleif et al., 2011; Bleif et al., 2012; 
Schmitz et al., 2012) and recently was also 
described as a regioselective hydroxylase for the 
3-hydroxy-Δ5 steroid dehydroepiandrosterone 
(Schmitz et al., 2014). Although its original name, 
15β-hydroxylase, suggests mainly hydroxylation 
at the 15β position, the long-thought strict 
regioselectivity was contradicted by the 
identification of 6β, 7α/β, 9α, 11α and 15α-
hydroxy products  (Lisurek et al., 2004; Lisurek et 
al., 2008; Nguyen et al., 2012; Virus et al., 2006). 
Even though, these hydroxylations occur in lower 
proportions, the resulting products are of industrial 
interest. This means a unique potential for 
industrial applications, since there is a wide 
variety of compounds that could serve as 
substrates for this enzyme. Its natural substrate is 
yet to be identified and its substrate range is 
continuously broadening as a result of library 
screening (Schmitz et al., 2012; Schmitz et al., 
2014). 
The lesser known CYP106A1 shares 63 % 
amino acid sequence identity and 76 % similarity 
with its well-studied sibling, CYP106A2 (He et 
al., 1995; He et al., 1989). CYP106A1 from           
B. megaterium DSM319 was recently purified and 
characterized by our group (Brill et al., 2014) and 
successfully applied in a whole-cell system for the 
hydroxylation of a triterpene, 11-keto-β-boswellic 
acid (KBA), at 7β and 15α positions. The 
CYP106A1-dependent conversion showed a 
different product pattern compared with 
CYP106A2 (Bleif et al., 2012), resulting in two 
additional products, identified as 7β-hydroxy-
KBA and 7β,15α-dihydroxy KBA. Furthermore, 
CYP106A1 was also characterized in vitro from 
another B. megaterium strain, ATCC 14581 by 
Lee et al., who recognized some steroids as 
convertible substrates, but leaving product 
structures unidentified (Lee et al., 2014). Based on 
the high sequence identity between the two 
enzymes, CYP106A1 was proposed to be an 
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equally promising candidate in a possible 
transition of the pharmaceutical industry towards 
greener processes. In order to exploit the potential 
of CYP106A1 and to reveal the anticipated 
differences in activity and selectivity between the 
two subfamily members, we decided to focus on 
steroid conversions. Steroids are pharmaceuticals 
of great importance. Drugs based on the steroid 
structure are widely used in almost all fields of 
healthcare, from anti-microbial and anti-viral 
agents to the treatment of hormone-dependent 
cancer forms (Donova and Egorova, 2012). 
Moreover, steroid hydroxylation is considered to 
be one of the most important reactions in steroid 
functionalization, since the derivatives have 
enhanced biological activity or can be further 
modified in drug development (Choudhary et al., 
2011; Choudhary et al., 2005; Janeczko et al., 
2009). 
Here we tested a focused substrate library with 
both CYP106A subfamily members and extended 
their substrate ranges with respect to different 
steroid molecules. Nineteen of the 23 screened 
steroids were successfully converted by both 
enzymes during in vitro and in vivo reactions. 
Using recombinant B. megaterium MS941 whole-
cell systems, overexpressing each enzyme, 
sufficient amounts of product were obtained for 
structure characterization by nuclear magnetic 
resonance (NMR). Besides confirming the 
production of mono- and dihydroxylated products 
at 6β, 7β, 9α and 15β positions, we were able to 
demonstrate a previously unknown reaction 
among these P450s, an 11β-hydroxysteroid 
dehydrogenase activity. Our recent findings 
underline the role of the CYP106A subfamily in 
the field of drug development and production. 
Materials and methods 
Reagents and chemicals 
All steroid substrates were purchased from Sigma-
Aldrich (Sigma Aldrich Biochemie Gmbh, 
Germany), all other chemicals were obtained from 
standard sources and of highest grade available. 
Expression and purification of the enzymes 
The expression and purification of the CYP106A1 
and CYP106A2 proteins was performed as 
described previously (Brill et al., 2014; Lisurek et 
al., 2004; Simgen et al., 2000). For the 
reconstituted in vitro system, a truncated form of 
bovine adrenodoxin (Adx4-108) was used in 
combination with bovine adrenodoxin reductase 
(AdR). Their expression and purification was 
completed as described elsewhere (Sagara et al., 
1993; Uhlmann et al., 1992). 
UV-visible absorbance spectroscopy 
To analyze the characteristics of the purified 
CYP106A family members, the UV-visible 
absorbance spectrum of the proteins was recorded 
in a range of 200-700 nm with a double beam 
spectrophotometer (UV-2101 PC, Shimadzu, 
Japan). The spectra were constantly analyzed 
during the purification process, approaching a       
Q value (A417/A280) higher then 1.5, suggesting a 
high amount of well-folded, heme-containing and 
active P450s. The concentration of the proteins for 
further experiments was determined by CO 
difference spectroscopy according to the method 
of Omura and Sato (Omura and Sato, 1964), using 
an extinction coefficient for the CO-bound P450 
of 91 mM-1 cm-1. 
Substrate binding assay 
The substrate binding difference spectra were 
investigated using a double-beam 
spectrophotometer (UV-2101PC, Shimadzu, 
Japan) and tandem quartz cuvettes. The reaction 
was carried out in 800 µl total volume. One 
chamber of each cuvette contained 10 µM solution 
of the enzymes in 50 mM potassium phosphate 
buffer pH 7.4, while the other chamber was filled 
with the buffer only. The substrate was dissolved 
in DMSO at a stock concentration of 20 mM. The 
enzyme solution was then titrated with increasing 
concentrations of the substrate. In each step the 
same amount of substrate was also added to the 
buffer-containing chamber of the reference 
cuvette. After each titration step, the spectrum was 
recorded between 350 nm and 500 nm. The Kd 
value was calculated after the titration of the 
substrate until saturation. The data was analyzed 
by plotting the peak-to-through differences against 
the concentrations of the substrate. The data was 
fitted in Origin (OriginLab Corporations, 
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Massachusetts, USA) using hyperbolic regression. 
The Kd values are averaged from three 
independent measurements. 
In vitro conversions 
The in vitro conversion of the substrates was 
carried out with a reconstituted system in a final 
volume of 250 µL at 30 °C for 60 min in 50 mM 
potassium phosphate buffer (pH 7.4), containing 
20 % (v/v) glycerol. The reconstituted system 
contained AdR (1 µM), the truncated form of 
bovine Adx4-108 (10 µM), CYP106A1 and 
CYP106A2 (1 µM), an NADPH-regenerating 
system [MgCl2 (1 mM), glucose-6-phosphate      
(5 mM), glucose-6-phosphate dehydrogenase       
(1 U), and NADPH (0.1 µM)] and the substrate 
(200 µM). The reaction was started by adding 
NADPH (100 µM) and stopped by the addition of 
250 μl of ethyl acetate, mixed vigorously, and 
extracted twice. After evaporating the combined 
organic phases to dryness, the residues were 
dissolved in the high-performance liquid 
chromatography (HPLC) mobile phase and 
subjected to HPLC analysis. 
In vivo conversions 
The in vivo steroid conversions were performed 
using the recombinant B. megaterium MS941 
strain, derived from the strain DSM319 (Wittchen 
and Meinhardt, 1995), lacking the major 
extracellular protease gene nprM. The                       
B. megaterium MS941 strain was transformed 
with the corresponding plasmid pSMF2.1B 
(containing CYP106A1 cloned into SpeI/MluI 
sites (Brill et al., 2014)) or pSMF2.1C (containing 
CYP106A2 cloned into SpeI/MluI sites (Bleif et 
al., 2012)) applying a polyethylene glycol-
mediated technique using protoplasts (Barg et al., 
2005). To make sure that the conversion was 
catalyzed by the anticipated enzyme, the 
conversions were compared to transformations 
with the wild type strain MS941 (lacking the 
pSMF2.1 plasmid, but naturally containing 
cytochrome P450 genes) as a control. According 
to these results, the wild type strain did not show 
any conversion. 
Precultures were inoculated from -80 °C 
glycerol stock, using 25 ml complex TB medium 
(24 g/l yeast extract, 12 g/l soytone, 2.31 g/l 
KH2PO4 and 12.5 g/l K2HPO4) supplemented with 
10 µg/ml tetracycline and incubated overnight, at 
150 rpm, 30 °C. The main culture (supplemented 
with the corresponding amount of tetracycline) 
was inoculated with 1% of the culture volume 
from the overnight culture. Following the 
inoculation of the main culture, it was further 
incubated for 2-3 hours, until it reached an      
OD578 = 0.4 when 0.5 g/l xylose solution was 
added to induce the expression. Cells were 
cultivated for 24 h under the same conditions prior 
to the addition of the substrate. For analytical 
purposes, the experiments were performed in 2 ml 
reaction tubes with a 500 µl volume of the freshly 
aliquoted main culture. The transformations 
required the use of an Eppendorf thermomixer 
(Eppendorf, Hamburg, Germany) for the 
continuous mixing with 1000 rpm, keeping the 
temperature constant at 30°C, for 1-4 h. For the 
preparative scale conversions, 50 ml culture 
volume was used in 300 ml baffled shake flasks, 
inoculated with 500 µl of the precultures, induced 
and cultivated for 24 h at 30°C, before the addition 
of the substrates. Conversions at a larger scale 
were performed with resting cells, either adding 
the substrate directly 24 hours after the expression 
or after harvesting the cells and suspending them 
in 100 mM potassium phosphate buffer (pH 7.4). 
The steroids were added as ethanolic solution to 
the culture medium (the use of ethanol did not 
exceed 5% of the culture volume). Following the 
corresponding conversion time, the reaction was 
stopped and the steroids were extracted twice by 
the addition of 50 ml ethyl acetate. The organic 
phase was dried over anhydrous MgSO4 and 
concentrated to dryness in a rotatory evaporator 
(Büchi R-114). The yellowish residue was 
dissolved in the mobile phase of the HPLC and 
filtered through a sterile syringe filter (Rotilabo 
syringe filter, 0.22 μm, Carl Roth GmbH, 
Karlsruhe, Germany). The products were 
separated by preparative HPLC, according to its 
retention time. The collected fractions were 
evaporated to dryness and analyzed by NMR 
spectroscopy and high-resolution mass 
spectrometry (HRMS). 
20 
 
HPLC analysis 
The HPLC analysis was performed on a Jasco 
system consisting of a Pu-980 HPLC pump, an 
AS-950 sampler, a UV-975 UV/Vis detector, and 
an LG-980–02 gradient unit (Jasco, Gross-
Umstadt, Germany). A reversed-phase ec MN 
Nucleodor C18 (3µM, 4.0x125mm) column 
(Macherey-Nagel, Betlehem, PA, USA) was used 
to carry out the experiments, kept at an oven 
temperature of 40 °C. The steroids were eluted 
from the column using a gradient method, starting 
with a mobile phase ratio of 1:9 of ACN:H2O and 
increasing it to 1:1. The used flow rate was               
1 ml/min and the UV detection of the substrate and 
product was accomplished at 240 or 254 nm. In the 
case of the isolation of conversion products the 
conditions of the preparative reversed-phase 
HPLC (ec MN Nucleodur C18 VP (5µM, 
8x250mm), Macherey-Nagel, Betlehem, PA, 
USA) varied according to the size of the column, 
consequently the maximum injectable amount of 
sample could reach 1 ml and the flow rate              
2.5 ml/min. 
The conversion and product distribution were 
calculated from the relative peak area (area %) of 
the HPLC chromatograms. Following the 
conversion, all peak areas were summed up and 
the respective product peak area was divided by 
the total area of all peaks. The results are presented 
as conversion % and product formation %. 
HRMS analysis 
Analyses were performed using a solariX 7 Tesla 
FTICR mass spectrometer (Bruker Daltonik, 
Bremen, Germany). All samples were ionized by 
atmospheric pressure chemical ionization (APCI) 
in negative ionization mode, using the following 
parameters: dry temperature 350 °C, vaporizing 
temperature 350 °C, corona needle 40000 nA, 
capillary voltage 2000 V, end plate offset -500 V, 
estimated R. P. (400 m/z) 70000. The calculated 
exact and measured accurate masses are presented 
next to each identified compound name in the 
NMR section. 
NMR characterization of the metabolites 
The NMR spectra were recorded in CDCl3 or 
CD3OD with a Bruker DRX 500 or a Bruker 
Avance 500 NMR spectrometer at 300 K. The 
chemical shifts were relative to CHCl3 at δ 7.26 or 
CH3OD at δ 3.30 (1H NMR) and CDCl3 at δ 77.00 
or CD3OD at δ 49.00 (13C NMR) respectively 
using the standard δ notation in parts per million. 
The 1D NMR (1H and 13C NMR, DEPT135) and 
the 2D NMR spectra (gs-HH-COSY, gs-NOESY, 
gs-HSQCED, and gs-HMBC) were recorded using 
the BRUKER pulse program library. All 
assignments were based on extensive NMR 
spectral evidence. (For detailed substrate and 
product structures, see Table 4.) 
6-hydroxyandrost-4-ene-3,17-dione 
Product A4 (2.6 mg) in the conversion of 
androstenedione with CYP106A1 (HRMS (APCI) 
calculated exact mass [Da] C19H26O3 [M+TFA-H]- 
415.1732; measured accurate mass [Da] 415,1733, 
error [ppm] -0.44). Its 1H NMR data matched 
those in literature (Kirk et al., 1990). 1H NMR 
(CDCl3, 500 MHz): δ 0.95 s (3xH-18), 0.98 ddd 
(12.3, 10.8 and 4.2 Hz, H-9), 1.29 m (H-12a), 1.31 
m (H-14), 1.33 m (H-7a), 1.41 s (3xH-19), 1.53 m 
(H-11a), 1.63 m (H-15a), 1.66 m (6-OH), 1.70 m 
(H-11b), 1.73 m (H-1a), 1.89 ddd (13.3, 4.2 and 
3.0 Hz, H-12b), 1.99 ddd (13.2, 4.0 and 3.0 Hz, H-
15b), 2.06 ddd (13.3, 5.0 and 3.0 Hz, H-1b), 2.12 
m (H-16a), 2.14 m (H-7b), 2.18 m (H-8), 2.41 m 
(H-2a), 2.49 m (H-16b), 2.53 m (H-2b), 4.41 ddd 
(3x2.5 Hz, H-6), 5.84 brs (H-4). 13C NMR (CDCl3, 
125 MHz): δ 13.79 (CH3, C-18), 19.59 (CH3, C-
19), 20.29 (CH2, C-11), 21.72 (CH2, C-15), 29.43 
(CH, C-8), 31.30 (CH2, C-12), 34.20 (CH2, C-2), 
35.76 (CH2, C-16), 37.13 (CH2, C-1), 37.22 (CH2, 
C-7), 38.05 (C, C-10), 47.63 (C, C-13), 50.93 (CH, 
C-14), 53.68 (CH, C-9), 72.94 (CH, C-6), 126.64 
(CH, C-4), 167.43 (C, C-5), 199.97 (C, C-3), 
220.33 (C, C-17).  
7-hydroxyandrost-4-ene-3,17-dione 
Product A2 (3 mg) in the conversion of 
androstenedione with CYP106A1 (HRMS (APCI) 
calculated exact mass [Da] C19H26O3 [M+TFA-H]- 
415.1732; measured accurate mass [Da] 415,1731, 
error [ppm] 0.06). Its 1H NMR data matched those 
in literature (Kirk et al., 1990): 1H NMR (CDCl3, 
500 MHz): δ 0.95 s (3xH-18), 1.01 ddd (12.4, 10.5 
and 4.0 Hz, H-9), 1.24 s (3xH-19), 1.26 ddd 
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(2x13.3 and 4.2 Hz, H-12a), 1.47 m (H-14), 1.50 
m (H-11a), 1.57 m (7-OH),  1.67 ddd (13.5, 13.5 
and 5.0 Hz, H-1a), 1.75 m (H-11b), 1.76 ddd 
(3x10.5 Hz, H-8), 1.88 ddd (13.3, 5.0 and 3.3 Hz, 
H-12b), 1.94 m (H-15a), 2.06 ddd (13.5, 5.0 and 
3.3 Hz, H-1b), 2.13 ddd (19.5 and 2x9.5 Hz, H-
16a), 2.32 m (H-15b), 2.39 m (H-2a), 2.45 m (H-
2b), 2.48 m (H-16b), 2.49 m (H-6a), 2.58 dd (14.0 
and 5.2 Hz, H-6b), 3.59 m (H-7), 5.78 d (2.0 Hz, 
H-4). 13C NMR (CDCl3, 125 MHz): δ 13.96 (CH3, 
C-18), 17.38 (CH3, C-19), 20.37 (CH2, C-11), 
24.98 (CH2, C-15), 31.22 (CH2, C-12), 33.89 
(CH2, C-2), 35.65 (CH2, C-1), 35.97 (CH2, C-16), 
38.04 (C, C-10), 42.59 (CH, C-8), 42.69 (CH2, C-
6), 48.01 (C, C-13), 50.52 (CH, C-14), 50.78 (CH, 
C-9), 74.37 (CH, C-7), 125.09 (CH, C-4), 166.35 
(C, C-5), 198.95 (C, C-3), 220.39 (C, C-17).  
15-hydroxyandrost-4-ene-3,17-dione 
Product B6 (3.7 mg) in the conversion of 
androstenedione with CYP106A2 (HRMS (APCI) 
calculated exact mass [Da] C19H26O3 [M+TFA-H]- 
415.1732; measured accurate mass [Da] 415,1752, 
error [ppm] 4.78). Its 13C NMR data matched those 
in literature (Mineki et al., 1995) 1H NMR (CDCl3, 
500 MHz): δ 1.04 ddd (14.8, 10.7 and 4.2 Hz, H-
9), 1.22 m (H-7a), 1.23 s (3xH-18), 1.26 s (3xH-
19), 1.29 m (H-12a), 1.30 m (H-14), 1.52 m (H-
11a), 1.74 m (H-1a), 1.75 m (H-11b), 1.85 ddd 
(13.2, 4.8 and 3.2 Hz, H-12b), 2.06 m (H-1b), 2.11 
m (H-8), 2.15 m (H-7b), 2.36 m (H-2a), 2.37 m 
(H-6a), 2.43 m (H-2b), 2.50 m (H-6b), 2.52 dd 
(19.6 and 6.0 Hz, H-16a), 2.59 dd (19.6 and 1.3 
Hz, H-16b), 4.59 ddd (6.0, 4.5 and 1.3 Hz, H-15), 
5.77 brs (H-4). 13C NMR (CDCl3, 125 MHz): δ 
17.26 (CH3, C-19), 17.59 (CH3, C-18), 20.26 
(CH2, C-11), 30.47 (CH2, C-7), 31.44 (CH, C-8), 
32.46 (CH2, C-6), 32.61 (CH2, C-12), 33.91 (CH2, 
C-2), 35.73 (CH2, C-1), 38.80 (C, C-10), 46.70 (C, 
C-13), 47.06 (CH2, C-16), 54.24 (CH, C-9), 54.96 
(CH, C-14), 67.16 (CH, C-15), 124.23 (CH, C-4), 
170.12 (C, C-5), 199.30 (C, C-3), 219.05 (C, C-
17).  
7-dihydroxyandrost-4-ene-3,17-dione 
Product B3 (2 mg) in the conversion of 
androstenedione with CYP106A2 (HRMS (APCI) 
calculated exact mass [Da] C19H26O4 [M+TFA-H]- 
431.1682; measured accurate mass [Da] 431,1685, 
error [ppm] 0.81. The 1H and 13C NMR spectra 
showed signals for two secondary hydroxyl 
groups with similar chemical shifts to those of the 
monohydroxylated androstenedione derivatives 
A2 and B6. The positions of the hydroxyl groups 
at C-7 and C-15 were supported by the results of 
2D NMR experiments (HHCOSY, HSQC and 
HMBC). For example, H-7 (δH 3.74 ddd) showed 
correlations to the H-6a and H-6b (2.58 m, 2H) 
and H-8 (2.12 ddd) in the HHCOSY, H-15 could 
be assigned by its vicinal couplings to H-14, H-
16a and H-16b in the HHCOSY and its 3JCH 
correlation with carbonyl C-17 in the HMBC. The 
-orientation for both hydroxyls could be 
concluded by results of the NOESY spectrum. H-
7 and H-15 showed an effect to each other and 
both to the -orientated H-14; H-7 showed an 
additional effect to the -orientated H-9. 
Therefore, both H-7 and H-15 were in -position 
and as a consequence their corresponding 
hydroxyls -orientated. To our knowledge the 
structure of this dihydroxylated androstenedione 
has not been reported so far. 1H NMR (CDCl3, 500 
MHz): δ 1.06 ddd (12.5, 10.7 and 4.2 Hz, H-9), 
1.26 s (3xH-18), 1.27 m (H-12a), 1.28 s (3xH-19), 
1.40 dd (10.7 and 4.5 Hz, H-14), 1.58 m (H-11a), 
1.68 ddd (2x13.5 and 5.0 Hz, H-1a), 1.76 m (H-
11b), 1.83 ddd (12.7, 4.0 and 2.5 Hz, H-12b), ), 
2.08 ddd (13.5, 5.0 and 3.3 Hz, H-1b), 2.12 ddd 
(3x 10.7 Hz, H-8) 2.38 m (H-2a), 2.44 m (H-2b), 
2.53 dd (20.0 and 8.0 Hz, H-16a), 2.58 m (2H, H-
6a and H-6b), 2.67 dd (20.0 and 1.2 Hz, H-16b), 
3.74 ddd (9.5 and 2x8.0 Hz, H-7), 4.66 ddd (7.0, 
4.5 and 1.2 Hz, H-15), 5.79 brs (H-4). 13C NMR 
(CDCl3, 125 MHz): δ 17.34 (CH3, C-19), 17.65 
(CH3, C-18), 20.38 (CH2, C-11), 32.16 (CH2, C-
12), 33.86 (CH2, C-2), 35.58 (CH2, C-1), 38.01 (C, 
C-10), 38.56 (CH, C-8), 42.46 (CH2, C-6), 44.53 
(CH2, C-16), 47.06 (C, C-13), 51.01 (CH, C-9), 
55.07 (CH, C-14), 68.52 (CH, C-15), 73.74 (CH, 
C-7), 125.37 (CH, C-4), 165.67 (C, C-5), 198.90 
(C, C-3), 219.50 (C, C-17).  
15-hydroxycorticosterone 
Product D1 (1.2 mg) in the conversion of 
corticosterone with CYP106A2 (HRMS (APCI) 
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calculated exact mass [Da] C21H30O5 [M-H]- 
361.2015; measured accurate mass [Da] 361.2020, 
error [ppm] 1.27). Its NMR data showed 
resonances for an additional hydroxyl group (δC 
70.24; δH 4.41 m), which could be located at 
position 15 by means of 2D NMR. 1H NMR 
(CDCl3, 500 MHz): δ 1.02 m (H-14), 1.06 m (H-
9), 1.15 m (H-7a), 1.19 s (3xH-18), 1.48 s (3xH-
19), 1.62 dd (13.8 and 3.3 Hz, H-12a), 1.86 ddd 
(2x13.5 and 4.5 Hz, H-1a), 2.08 dd (13.8 and 2.8 
Hz, H-12b), 2.21 ddd (13.5, 5.0 and 4.0 Hz, H-1b), 
2.28 m (2H, H-6a and H-7b), 2.33 m (2H, H-16a 
and b), 2.34 m (H-17), 2.37 m (H-2a), 2.38 m (H-
8), 2.49 m (H-2b), 2.55 m (H-6b), 3.23 dd (2x 4.5 
Hz, 21-OH), 4.19 dd (18.5 and 4.5 Hz, H-21a), 
4.24 dd (18.5 and 4.5 Hz, H-21b), 4.41 m (H-15), 
5.70 d (2.0 Hz, H-4). 13C NMR (CDCl3, 125 
MHz): δ 18.65 (CH3, C-18), 20.80 (CH3, C-19), 
27.78 (CH, C-8), 31.70 (CH2, C-7), 31.82 (CH2, 
C-6), 33.79 (CH2, C-2), 34.78 (C, C-10), 35.04 
(CH2, C-1), 35.53 (CH2, C-16), 43.46 (C, C-13), 
49.13 (CH2, C-12), 56.64 (CH, C-9), 59.80 (CH, 
C-17), 61.74 (CH, C-14), 67.80 (CH, C-11), 69.22 
(CH2, C-21), 70.24 (CH, C-15), 122.55 (CH, C-4), 
171.36 (C, C-5), 199.32 (C, C-3), 208.77 (C, C-
20). 
11-dehydrocorticosterone 
Product C5 (2.5 mg) and D4 (1 mg) in the 
conversion of corticosterone with CYP106A1 and 
CYP106A2 respectively (HRMS (APCI) 
calculated exact mass [Da] C21H28O4 [M-H]- 
343.1909; measured accurate mass [Da] 343.1921, 
error [ppm] 3.34). The NMR spectra of C5 lacked 
of resonances for the 11-hydroxy group but 
revealed an additional carbonyl (δC 207.49) for C-
11. 1H NMR (CDCl3, 500 MHz): δ 0.67 s (3xH-
18), 1.27 m (H-7a), 1.41 s (3xH-19), 1.45 m (H-
15a), 1.63 ddd (2x14.5 and 4.5 Hz, H-1a), 1.80 m 
(H-14), 1.92 m (2H, H-9 and H-16a), 1.93 m (H-
8), 1.95 m (H-15b), 1.98 m (H-7b), 2.29 m (H-
16b), 2.30 m (2H, H-2a and H-6a), 2.44 m (H-6b), 
2.47 d (12.0 Hz, H-12a), 2.48 ddd (17.0, 14.5 and 
5.0 Hz, H-2b), 2.56 d (12.0 Hz, H-12b), 2.68 dd 
(2x9.5 Hz, H-17), 2.77 ddd (14.5, 5.0 and 3.3 Hz, 
H-1b), 3.16 dd (2x 3.5 Hz, 21-OH), 4.14 dd (19.5 
and 3.5 Hz, H-21a), 4.19 dd (19.5 and 3.5 Hz, H-
21b), 5.73 brs (H-4). 13C NMR (CDCl3, 125 
MHz): δ 14.35 (CH3, C-18), 17.15 (CH3, C-19), 
23.34 (CH2, C-16), 24.00 (CH2, C-15), 32.13 
(CH2, C-7), 32.15 (CH2, C-6), 33.69 (CH2, C-2), 
34.74 (CH2, C-1), 36.74 (CH, C-8), 38.16 (C, C-
10), 47.50 (C, C-13), 54.93 (CH, C-14), 56.20 
(CH2, C-12), 57.56 (CH, C-17), 62.67 (CH, C-9), 
69.24 (CH2, C-21), 124.70 (CH, C-4), 168.03 (C, 
C-5), 199.53 (C, C-3), 207.49 (C, C-11), 208.98 
(C, C-20). 
9-hydroxy-11-dehydrocorticosterone 
Product C2 (1 mg) in the conversion of 
corticosterone with CYP106A1 (HRMS (APCI) 
calculated exact mass [Da] C21H28O5 [M-H]- 
359.1859; measured accurate mass [Da] 343.1867, 
error [ppm] 2.45). C2 was the only product in our 
conversion study that formed a tertiary hydroxyl 
group with the P450 enzymes.  Its resonance line 
at δC 79.31 showed 3JCH couplings to H-1a, H-12a 
and methyl H-19 in the HMBC spectrum 
indicating that C-9 bared the additional hydroxyl 
group. As H-9 in the substrate 9-OH of the 
conversion product C2 was -oriented. This was 
obvious by the cross peaks found in NOESY 
spectrum. Key correlations were found between 
H-8 and the methyls H-18 and H-19, which 
therefore must be positioned on the same side of 
the steroid skeleton. Only two citations from the 
fifties could be found for the structure of 9-
hydroxy-11-dehydrocorticosterone but both 
without NMR data. 1H NMR (CDCl3, 500 MHz): 
δ 0.66 s (3xH-18), 1.39 m (H-15a), 1.49 s (3xH-
19), 1.66 m (H-7a), 1.71 m (H-7b), 1.82 m (H-
15b), 1.94 m (H-16a), 2.10 m (H-1a), 2.17 m (H-
8), 2.22 m (H-14), 2.26 m (H-16b), 2.30 ddd (15.0, 
4.7 and 2.0 Hz, H-6a), 2.37 m (H-2a), 2.38 d (12.0 
Hz, H-12a), 2.47 m (H-2b), 2.48 m (H-6b), 2.50 m 
(H-1b), 2.73 dd (2x9.5 Hz, H-17), 3.05 dd (12.0 
and 1.0 Hz, H-12b), 3.16 dd (2x 5.0 Hz, 21-OH), 
4.13 dd (19.2 and 4.7 Hz, H-21a), 4.19 dd (19.2 
and 4.7 Hz, H-21b), 5.86 d (2.0 Hz, H-4). 13C 
NMR (CDCl3, 125 MHz): δ 13.91 (CH3, C-18), 
18.89 (CH3, C-19), 23.32 (CH2, C-16), 23.72 
(CH2, C-15), 24.52 (CH2, C-7), 28.15 (CH2, C-1), 
31.29 (CH2, C-6), 33.74 (CH2, C-2), 38.65 (CH, 
C-8), 43.66 (C, C-10), 47.11 (C, C-13), 48.73 (CH, 
C-14), 51.98 (CH2, C-12), 57.41 (CH, C-17), 
69.28 (CH2, C-21), 79.31 (C, C-9), 127.68 (CH, C-
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4), 165.89 (C, C-5), 198.83 (C, C-3), 206.83 (C, 
C-11), 209.09 (C, C-20).  
6β-hydroxy-11-deoxycorticosterone                       
(6β-hydroxy-DOC) 
Product E5 (1.1 mg) in the conversion of 11-
deoxycorticosterone with CYP106A1 (HRMS 
(APCI) calculated exact mass [Da] C21H30O4 [M-
H]- 345.2066; measured accurate mass [Da] 
345.2076, error [ppm] 2.82). Selected 1H NMR 
data were published by Matsuzaki (Matsuzaki et 
al., 1995). Our 1H NMR of E4 matched these data. 
1H NMR (CDCl3, 500 MHz): δ 0.73 s (3xH-18), 
0.96 ddd (12.5, 11.0 and 4.5 Hz, H-9), 1.17 m (H-
14), 1.28 m (H-7a), 1.38 m (H-12a), 1.39 s (3xH-
19), 1.40 m (H-15a) 1.49 m (H-11a), 1.63 m (H-
11b), 1.73 m (H-1a), 1.77 m (H-16a), 1.79 m (H-
15b), 1.97 ddd (12.0, 3.5 and 2.5 Hz, H-12b), 2.01 
m (H-8), 2.03 m (H-7b), 2.04 ddd (10.5, 5.0 and 
2.8 Hz, H-1b), 2.23 m (H-16b), 2.40 dddd (17.3, 
4.5, 3.0 and 1.0 Hz, H-2a), 2.47 brd (9.0 Hz, H-
17), 2.49 m (H-16b), 2.53 ddd (17.3, 15.0 and 5.0 
Hz, H-2b), 3.25 dd (2x4.5 Hz,far 19-OH), 4.17 dd 
(19.0 and 4.5 Hz, H-21a), 4.22 dd (19.0 and 4.5 
Hz, H-21b), 4.37 dd (2x2.5 Hz, H-6), 5.83 brs (H-
4). 13C NMR (CDCl3, 125 MHz): δ 13.50 (CH3, C-
18), 19.53 (CH3, C-19), 20.87 (CH2, C-11), 22.91 
(CH2, C-16), 24.43 (CH2, C-15), 29.74 (CH, C-8), 
34.20 (CH2, C-2), 37.12 (CH2, C-1), 37.94 (C, C-
10), 38.35 (2xCH2, C-7 and C-12), 44.75 (C, C-
13), 53.38 (CH, C-9), 56.06 (CH, C-14), 59.09 
(CH, C-17), 69.69 (CH2, C-21), 73.03 (CH, C-6), 
126.51 (CH, C-4), 167.60 (C, C-5), 200.08 (C, C-
3), 210.06 (C, C-20). 
15-hydroxy-11-deoxycorticosterone                      
(15β-hydroxy-DOC) 
Product E4 (3.5 mg) and F5 (4 mg) in the 
conversion of 11-deoxycorticosterone with 
CYP106A1 and CYP106A2 respectively (HRMS 
(APCI) calculated exact mass [Da] C21H30O4 [M-
H]- 345.2066; measured accurate mass [Da] 
345.2055, error [ppm] -3.06). In comparison to 11-
deoxycorticosterone the NMR data of E4 and F5 
showed signals for an additional secondary 
hydroxyl group (δH 4.38 ddd, δC 70.34). Its 
position at C-15 could be deduced by vicinal 
couplings of the methin proton with H-14 (δH 
1.04) and H-16a (δH 2.32) in the HHCOSY and 
with C-13 (δC 44.29) and C-17 (δC 59.28) in 
HMBC. The -orientation of the hydroxyl was 
obvious by the NOESY effects of H-15 with H-14 
and H-16a, both in -position. In addition to these 
results the chemical shifts of the epimeric 15-
hydroxy-11-deoxycorticosterone (Faramarzi et 
al., 2003) differed significantly from our values.  
1H NMR (CDCl3, 500 MHz): δ 0.96 s (3xH-18), 
1.04 m (H-9), 1.06 m (H-14), 1.16 m (H-7a), 1.22 
s (3xH-19), 1.38 m (H-12a), 1.43 dddd (3x 13.5 
and 3.5 Hz, H-11a), 1.66 dddd (13.5 and 3x 4.0 
Hz, H-11b), 1.73 ddd (2x13.5 and 5.0 Hz, H-1a), 
1.95 m (H-12b), 1.97 m (H-8), 2.05 ddd (13.5, 5.0 
and 3.0 Hz, H-1b), 2.14 m (H-7b), 2.32 m (H-16a), 
2.33 m (2H, H-6a and H-6b), 2.38 m (H-2a), 2.43 
m (2H, H-2b and H-17), 2.49 m (H-16b), 4.18 d 
(19.0 Hz, H-21a), 4.24 d (19.0 Hz, H-21b), 4.38 
ddd (3x5.5 Hz, H-15), 5.75 brs (H-4). 13C NMR 
(CDCl3, 125 MHz): δ 15.98 (CH3, C-18), 17.29 
(CH3, C-19), 20.84 (CH2, C-11), 31.11 (CH2, C-
7), 31.74 (CH, C-8), 32.61 (CH2, C-16), 33.92 
(CH2, C-2), 35.78 (CH2, C-1), 36.03 (CH2, C-6), 
38.69 (C, C-10), 39.87 (CH2, C-12), 44.29 (C, C-
13), 53.94 (CH, C-9), 59.28 (CH, C-17), 60.37 
(CH, C-14), 69.39 (CH2, C-21), 70.34 (CH, C-15), 
124.09 (CH, C-4), 170.46 (C, C-5), 199.35 (C, C-
3), 209.01 (C, C-20). 
7, 15-dihydroxy-11-deoxycorticosterone 
(7β, 15β-dihydroxy-DOC) 
Product E2 (1.8 mg) and F4 (3 mg) in the 
conversion of 11-deoxycorticosterone with 
CYP106A1 and CYP106A2 respectively (HRMS 
(APCI) calculated exact mass [Da] C21H30O5 [M-
H]- 361.2015; measured accurate mass [Da] 
361.2019, error [ppm] 1.16).  The NMR spectra of 
E2 and F4 were similar to those of E4, especially 
for the resonances of C-15 (δC 71.55) and H-15 (δH 
4.50 ddd, 3x5.5 Hz) as well as the coupling pattern 
of H-15.  But E2 beared an additional secondary 
hydroxyl group with resonances at δH 3.62 (ddd, 
9.5 and 2x8.0 Hz) and δC 74.36. These resonances 
and the coupling pattern were close to those of the 
7-hydroxy group found for B3. Therefore, the 
structure of E2 was elucidated as 7, 15-
dihydroxy-11-deoxycorticosterone, a structure 
which has not been published so far. 2D NMR 
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measurements supported the structure and led to 
the full assignments. 1H NMR (CDCl3, 500 MHz): 
δ 0.99 s (3xH-18), 1.03 m (H-9), 1.12 dd (10.8 and 
5.0 Hz, H-14), 1.25 s (3xH-19), 1.33 ddd (2x13.0 
and 4.0 Hz, H-12a), 1.50 dddd (3x 13.5 and 4.0 
Hz, H-11a), 1.67 m (H-1a), 1.68 m (H-11b), 1.95 
ddd (13.0, 4.0 and 3.0 Hz, H-12b), 2.05 m (H-8), 
2.07 m (H-1b), 2.33 m (2H, H-16a and H-16b), 
2.35 m (H-2a), 2.36 m (H-17), 2.41 m (H-2b), 2.55 
m (2H, H-6a and H-6b), 3.62 ddd (9.5 and 2x8.0 
Hz, H-7), 4.22 s (2H, H-21a and H-21b), 4.50 ddd 
(3x5.5 Hz, H-15), 5.77 brs (H-4). 13C NMR 
(CDCl3, 125 MHz): δ 15.63 (CH3, C-18), 17.25 
(CH3, C-19), 20.74 (CH2, C-11), 33.54 (CH2, C-
16), 33.89 (CH2, C-2), 35.66 (CH2, C-1), 37.95 (C, 
C-10), 38.52 (CH, C-8), 39.36 (CH2, C-12), 42.60 
(CH2, C-6), 44.47 (C, C-13), 50.74 (CH, C-9), 
59.01 (CH, C-17), 60.11 (CH, C-14), 69.35 (CH2, 
C-21), 71.55 (CH, C-15), 74.36 (CH, C-7), 125.10 
(CH, C-4), 166.10 (C, C-5), 198.99 (C, C-3), 
209.24 (C, C-20). 
15-hydroxy-11-deoxycortisol                              
(15-hydroxy-RSS) 
Product G4 (5 mg) and H3 (5 mg) in the 
conversion of RSS with CYP106A1 and 
CYP106A2 respectively (HRMS (APCI) 
calculated exact mass [Da] C21H30O5 [M-H]- 
361.2015; measured accurate mass [Da] 361.2013, 
error [ppm] 0.72). Its NMR data showed 
resonances for an additional hydroxyl group (δC 
70.29; δH 4.31 ddd), which could be located at 
position 15 by means of 2D NMR. Although 
15-hydroxy-11-deoxycortisol is a known 
structure NMR data were not available in 
literature. It should be mentioned that the coupling 
constants found for H-15 (7.8, 6.0 and 2.3 Hz) 
differed completely from those found for it in 15-
hydroxy-11-deoxycorticosterone (3x5.5 Hz) and 
in 15-hydroxyandrost-4-ene-3,17-dione (6.0, 4.5 
and 1.3 Hz). This is caused by the high flexibility 
of the trans-annulated cyclopentane ring and by 
the strong influence of the C-17 substitution 
pattern of its preferred configuration. 1H NMR 
(CD3OD, 500 MHz): δ 0.89 s (3xH-18), 1.04 ddd 
(12.3, 10.8 and 4.0 Hz, H-9), 1.13 dddd (13.8, 
12.5, 11.5 and 4.0 Hz, H-7a), 1.25 s (3xH-19), 1.41 
ddd (12.5, 4.0 and 2.8 Hz, H-12a), 1.48 ddd (2x 
13.5 and 4.0 Hz, H-11a), 1.67 m (H-11b), 1.71 m 
(H-1a), 1.72 dd (11.5 and 6.0 Hz, H-14), 1.86 ddd 
(2x12.5 and 4.0 Hz, H-12b), 2.03 ddd (2x11.2 and 
3.2 Hz, H-8), 2.06 dd (15.5 and 7.5 Hz, H-16a), 
2.10 ddd (13.5, 5.2 and 3.0 Hz, H-1b), 2.20 dddd 
(12.5, 5.7 and 2x 2.8 Hz, H-7b), 2.30 m (H-2a), 
2.32 m (H-6a), 2.48 ddd (17.0, 15.0 and 5.3 Hz, H-
2b), 2.53 dddd (2x15, 5.5 and 1.7 Hz, H-6b), 2.73 
dd (15.5 and 2.3 Hz, H-16b), 4.27 d (19.2 Hz, H-
21a), 4.31 ddd (7.8, 6.0 and 2.3 Hz, H-15), 4.62 d 
(19.2 Hz, H-21b), 5.72 brs (H-4). 13C NMR 
(CD3OD, 125 MHz): δ 17.63 (CH3, C-19), 18.04 
(CH3, C-18), 21.68 (CH2, C-11), 32.66 (CH2, C-
7), 32.72 (CH2, C-12), 32.94 (CH, C-8), 33.90 
(CH2, C-6), 34.73 (CH2, C-2), 36.81 (CH2, C-1), 
40.16 (C, C-10), 47.54 (CH2, C-16), 48.40 (C, C-
13), 55.32 (CH, C-9), 55.73 (CH, C-14), 67.70 
(CH2, C-21), 70.29 (CH, C-15), 90.27 (C, C-17), 
124.17 (CH, C-4), 175.17 (C, C-5), 202.35 (C, C-
3), 212.64 (C, C-20). 
7, 15-dihydroxy-11-deoxycortisol 
(7, 15-dihydroxy-RSS) 
Product G1 (3.5 mg) in the conversion of RSS with 
CYP106A1 (HRMS (APCI) calculated exact mass 
[Da] C21H30O6 [M-H]- 377.1964; measured 
accurate mass [Da] 377.1976, error [ppm] 3.01). 
Its 1H and 13C NMR spectra revealed two 
additional secondary hydroxyl groups. One of 
them (δC 71.26; δH 4.56 ddd , 8.0, 5.6 and 2.6 Hz) 
gave  similar values as found for the 15-hydroxy 
group in H3. The other one (δC 74.67; δH 3.68 ddd, 
2x10.0 and 6.5 Hz) showed vicinal couplings to 
the isochronic protons of H-6 (δH 2.56 m, 2H) and 
to H-8 (δH 2.06 m) in the HHCOSY. NOESY cross 
peaks between H-7 and the -oriented H-9, H-14 
and H-15 revealed the stereochemistry at C-7 with 
the hydroxy group in -orientation. The structure 
of 7, 15-dihydroxy-11-deoxycortisol has not 
beeen published so far. 1H NMR (CDCl3, 500 
MHz): δ 1.03 s (3xH-18), 1.06 ddd (2x12.0 and 3.7 
Hz, H-9), 1.26 s (3xH-19), 1.39 m (H-12a), 1.48 
m (H-11a), 1.67 m (H-1a), 1.70 m (H-12b), 1.72 
m (H-11b), 1.77 dd (11.0 and 5.5 Hz, H-14), 2.06 
m (H-8), 2.07 m (H-1b), 2.22 dd (15.5 and 8.0 Hz, 
H-16a), 2.40 m (H-2a), 2.45 m (H-2b), 2.56 m 
(2H, H-6a and H-6b), 2.63 dd (15.5 and 2.5 Hz, H-
16b), 3.68 ddd (2x10.0 and 6.5 Hz, H-7), 4.36 d 
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(19.8 Hz, H-21a), 4.56 ddd (8.0, 5.6 and 2.6 Hz, 
H-15), 4.70 d (19.8 Hz, H-21b), 5.77 brs (H-4). 13C 
NMR (CDCl3, 125 MHz): δ 17.28 (CH3, C-19), 
17.62 (CH3, C-18), 20.19 (CH2, C-11), 30.22 
(CH2, C-12), 33.90 (CH2, C-2), 35.65 (CH2, C-1), 
37.95 (C, C-10), 38.25 (CH, C-8), 42.65 (CH2, C-
6), 43.25 (CH2, C-16), 48.70 (C, C-13), 50.33 
(CH, C-9), 53.96 (CH, C-14), 67.71 (CH2, C-21), 
71.26 (CH, C-15), 74.67 (CH, C-7), 87.65 (C, C-
17), 125.19 (CH, C-4), 165.99 (C, C-5), 198.98 (C, 
C-3), 212.29 (C, C-20) 
Cortisone 
Product I6 (1 mg) in the conversion of cortisol 
with CYP106A1 (HRMS (APCI) calculated exact 
mass [Da] C21H28O5 [M-H]- 359.1858; measured 
accurate mass [Da] 359.1842, error [ppm] -4.62). 
Its 1H NMR data matched those in literature (Kirk 
et al., 1990). 1H NMR (CD3OD, 500 MHz): δ 0.60 
s (3xH-18), 1.33 m (H-7a), 1.42 s (3xH-19), 1.46 
m (H-15a), 1.70 m (H-16a), 1.72 m (H-1a), 1.92 m 
(H-15b), 2.01 m (H-8), 2.02 m (H-7b), 2.04 d (12.5 
Hz, H-12a), 2.11 d (10.5 Hz, H-9), 2.23 ddd (17.0 
and 2x 3.8 Hz, H-2a), 2.33 ddd (15.0, 4.0 and 2.5 
Hz, H-6a), 2.45 m (H-14), 2.50 m (H-2b), 2.52 m 
(H-6b), 2.70 m (H-1b), 2.72 m (H-16b), 2.95 d 
(12.5 Hz, H-12b), 4.22 d (19.5 Hz, H-21a), 4.60 d 
(19.5 Hz, H-21b), 5.71 brs (H-4). 13C NMR 
(CD3OD, 125 MHz): δ 16.15 (CH3, C-18), 17.58 
(CH3, C-19), 24.14 (CH2, C-15), 33.43 (CH2, C-
6), 33.58 (CH2, C-7), 34.44 (CH2, C-2), 35.23 
(CH2, C-16), 35.62 (CH2, C-1), 37.88 (CH, C-8), 
39.60 (C, C-10), 50.98 (CH, C-14), 51.45 (CH2, C-
12), 52.24 (C, C-13), 63.47 (CH, C-9), 67.88 
(CH2, C-21), 89.35 (C, C-17), 124.76 (CH, C-4), 
172.87 (C, C-5), 202.45 (C, C-3), 212.01 (C, C-
11), 212.78 (C, C-20). 
6-hydroxycortisone 
The only under in vivo conditions observed 
product (2 mg) downstream K1 in the conversion 
of cortisone with CYP106A1 (HRMS (APCI) 
calculated exact mass [Da] C21H28O6 [M-H]- 
375.1808; measured accurate mass [Da] 375.1792, 
error [ppm] -4.22). Comparison of its 1H and 13C 
NMR data with those of the 6-hydroxy 
derivatives, A4 and E5 showed striking 
similarities especially for the hydroxyl moiety. 
The results of 2D NMR analysis supported the 
structure.  1H NMR (CDCl3, 500 MHz): δ 0.69 s 
(3xH-18), 1.26 m (H-16a), 1.53 m (H-7a), 1.57 m 
(H-15a), 1.60 s (3xH-19), 1.64 m (H-1a), 1.88 m 
(H-9), 2.03 m (H-15b), 2.14 m (H-12a), 2.15 m 
(H-7b), 2.32 m (H-16b), 2.36 m (H-2a), 2.38 m 
(H-14), 2.42 m (H-8), 2.57 ddd (17.5, 15.0 and 5.0 
Hz, H-2b), 2.81 m (H-12b), 2.82 m (H-1b), 4.29 d 
(19.8 Hz, H-21a), 4.38 dd (2x3.0 Hz, H-6), 4.65 d 
(19.8 Hz, H-21b), 5.83 brs (H-4). 13C NMR 
(CDCl3, 125 MHz): δ 16.00 (CH3, C-18), 19.15 
(CH3, C-19), 23.42 (CH2, C-15), 30.62 (CH, C-8), 
32.06 (CH2, C-16), 34.04 (CH2, C-2), 35.98 (CH2, 
C-1), 37.81 (C, C-10), 38.91 (CH2, C-7), 49.37 
(CH, C-14), 49.76 (CH2, C-12), 51.68 (C, C-13), 
62.17 (CH, C-9), 67.54 (CH2, C-21), 72.41 (CH, 
C-6), 88.06 (C, C-17), 127.20 (CH, C-4), 166.06 
(C, C-5), 199.94 (C, C-3), 208.47 (C, C-11), 
211.53 (C, C-20). 
15-hydroxycortisone 
Product K3 and L3 (1 mg) in the conversion of 
cortisone with CYP106A1 and with CYP106A2 
respectively (HRMS (APCI) calculated exact 
mass [Da] C21H28O6 [M-H]- 375.1808; measured 
accurate mass [Da] 375.1822, error [ppm] 3.87). 
Due to the low amount only a 1H NMR and a 
HHCOSY could be recorded for the samples, 
indicating an additional secondary hydroxyl group 
for the conversion product. Comparison of the 
chemical shift and the coupling pattern of the 
CHOH resonance (4.62 dd 7.5, 5.5 and 2.0 Hz) 
with those of all the other conversion products led 
to the structure of 15-hydroxycortisone. 1H NMR 
(CDCl3, 500 MHz): δ 0.67 s (3xH-18) 1.47 s (3xH-
19), 4.33 d (19.8 Hz, H-21a), 4.62 ddd (7.5, 5.5 
and 2.0 Hz, H-15), 4.77 d (19.8 Hz, H-21b), 5.77 
brs (H-4). 
Results 
Expression, purification and spectral 
characterization of the proteins 
The proteins were expressed and purified (to 
homogeneity) using a recombinant E. coli C43 
(DE3) strain. The UV-Vis spectra of both proteins 
showed characteristic absorbance peaks at 356, 
417, 534, 567 nm in the oxidized form. In the 
carbon monoxide-bound reduced form, a peak at 
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450 nm was clearly observed without a visible 
peak at 420 nm suggesting no inactive P450 form 
(Schenkman and Jansson, 1998) (Fig. S1).  
Substrate binding  
To compare the steroid hydroxylating capacity of 
the CYP106A subfamily members, a focused 
library of 23 steroids was screened for high-spin 
shift induction using difference spectroscopy 
(Table 1). The study was performed using 
difference spectroscopy due to its higher 
sensitivity, since the extent of the obtained shifts 
was very small, in all cases less than 10 %. The 
library included 14 compounds formerly tested 
with CYP106A2 and 9 additional 3-oxo-steroids, 
derivatives of already known substrates of 
CYP106A2. P450 substrates usually induce a shift 
of the heme iron to the high-spin state, resulting in 
a so-called type I shift spectrum (Schenkman et al., 
1981). It is known that type I shift-inducing 
compounds are converted more often than those 
which do not induce a high spin shift. However, it 
has been shown previously that even compounds 
which do not induce a clear type I shift can be 
converted by P450s (Ferrero et al., 2012; Girhard 
et al., 2010; Schmitz et al., 2014; Simgen et al., 
2000), yet the induction of a type I shift does not 
necessarily lead to product formation (Khatri et 
al., 2013; Schmitz et al., 2012). In our case, there 
are two examples listed in Table 1, where type I 
shift-inducing compounds were not converted 
(adrenosterone, 19-hydroxyandrostenedione), 
while successful conversion was observed with 
pregnenolone and 17-hydroxypregnenolone 
inducing no shift. The type I binding assay allows 
us a straight forward comparison of the binding 
behavior of CYP106A1 and CYP106A2. Only 
four steroids, β-estradiol, estrone, pregnenolone 
and 17β-hydroxypregnenolone, did not induce any 
spin-shift alteration in CYP106A1 and 
CYP106A2. There was only one steroid,               
19-nortestosterone, which despite being converted 
by both enzymes, did not induce any spectral shift 
with CYP106A2, but induced a type I shift with 
CYP106A1. Out of 23 steroids tested, 18 showed 
a clear type I shift induction by both enzymes and 
product formation was observed with all but four 
steroids (Table 1). As expected, the two CYP106A 
family members show similar steroid binding 
behavior according to spin-state alterations, 
caused by the displacement of the water molecule 
as sixth heme iron ligand. 
Catalytic activity and dissociation constants 
The catalytic activity of the CYP106A subfamily 
was compared with respect to all 23 steroids 
(Table 1). Most of the steroids contained the           
3-oxo-Δ4 moiety, others possessed 3-oxo-Δ2,4 or 
3-hydroxy-Δ5 structures. Following the HPLC 
analysis, 19 out of 23 steroids, except                      
19-hydroxyandrostenedione, adrenosterone,         
β-estradiol and estrone, were observed to be 
converted by both subfamily members, with 
detectable conversion products. Though all 19 
steroids were converted both by CYP106A1 and 
CYP106A2, differences in the product pattern 
and/or activity were observed when studying         
3-oxo-Δ4-steroids (Table 2). There was no clear 
correlation found between the steroid structures, 
the differences in conversion velocity or side 
product formation. 
However, testing C18-, C19-, C20- or C21-
steroids, CYP106A2 seemed in all cases to be 
more selective than CYP106A1, showing one or 
two main products. In most cases CYP106A1 
produced the same main product, but a higher 
number of side-products. CYP106A2 also showed 
slightly higher conversion velocity in all 
transformations except for 11β-hydroxysteroids. 
To get deeper insight into the structural basis 
for the activity and selectivity of steroid 
hydroxylation, the substrates were narrowed down 
to six 3-oxo-Δ4 steroids (Table 4) whose 
conversion showed significant differences 
between CYP106A1 and CYP106A2, either in 
product pattern or enzyme activity. Since the main 
product of CYP106A2 was already identified for 
some of these substrates (Table 1), the recognized 
differences in the product pattern produced by 
CYP106A1 suggested hidden potentials in terms 
of novel products. The dissociation constant of 
these steroids and their in vitro and in vivo 
conversion with the resulting product(s) was 
therefore further investigated. 
The binding of the six substrates induced a type 
I shift with both CYP106A enzymes (Table 1).
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Table 1 Overview of the 23 tested steroids concerning their binding and conversion with CYP106A1 and CYP106A2 
Steroid 
In vitro conversion Known product formation by 
CYP106A2 
Induction of high spin shift 
CYP106A1 CYP106A2 CYP106A1 CYP106A2 
Testosterone + + 15βa + + 
17α-methyltestosterone + + n.d. + + 
19-nortestosterone + + n.d. + - 
Ethisterone + + n.d. + + 
Progesterone + + 15βa (11α, 6β, 9α) + + 
17α-hydroxyrogesterone + + 15βa + + 
Androstenedione + + 15βa + + 
11-deoxycorticosterone (DOC) + + 15βa + + 
11-deoxycortisol (RSS) + + n.d + + 
Corticosterone + + 15βa + + 
Cortisol + + n.d. + + 
Cortisone + + n.d. + + 
Prednisolone + + n.d. + + 
Prednisone + + n.d. + + 
Dexamethasone + + n.d. + + 
11β-hydroxyandrostenedione + + n.d. + + 
19-hydroxyandrostenedione - - - + + 
Adrenosterone - - - + + 
β-estradiol - - - - - 
Estrone - - - - - 
Pregnenolone + + 7βb - - 
17α-hydroxypregnenolone + + 7β (7α)b - - 
Dehydroepiandrosterone + + 7β (7α)b + + 
+ / - = positive and negative outcomes of what is stated in the column headers, respectively, n.d  hydroxylation position not determined 
a Berg et al. (1976)      
b Schmitz et al. (2014)      
The equilibrium dissociation constants were 
determined to investigate the binding affinities 
towards both enzymes (Table 3), each of which 
was titrated with increasing concentrations of the 
corresponding substrates. Saturation of binding 
was observed in all cases and the binding constants 
were estimated by hyperbolic regression. In Fig. 
S2, the binding curves of three substrates tested in 
this study (corticosterone, cortisol and cortisone to 
CYP106A1 and CYP106A2) are shown as an 
example. Interestingly, both enzymes bind the six 
steroids with similar affinities, with dissociation 
constants ranging from 50 µM for                              
11-deoxycorticosterone (DOC) to 543 µM for 
cortisol (CYP106A2) and from 68 µM for DOC to 
464 µM for cortisone (CYP106A1). The binding 
affinities of corticosterone, cortisone and cortisol 
showed the highest differences, being 2.5 fold and 
1.7 fold higher for corticosterone and cortisone, 
respectively, with CYP106A1 compared with 
CYP106A2, whereas for cortisol the Kd value was 
0.6 fold lower with CYP106A1 than with 
CYP106A2. The binding affinities are in the 
higher micromolar range with both enzymes, 
except for androstenedione and DOC.  
Table 2 Summary of the in vitro substrate conversion of steroid compounds with the CYP106A subfamily members 
Steroids Conversion with CYP106A1 and  CYP106A2 
3-oxo-Δ4 steroids 
Conversion, similar or same product pattern and activity with exceptions 
    (generally more side-product formation for CYP106A1) 
3-oxo-Δ2,4 steroids Conversion, same product pattern 
3-hydroxy-Δ5 steroids Conversion, same product pattern 
Other steroids No conversion (19-hydroxyandrostenedione, adrenosterone, β-estradiol, estrone) 
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In vitro conversions 
To shed more light on the differences in the 
hydroxylation pattern of both CYP106A 
subfamily members, the in vitro conversion of the 
six chosen steroids was further investigated and 
the main and some minor conversion products 
were identified. In order to compare both enzymes 
with one another and with previously published 
results, the redox system from bovine adrenals, 
known to be an efficient electron supplier for 
bacterial P450s, especially for CYP106A2  (Ewen 
et al., 2012; Virus et al., 2006), was used in this 
work as described elsewhere (Bleif et al., 2012; 
Schmitz et al., 2012). 
Androstenedione was successfully converted 
by both enzymes, but with different velocities. 
Using equal enzyme concentrations, after 30 
minutes CYP106A2 converted nearly 100 % of the 
substrate, producing two main products, B3 and 
B6, as well as several side products (Fig. 1b). In 
contrast, CYP106A1 could reach a maximal 84 % 
total conversion after 60 minutes (Fig. 1a). 
Consequently, the activity of CYP106A1 was 
considered to be lower towards androstenedione, 
though it also formed two main products, A2 and 
A4, besides a few minor metabolites. A2, A4 and 
A6 showed very similar retention times as the 
CYP106A2’s products, B3, B6 and B7 
respectively. The minor products A2 and B3 had 
shorter retention times, thus higher 
hydrophobicity. 
Within 30 minutes, CYP106A1 converted       
41 % of corticosterone into one main product (C5) 
with low amounts of minor product formation 
(C1-C4). No significant increase in conversion 
was observed with longer incubation times       
(Fig. 1c). The conversion with CYP106A2 
resulted in a rather different product pattern. After 
30 minutes, CYP106A2 converted 47 % of the 
substrate mainly to D1 and D2, whose peaks 
increased over time, resulting in 57 % conversion 
within 60 minutes (Fig. 1d). The CYP106A1 main 
and minor products (except for C1) showed 
matching retention times with the CYP106A2 
metabolites. 
The activity of the CYP106A subfamily 
members was considered to be similar towards 
DOC, since they both converted 100 % of the 
substrate within 60 minutes to one main (E4, F5) 
and several minor products (Fig. 1e, f). The main 
product (E4, F5) of both enzymes, as well as the 
minor products (E2, F4), had identical retention 
times. In addition, the minor product ratios 
increased from 30 to 60 minutes of conversion, 
along with the decrease of the main product peak, 
hence these products were thought to be further 
oxidized derivatives of the main product. 
CYP106A2 showed complete conversion of 
11-deoxycortisol (RSS) into one main (H3) and 
four minor products (H1-H5), already within 30 
minutes (Fig. 1h). CYP106A1 showed similar 
activity towards the substrate with lower 
conversion rate and produced a main product (G4) 
with the same retention time as the CYP106A2 
main product (H3) (Fig. 1g). Both enzymes 
showed side product formation of which G1 and 
H2 also had identical retention times. 
After 4 hours CYP106A1 transformed 77 % of 
cortisol, while CYP106A2 converted only 55 %. 
Therefore, the activity of CYP106A2 was 
considered to be lower towards cortisol. 
CYP106A1 produced two main products, I5 
downstream and I6 upstream the substrate peak 
and four side products (I1-I4) (Fig. 1i). 
Interestingly, using CYP106A1 only the ratio of 
I3, I4 and I5 increased, while the amounts of the 
substrate and I6 simultaneously decreased over 
time. According to the used reversed-phase HPLC 
system, I6 was believed to be more hydrophobic 
than the substrate (Fig. 1i). Cortisol conversion 
with CYP106A2 produced somewhat different 
results. After 1 hour, cortisol was converted into 
Table 3 Overview of the substrate binding to CYP106A1 
and CYP106A2 showing the respective Kd values (R2 ≥ 
0.98 in all cases) 
Steroid 
Kd value [µM] 
CYP106A1 CYP106A2 
Androstenedione 77 ± 2a 81 ± 10b 
Corticosterone 471 ± 14c 185 ± 8c 
11-deoxycorticosterone (DOC) 68 ± 2a 50 ± 1c 
11-deoxycortisol (RSS) 161 ± 5a 102 ± 4c 
Cortisol 307 ± 19c 543 ± 31c 
Cortisone 464 ± 8c 260 ± 7c 
a Brill (2013) 
b Schmitz et al. (2014) 
cTested in this work 
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J1 and J3 with low amounts of J2 and J4. The 
amount of J1 and J3 increased throughout the 
substrate conversion, showing again more 
hydrophobic side-product formation (Fig. 1j). The 
CYP106A1 products I2, I5 and I6 showed exactly 
the same retention times as J1, J3 and J4 from 
CYP106A2, suggesting identical structures. 
When studying the conversion of cortisone, 
93% of the substrate was converted by CYP106A2 
within 1 hour, while CYP106A1 showed 
significantly lower activity with 58% conversion 
and reaching only 76% during the 4 hour reaction 
time (Fig. 1k, l). Besides the difference in their 
activities, both subfamily members produced one 
main product (K3 and L3) with the same retention 
time and two-three minor side products. 
Interestingly, the main products, K3 and L3 had 
matching retention times not only with each other, 
but also with I5 and J3 from the cortisol 
conversion (Fig. 1i, j). 
In vivo whole-cell conversions and product 
identification 
Following the comparison of the in vitro activities 
of both enzymes, which revealed some differences 
in the product pattern, we aimed to identify the 
main products via NMR spectroscopy. For this, 
200 µM final concentration of the substrate was 
added to B. megaterium resting cells 
overexpressing the corresponding P450, 24 hours 
after induction. Samples were taken at 1 h, 2 h,       
4 h, 8 h and 24 h to follow the main and side 
product formations over time for the final isolation 
of the main products. Compared with the in vitro 
results, the product pattern slightly differed using 
the whole-cell catalyst (Fig. S3). However, the 
main products remained present in all cases. The 
novel peaks observed in the in vivo system are 
most likely further metabolized intermediate 
products by enzymes naturally present in the strain 
or remaining traces of the cultivation medium. For 
this reason, we decided to purify the 
corresponding main products and some of the 
minor products already identified during the in 
vitro experiments. To avoid confusion, the 
products seen in vitro (Fig. 1) were labelled the 
same fashion as on the in vivo HPLC 
chromatograms (Fig. S3). The structures of all six 
substrates and their identified conversion products 
are summarized in Table 4. 
In vivo, CYP106A1 showed a lower 
conversion rate with androstenedione compared 
with CYP106A2, consistent with the in vitro 
observations. However, both enzymes reached 
100 % substrate consumption after 24 hours (data 
not shown). CYP106A1 showed the same product 
distribution after 4 hours (Fig. S3a) as in vitro 
(Fig. 1a), while CYP106A2 showed a slightly 
altered one (Fig. S3b). The main metabolite of 
androstenedione by CYP106A2 was identified as 
15β-hydroxyandrostenedione (B6), confirming 
the results by Berg et al. (1976). After 8 hours, a 
significant increase in the minor product B3 
formation was observed (Fig. S3b), identified as 
7β, 15β-dihydroxyandrostenedione. Interestingly, 
CYP106A1 did not show 15β-hydroxylase 
activity towards its novel substrate. It produced 
the pharmaceutically promising 6β- and                
7β-hydroxyandrostenedione (A4 and A2 
respectively) as main metabolites, highlighting the 
difference in selectivity between the two 
subfamily members (Fig. S3a).  
CYP106A1 applied in the whole-cell system 
showed 89 % conversion of corticosterone in          
8 hours compared with a maximum 45 % product 
formation in vitro. The product pattern within         
4 hours was similar to the one seen in vitro, 
showing C5 as main product. However, after           
8 hours it shifted towards the minor products (C1-
C4) (Fig. S3c). CYP106A2 converted 56 % of the 
substrate within 8 hours under in vivo conditions, 
comparable to the in vitro conversion. The product 
distribution was similar as seen before, with D1 
and D2 as main products and a small amount of 
D4 formation. An additional product peak was 
also observed downstream D1, having the same 
retention time as C1 (Fig. S3d). The main product 
of CYP106A1 (C5) with matching retention time 
to the minor metabolite of CYP106A2 (D4) were 
both identified as 11-dehydrocorticosterone, 
justifying the assumption of Lee et al. (2014), that 
a dehydrogenation takes place during the 
corticosterone conversion. This is the first case 
where an 11β-hydroxysteroid dehydrogenation is 
observed, an unexampled transformation by the 
CYP106A subfamily. In addition, the main 
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metabolite of CYP106A2 (D1) was characterized 
as the 15β-hydroxylated derivative, matching the 
results of Berg et al. (1976). The minor metabolite 
of CYP106A1 was also successfully characterized 
as 9α-hydroxy-11-dehydrocorticosterone (C2). 
Both CYP106A enzymes showed high activity 
towards DOC, with complete conversion within    
2 hours (Fig. S3e, f) and the same product pattern 
as seen in vitro (Fig. 1e, f). The NMR 
characterization of the CYP106A1 main product 
exposed the 15β-hydroxy derivative (E4) just like 
in the case of CYP106A2 (F5) which was formerly 
identified by Berg et al. (1976). CYP106A1 
showed 6β-hydroxy metabolite formation as well 
(E5), demonstrating again a stronger affinity for 
B-ring oxidations compared to CYP106A2.
 
Fig. 1 HPLC chromatograms of the in vitro conversion of androstenedione (a, b), corticosterone (c, d), 11-deoxycorticosterone 
(e, f), 11-deoxycortisol (g, h), cortisol (i, j) and cortisone (k, l) by CYP106A1 and CYP106A2 respectively. The reaction was 
performed in 50 mM potassium-phosphate buffer containing 20 % glycerol at 30 °C, using 1 µM AdR, 10 µM Adx4-108 and       
0.5 µM CYP106A enzymes.
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Fig. 1 (continued)
The latter also produced a metabolite (F6) with the 
same retention time as the 6β-hydroxy-DOC but in 
significantly minor amounts. The minor 
metabolites, E2 and F4, increased over time, while 
the 15β-hydroxy-DOC decreased, indicating 
further hydroxylation of the main metabolite   
(Fig. S3e, f). These minor products (E2, F4) were 
successfully purified and identified as 7β, 15β-
dihydroxy-DOC. 
In vivo, the CYP106A enzymes displayed 
similarly high activity to RSS, both completing the 
conversion after 4 hours. Within the first hour of 
conversion both enzymes displayed similar 
product distribution as observed in vitro. G4 and 
H3 were identified as main metabolites with the 
same retention time, and their structure was 
elucidated as 15β-hydroxy-RSS (Fig. S3g, h). In 
the case of CYP106A1 additional minor products 
appeared downstream the main product, 
increasing over time, together with the decrease of 
the main metabolite (Fig. S3g, h). From these, G1, 
with identical retention time to H2 produced by 
CYP106A2, was obtained in sufficient purity and 
quantity to be elucidated and turned out to be the 
7β,15β-dihydroxy-RSS (Fig. S3g, h). 
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Table 4 Overview of the 6 studied steroids, including their conversion products by the CYP106A1 and CYP106A2 enzymes. 
(The product distribution is given in % after 4 h of conversion, if not otherwise indicated.) 
CYP106A1 reached 38 % in vivo cortisol 
conversion within 4 hours. After 24 hours, the 
substrate was entirely converted, but the product 
distribution seen in the in vitro study was 
completely altered. The products had the same 
retention times, but the in vivo observed ratios   
Converted steroids 
Identified conversion products 
CYP106A1 CYP106A2 
               
                       (31 %)                                                  (22 %) 
 
  
                    (67 %)                                                (9 %) 
 
     
                       (38 %)                                                    (4 %) 
    
       (16 % in 4h, 26 % in 8h)               (7 % in 4h, 5 % in 8h) 
 
          
                    (28 %)                                                  (9 %) 
 
                                                      (37 %) 
     
                   (66 %)                                                 (21%) 
 
 
        (36 % in 1h, 9 % in 4h)                       (8 % in 1h, 18 % in 4h)      
 
                                 (76 % in 1h,  33 %  in 4h) 
 
 
                                                   (19 %) 
n.d. 
  
                   (14 %)                                                   (6 %) 
 
                                              (40 %) 
*Also identified by Berg et al. (1976) 
n.d. product structure not determined 
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(I5, 4 % and I6, 20 %) were lower (Fig. 1i) 
compared with the in vitro results (I5, 22 % and 
I6, 28 %)  (Fig. 1i). The main product (I6) of this 
newly identified CYP106A1 substrate was 
characterized as 11-dehydrocortisol (cortisone). 
CYP106A2 showed lower activity towards 
cortisol with only 16 % conversion within 4 hours 
and no complete substrate consumption even after 
24 hours. Unlike the product distribution in vitro 
(Fig. 1j), here J1 was present as main product  
(Fig. 3Sj). However, CYP106A2 also produced a 
minor metabolite (J4) with matching retention 
time to 11-dehydrocortisol (I6), which was 
suggested to be the 11-keto compound. 
Regarding cortisone, CYP106A1 converted    
80 % of the substrate, while CYP106A2 
performed complete conversion within 8 hours. 
Both enzymes produced the main metabolite as 
observed in vitro (K3 and L3), whose structure 
was elucidated as 15β-hydroxycortisone            
(Fig. 3Sk, l). In vivo the highest 15β-hydroxy 
product formation was 14 % by CYP106A1 within                
4 hours, while in vitro it reached 56 % (Fig. S3k). 
CYP106A2 produced 40% of the 15β-hydroxy 
metabolite in 4 hours and two previously 
undetected minor metabolites were also observed, 
one showing the same retention time as K4, the 
other downstream L1 (Fig. S3l). A CYP106A1 
product observed only in vivo, downstream K1 
was also purified and characterized as the             
6β-hydroxylated compound. Interestingly, the 
minor products from the previous cortisol 
conversion (I2, I5 for CYP106A1 and J1, J3 for 
CYP106A2, see Fig. S3k, l) showed the exact 
same retention times as the 6β- and                        
15β-hydroxycortisone. This suggests that their 
structures are identical, consequently, that both 
enzymes convert cortisol to cortisone, but the 
resulting 11-oxo steroid is further hydroxylated to 
its 6β- and 15β-hydroxy derivatives. 
Discussion 
The present paper reveals that out of 23 steroids 
studied, 19 were successfully converted by the 
CYP106A subfamily members, with 13 novel 
substrates identified for CYP106A1 and 7 for 
CYP106A2. Thus, CYP106A1, similarly to 
CYP106A2, is a highly active steroid hydroxylase, 
with 19 identified steroid substrates. A focused 
steroid library was used to compare both the 
CYP106A subfamily members, including 14 
steroids formerly tested with CYP106A2 and 9 
additional 3-oxo-steroids, derivatives of 
testosterone, corticosterone and androstenedione 
with distinct functional groups at C11, C17 and 
C19 positions. Difference spectroscopy revealed 
similar binding behaviors for all steroids towards 
both, CYP106A1 and CYP106A2 (Table 1). Out 
of 23 steroids tested, only four, namely                     
β-estradiol, estrone, pregnenolone and                  
17α-hydroxypregnenolone, do not shift the heme 
iron into the high-spin form. Interestingly, all four 
compounds are 3-hydroxy steroids, either having 
an aromatic A-ring or a double bond between C5 
and C6 (Fig. 2). Why the other tested                           
3-hydroxy-Δ5 steroid, DHEA, was able to induce 
a type I shift with both enzymes, is subject of 
further investigations and cannot be explained at 
this point. 
Although not inducing an alteration of              
the spin-state, pregnenolone and                             
17α-hydroxypregnenolone were converted with 
both enzymes, supporting previous observations 
that type I binding is not necessary for conversion 
(Ferrero et al., 2012; Girhard et al., 2010; Schmitz 
et al., 2014; Simgen et al., 2000). Interestingly, the 
similarly functionalized 3-oxo-steroids 
progesterone and 17α-hydroxyprogesterone, 
induced a type I shift and were also converted. It 
is possible that the lacking hydrogen bond 
acceptor in the pregnenolone structure leads to a 
much weaker binding to the heme iron, thus not 
being able to displace the water and shift the 
spectrum. In contrast, estrogens (β-estradiol, 
estrone) are most probably not bound by 
CYP106A1 and CYP106A2, because no type I 
shift and no conversion have been observed for 
either substance. A possible explanation can be the 
lower flexibility of the aromatic A-ring, 
interfering with the binding of the substrate      
(Fig. 2) (Schmitz et al., 2014). 
Although 3-oxo-Δ4-steroids are described as 
suitable substrates of CYP106A2, no              
conversion was observed for either                            
19-hydroxyandrostenedione or adrenosterone. 
These steroids have nearly identical structure to 
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androstenedione (which is converted by both 
CYP106A enzymes) beside the hydroxyl group at 
C19 position and the keto-function at C11 
position, respectively (Fig. 3). This suggests that 
these additional functional groups (perhaps in 
combination with other structural properties 
present on the steroid molecule) are responsible 
for disabling the conversion. 
 
 
Fig. 2 Investigated 3-hydroxy steroids, not inducing any 
spectral shift with either of the CYP106A subfamily 
members, except for dehydroepiandrosterone, showing a type 
I shift and conversion with both enzymes. 
Interestingly, the substrate spectrum was the 
same for both enzymes, although the activities and 
product patterns were not alike in several cases. 
Focusing on the identification of differences 
between the CYP106A enzymes, the 19 substrates 
were narrowed down to those 6, whose conversion 
resulted in different product patterns or changed 
activities (Table 4). As a first step, the dissociation 
constants of these 6 substrates (androstenedione, 
corticosterone, DOC, RSS, cortisol and cortisone) 
were determined. Steroid binding turned out to be 
similar with both CYP106A subfamily members, 
reflected by similar dissociations constants   
(Table 3). Strongest binding with both enzymes is 
observed for androstenedione (77 ± 2 µM with 
CYP106A1 and 81 ± 10 µM with CYP106A2) and 
DOC (68 ± 2 µM and 50 ± 1 µM respectively), 
while the other chosen substrates with a functional 
group either at C11 or C17 show a rather weak 
interaction. Corticosterone and cortisone bind 
stronger to CYP106A2, whereas cortisol binds 
stronger to CYP106A1. However, the differences 
are within one order of magnitude and, therefore, 
relatively small. Unfortunately, the role of the 
CYP106A enzymes in B. megaterium - whose 
knockout is not lethal, but leads to significantly 
reduced growth rates - is a question that remains 
to be solved. Most likely CYP106A enzymes play 
a role in the growth of B. megaterium strains on 
alternative carbon and energy sources such as 
steroids and terpenoids. This assumption is 
supported by the fact that endogenous CYP106A2 
is expressed only in the stationary phase of 
growth, when carbon and energy sources are 
depleted in the medium (Berg and Rafter, 1981). 
To obtain the hydroxylation products in 
sufficient amounts for NMR studies, whole-cell 
biotransformations were performed and the 
product structures elucidated (Table 4). Both 
enzymes favored the 15β-position when using 
C21-steroids such as DOC, RSS and cortisone. 
However, differences were observed with 
corticosterone and androstenedione. In the case of 
corticosterone, the main product was                       
11-dehydrocorticosterone using CYP106A1, 
while for CYP106A2 the main product was 
identified as 15β-hydroxycorticosterone. 
Androstenedione was hydroxylated at position 
15β by CYP106A2 and both at positions 6β and 7β 
with CYP106A1. 
 
Fig. 3 Derivatives of the CYP106A-substrate 
androstenedione, which induce a type I shift but show no 
conversion 
In order to get insight into the differences in 
steroid conversion between the CYP106A 
enzymes, an alignment was performed, where all 
conserved features of P450s were recognized in 
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both enzymes (Fig. 4). Focusing on the substrate 
recognition sites (SRS), previously identified by 
Gotoh (1992), the SRS1 and SRS4-6 regions of 
CYP106A1 showed considerable differences in 
the amino acid pattern from the ones present in 
CYP106A2 (Fig. 4). The different residues in the 
SRS1 region, being responsible for the final 
stabilization of the substrate in the active site and 
in the SRS4-6 regions, involved in the initial 
substrate recognition and binding, could provide 
an explanation for the different regio- and 
stereoselectivity of the isoenzymes. We also 
examined the hΦ-Pro motif in SRS1, where a 
hydrophobic residue precedes the amino acid 
proline before the B´helix, which is usually 
associated with high substrate selectivity or regio- 
and stereospecificity (Pochapsky et al., 2010). In 
CYP106A2, the hydrophobic residue is valine at 
position 82, followed by the proline while in 
CYP106A1 position 82 is occupied by a threonine, 
followed by a serine. This difference might 
contribute to the lower selectivity of CYP106A1. 
In case of androstenedione, for instance, 
CYP106A2 hydroxylates the C-ring at position 
15β preferentially, whereas CYP106A1 attacks at 
the B-ring with less selectivity resulting in 6β- and 
7β-hydroxysteroids as main products. 
Both enzymes hydroxylated the steroids 
mainly at the C- and B-rings. However, in the case 
of steroids with a hydroxyl group at C11, a 
completely different reaction was observed: The 
CYP106A1 enzyme enabled the dehydrogenation 
of cortisol and corticosterone, whereas 
CYP106A2 performed the same reaction only 
with corticosterone, converting these                    
11β-hydroxysteroids into their 11-keto forms 
(Scheme 1). This reaction was not yet described 
for the CYP106A subfamily and was only 
suggested to occur in one other case of P450s 
(Suhara et al., 1986). The mechanism is still 
unidentified and a highly interesting topic for 
further research. Yet, a very similar oxidation 
mechanism was studied by Bellucci et al., where 
the model reaction was the oxidation of an allylic 
alcohol and by Matsunaga et al., where the 
oxidation mechanism of hydroxy-Δ8-
tetrahydrocannabinols was investigated. Both 
studies concluded that the so-called gem-diol 
pathway could be an explanation of the 
mechanism, while as an alternative they proposed 
a combination of the gem-diol and the double 
hydrogen abstraction pathway (Bellucci et al., 
1996; Matsunaga et al., 2001).  
Besides the reaction mechanism, the 
transformation of cortisol to cortisone is also 
notable, since both steroid hormones have 
important roles as pharmaceutical agents 
(Carballeira et al., 2009).  Although, the                
 
Fig. 4 Alignment of the amino acid sequences of CYP106A1 and CYP106A2, showing the SRS regions identified by Gotoh 
(1992). The identical residues in the SRS region are shown in light blue, the different ones shown in red and the residues 
identified as lining the CYP106A2 active site by Janocha (2013) are marked with dark blue. The hΦ-Pro motif is shown with 
a blue frame 
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11-oxidase reaction catalyzed by CYP106A1 has 
shown only 19 % selectivity towards cortisone 
formation, we are confident that following the 
optimization of  the B. megaterium whole-cell 
system, in combination with enzyme engineering 
tools, the selectivity of the enzyme could be 
increased towards an alternative route for this 
reaction. 
In summary, in this work we extended the 
substrate range of the CYP106A subfamily, 
identifying 13 new steroidal substrates for 
CYP106A1 and 7 for CYP106A2. The enzymes 
produced hydroxylated metabolites at positions 
6β, 7β, 9α and 15β and showed furthermore an 
unprecedented 11-oxidase activity. The hydroxyl 
groups introduced selectively in the steroid 
backbone make these derivatives valuable for the 
pharmaceutical industry. Either used as standards 
for human drug metabolites or as drug precursors 
for further functionalization, the production of 
these compounds with the help of the CYP106A 
subfamily has undoubtable advantage over 
chemical approaches. Our results strongly support 
the importance of the CYP106A1 and CYP106A2 
enzymes for the pharmaceutical industry, 
especially for the production of human drug 
metabolites and drug precursors.  
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Fig. S1 UV-visible absorbance spectrum of the reduced and CO-bound form of the purified CYP106A1 (a) and CYP106A2 (c) 
enzyme, showing the characteristic peak at 450nm. UV-visible absorbance spectrum of the purified CYP106A1 (b) and 
CYP106A2 (d), showing the typical peaks at 356,417, 53 and 568 nm. 
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Fig. S2 Type I spectral shifts induced by the binding of corticosterone, cortisol and cortisone binding to CYP106A1 (a, c, e) and 
to CYP106A2 (b, d, f). Increasing amounts of substrates dissolved in DMSO were titrated (10 µM in 50 mM potassium phosphate 
buffer pH 7.4). The peak-to-through absorbance differences were plotted against the increasing concentrations of the substrate. 
The mean values of three independent measurements were fitted by hyperbolic regression. 
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*The peaks labelled with an asterisk represent compounds which were not observed during the in vitro conversions, thus not treated as specific CYP106A enzyme 
products. 
Fig. S3 HPLC chromatograms of the in vivo conversion of androstenedione (a, b), corticosterone (c, d), 11-deoxycorticosterone 
(e, f), 11-deoxycortisol (g, h), cortisol (I, j) and cortisone (k, l) by Bacillus megaterium MS941 strains, containing the plasmid 
pSMF2.1B (CYP106A1) or pSMF2.1C (CYP106A2). The reactions were performed with resting cells in 50 mM potassium 
phosphate buffer pH 7.4 at 30 °C for 24 hours with 200 µM substrate. Samples were collected at the indicated time points.  
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Identification of new substrates for the CYP106A1-mediated 
11-oxidation and investigation of the reaction mechanism 
Flora Marta Kiss1, Yogan Khatri1, Josef Zapp2, Rita Bernhardt1* 
Abstract 
CYP106A1 from Bacillus megaterium DSM319 was recently shown to catalyze steroid and terpene 
hydroxylations. Besides producing hydroxylated steroid metabolites at positions 6β, 7β, 9α and 15β, the 
enzyme displayed previously unknown 11-oxidase activity towards 11β-hydroxysteroids. Novel 
examples for 11-oxidation were identified and confirmed by 1H- and 13C-NMR for prednisolone, 
dexamethasone and 11β-hydroxyandrostenedione. However, only 11β-hydroxyandrostenedione formed 
a single 11-keto product. The latter reaction was chosen to investigate the kinetic solvent isotope effect 
on the steady-state turnover of the CYP106A1-mediated 11-oxidation. Our results reveal a large inverse 
kinetic isotope effect (~0.44) suggesting the involvement of the ferric peroxoanion as a reactive 
intermediate. 
Keywords: CYP106A1, 11β-hydroxysteroid, 11-oxidation, kinetic solvent isotope effect, cytochrome 
P450, ferric peroxoanion 
 
Highlights: 
 Novel substrates identified for the CYP106A1-mediated 11-oxidation 
 Selective 11-oxidation of 11β-hydroxyandrostenedione observed 
 11-oxidation mechanism investigated via kinetic solvent isotope effect 
 Inverse kinetic solvent isotope effect, suggesting the ferric peroxoanion as reactive intermediate 
 
Introduction 
The CYP106A1 enzyme from Bacillus 
megaterium DSM319 was recently isolated and 
characterized by our group (Brill et al. 2014). Its 
closest homologue, CYP106A2 from                        
B. megaterium ATCC13368 has been extensively 
investigated and recognized as a highly potent 
catalyst for both steroid and terpene 
hydroxylations (Bernhardt 2006; Bleif et al. 2011; 
Bleif et al. 2012; Schmitz et al. 2014; 
Zehentgruber et al. 2010). Based on the 63 % 
amino acid sequence identity between the 
subfamily members, the functional 
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subfamily members, the functional 
characterization of CYP106A1 concerning tri-
terpene hydroxylation (Brill et al. 2014), followed 
by the investigation of steroid hormone 
transformation (Kiss et al. 2015; Lee et al. 2014) 
was performed.  
We have demonstrated the 6β, 7β, 9α and 15β 
steroid-hydroxylase activity of CYP106A1, in 
addition to the 11-oxidation of corticosterone and 
cortisol (Kiss et al. 2015). The latter reaction was 
also observed for the human CYP11B1, 
converting cortisol to cortisone (Suhara et al. 
1986); however, the reaction mechanism has never 
been investigated. Since such 11-oxo steroid 
formation is uncommon in P450 catalysis, we 
were interested in studying the underlying 
mechanism by evaluating the kinetic solvent 
isotope effect (KSIE) in the CYP106A1-mediated 
11-oxidation. The effect of hydrogen substitution 
by deuterium on the catalytic activity provides 
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valuable information on proton involvement in the 
P450 catalytic steps. 
The catalytic cycle of a P450 (Fig. 1), based on 
CYP101 (Denisov et al. 2005; Makris et al. 2002), 
starts with the ferric resting state of the enzyme (1) 
(Raag et al. 1991; Raag and Poulos 1989). Upon 
substrate binding, the six-coordinated low-spin 
complex is shifted to the five-coordinated high-
spin state (2) and an electron transfer from an 
associated redox partner takes place (3) (Sligar 
1976; Tsai et al. 1970). On subsequent binding of 
a molecular oxygen, the oxy-ferrous state (4) is 
formed (Champion et al. 1978; Macdonald et al. 
1999), which is then reduced to a ferric 
peroxoanion (5a) leading to the formation of a 
hydroperoxo intermediate (5b), compound 0   
(Cpd 0), on acceptance of a proton (Harris and 
Loew 1996). The availability of a second proton 
causes the release of a water molecule and 
generates compound I (Cpd I) (6) (Groves 2006; 
Rittle and Green 2010). Subsequently, the product 
is released (7) regenerating the ferric heme, thus 
allowing the next catalytic cycle to begin. 
Alternatively, the activated oxygen can be 
released through one of the “uncoupling” 
pathways (shunts, depicted in dashed grey in     
Fig. 1), which can abort the catalytic cycle, being 
unproductive regarding substrate oxidation, yet 
still consuming pyridine nucleotide, 
NADP(H)/NADH.  
In general, standard P450-mediated reactions 
(e.g. hydroxylations) are considered to proceed 
through the classical Cpd I-mediated H-rebound 
mechanism, in which the reaction takes place with 
the help of two consecutive proton uptakes 
(Batabyal et al. 2013; Groves 2006; Liu and Ortiz 
de Montellano 2000; Vidakovic et al. 1998). 
However, the ferric peroxoanion (5a) can also 
intervene in the P450 catalysis, which has recently 
been observed in the CYP17A1-mediated lyase 
reaction (Gregory et al. 2013). 
In this study, we investigated the underlying 
reaction mechanism of the CYP106A1-mediated 
11-oxidation which has recently been described 
using corticosterone and cortisol as substrates 
(Kiss et al. 2015). Both steroid conversions 
displayed several hydroxy-derivatives in addition 
to the 11-keto-product. Therefore, further          
11β-hydroxysteroid analogues were screened to 
obtain a regio-selective C11-oxidation. The 
chosen steroids, prednisolone, dexamethasone and 
11β-hydroxyandrostenedione (11-OH-AD), were 
previously identified as high-spin-shift-inducing 
CYP106A1 substrates, yet, the reactions were not 
investigated in detail and the products were not 
characterized (Kiss et al. 2015). 
 
Fig. 1 – Cytochrome P450 catalytic cycle. The numbers     
(1-7) represent the actual state of the enzyme: 1 – Low-spin 
substrate-free state. 2 – High-spin enzyme-substrate complex. 
3 - High-spin ferrous state. 4 – Oxy-ferrous state. 5a - Ferric 
peroxo intermediate. 5b – Ferric hydroperoxo 
intermediate/compound 0. 6 – High-valent iron-oxo 
state/compound I. 7 - Product oxidation and release. RH and 
ROH illustrate the substrate and the product, respectively. 
The three unproductive shunt-pathways are marked with 
dashed grey arrows and the reduced oxygen products are 
shown as outlets. (The cycle has been adapted from Makris et 
al. (2002) and Denisov et al. (2005).) 
At first, we performed in vitro transformation 
of the substrates, followed by their in vivo turnover 
using a CYP106A1-based B. megaterium whole-
cell system to obtain higher product yields 
required for the structural elucidation by nuclear 
magnetic resonance (NMR). The product 
structures confirmed the 11-oxidation of all 
substrates; however, only the 11-OH-AD 
conversion led to a single 11-keto-product, 
whereas prednisolone and dexamethasone 
displayed several hydroxy-metabolites as well. As 
a result, the regio-selective 11-oxidation of          
11-OH-AD was chosen to study the reaction 
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mechanism employing the KSIE, a proven method 
to distinguish the involvement of P450 reaction 
intermediates Cpd I or the ferric peroxoanion 
during P450 catalysis (Aikens and Sligar 1994; 
Gregory et al. 2013; Khatri et al. 2014; Purdy et al. 
2006; Schowen 1977; Vidakovic et al. 1998; 
Xiang et al. 2000). 
Materials and methods 
Protein expression and purification 
The expression and purification of the CYP106A1 
enzyme was performed as described elsewhere 
(Brill et al. 2014). The truncated bovine 
adrenodoxin (Adx4-108) and the bovine 
adrenodoxin reductase (AdR) were expressed and 
purified as described by Uhlmann et al. (Uhlmann 
et al. 1992) and Sagara et al. (Sagara et al. 1993), 
respectively. 
In vitro conversion and steady state kinetic 
turnover 
Prednisolone, dexamethasone and 11-OH-AD 
were converted with a reconstituted system 
containing the CYP106A1 enzyme, AdR and 
Adx4-108 (in a ratio of 1:2:20), and a NADPH 
regenerating system, as formerly described by 
Kiss et al. (Kiss et al. 2015). The reaction was 
performed at 30 °C, for 60 min using 200 µM 
substrate. The final CYP106A1 concentration was 
2 µM in the case of 11-OH-AD and 5 µM for both 
prednisolone and dexamethasone. 
The steady state kinetic turnover of 11-OH-AD 
was performed in protiated and deuterated solvent 
systems using 2 µM enzyme and 50 µM final 
substrate concentration. To investigate the effect 
of radical scavengers on the catalytic rate, the in 
vitro conversions were performed with the 
addition of ascorbate (20 mM), catalase (20 U) and 
superoxide-dismutase (SOD) (3 U), individually 
as well as in combination. To determine whether 
hydrogen peroxide (H2O2) could be applied to 
reconstitute the activity of CYP106A1, H2O2 and 
cumene hydroperoxide were used in a final 
concentration of 50 µM. The reactions were 
stopped after 20 min and extracted twice by 
addition of 250 μL ethyl acetate. After evaporating 
the organic phases, the dried samples were 
dissolved in methanol and subjected to high-
performance liquid chromatography (HPLC) 
analysis. An ec MN Nucleodor C18 (3 µM, 
4.0x125 mm) column was used, with a mobile 
phase consisting of methanol, tetrahydrofuran and 
water in an 8:19:72 ratio. The steroids were eluted 
in an isocratic mode with a flow rate of                   
0.5 mL/min and detected at 240 nm. The 
conversions were analyzed using the peak areas 
(area %) of the HPLC chromatograms with the 
help of the ChromPass/Galaxie Chromatography 
Data System (Jasco, Gross-Umstadt,Germany). 
In vivo conversion and product purification 
The CYP106A1-based B. megaterium whole-cell 
system (harboring the plasmid pSMF2.1B) was 
used for biotransformation as described earlier 
(Brill et al. 2014; Kiss et al. 2015). The substrate 
was added in a final concentration of 400 µM to 
the B. megaterium resting cells in 100 mM 
potassium phosphate buffer (pH 7.4). The reaction 
was stopped after 24 h and extracted twice with 
ethyl acetate. The samples were dried and 
resuspended in the HPLC mobile phase. The 
product purification was performed with a 
preparative HPLC column (ec MN Nucleodur C18 
VP (5 µM, 8x250 mm) using gradient elution 
(solvent A: 10 % acetonitrile (ACN), solvent B: 
100 % ACN) with a flow rate of 2 mL/min. 
NMR characterization of the metabolites 
The NMR spectra were recorded in CD3OD or in 
CDCl3 with a Bruker DRX 500 or a Bruker 
Avance 500 NMR spectrometer at 300 K. The 
chemical shifts were relative to CH3OD at δ 3.30 
(1H NMR) and CD3OD at δ 49.00 (13C NMR) or 
to CHCl3 at δ 7.26 (1H NMR) and CDCl3 at δ 77.00 
(13C NMR) respectively, using the standard δ 
notation in parts per million. The 1D NMR (1H and 
13C NMR, DEPT135) and the 2D NMR spectra 
(gs-HH-COSY, gs-NOESY, gs-HSQCED, and gs-
HMBC) were recorded using the BRUKER pulse 
program library. All assignments were based on 
extensive NMR spectral evidence. For the detailed 
NMR data of the identified products see 
Supplementary Material.  
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Results and discussion 
Substrate conversions, product purification 
and characterization by NMR  
Since the previously identified substrates for the 
CYP106A1 11-oxidation (corticosterone and 
cortisol) gave rise to multiple product formation 
(Kiss et al. 2015), other 11β-hydroxysteroid 
analogues were investigated to identify a selective 
11-keto product formation. The in vitro 
conversion of the pharmaceutically relevant 
glucocorticoids, prednisolone and 
dexamethasone, also resulted in several products 
(Table 1, Fig. 2B and 3B) in contrast to the 
transformation of 11-OH-AD, where only a single 
product was formed with a yield of 50 %        
(Table 1, Fig. 4B). 
Even though single product formation was only 
observed with 11-OH-AD, we were interested in 
characterizing all 11β-hydroxysteroid metabolites 
by NMR, to identify novel 11-keto products and 
other glucocorticoid derivatives of potential 
pharmaceutical value. For the isolation and 
purification of the reaction products, the steroid 
bioconversions were performed via a CYP106A1-
based B. megaterium whole-cell system.  
The in vivo turnover of prednisolone led to   
~51 % conversion resulting in a main product, P1 
(35 %) with identical retention time (~3.6 min) to 
the one observed in vitro. Besides the major 
product, multiple side-products (<5%) were also 
detected, out of which P2 (~4.8 min) and P3    
(~8.3 min) eluted at the same time as the 
respective in vitro metabolites (Fig. 2 B, C). 
Although both P1 and P2 were well resolved 
during the purification, the NMR analysis of their 
purified fractions showed a mixture of several 
steroids, containing 15β-hydroxyprednisolone as a 
major compound. Likewise, product P3, which 
was identified as a 2:3 mixture of                              
15β-hydroxyprednisone and 1,2-dihydro-15β-
hydroxyprednisone displaying 11-oxidation 
catalyzed by CYP106A1 (Scheme 1). 
 
 
Fig. 2 - HPLC chromatograms of the CYP106A1 
catalyzed prednisolone conversion. (A) Negative control, 
containing prednisolone only. (B) In vitro prednisolone 
conversion, using bovine Adx4-108 (100 µM), bovine AdR (10 
µM) and CYP106A1 (5 µM). (C) In vivo conversion of 
prednisolone using the CYP106A1-overexpressing                   
B. megaterium MS941 strain. 
The unusual 1(2)-double bond hydrogenation 
has not been observed in our previous studies 
(Kiss et al. 2015), hence, it was proposed to be the 
result of an uncharacterized enzyme present in the 
B. megaterium MS941 strain. It has been reported 
that 3-ketosteroid-dehydrogenases present in 
Nocardia, Mycobacterium and Actinobacter sp. 
can be responsible for both 1(2)-hydrogenase and 
reductase reactions (Arinbasarova et al. 1996; 
Goren et al. 1983; van der Geize et al. 2000). 
However, these enzymes have not been described 
so far for B. megaterium. Therefore, the origin of 
Table 1 - In vitro conversion results showing relative conversion and product retention times, when applicable. 
Substrate (RT/min) RC (%) 
Product RT (min) 
Remark 
P1 P2 P3 P4 
Prednisolone (10.5) 33 3.6 4.8 8.4 - Fig. 2B 
Dexamethasone (20.4) 40 5.1 6.9 8.3 15.8 Fig. 3B 
11-OH-AD (13.0) 50 10.5 - - - Fig. 4B 
              *RT, Retention time; RC, Relative conversion 
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the 1(2)-hydrogenase reaction remains unclear. 
The above described prednisolone metabolites 
were previously unidentified, and therefore, no 
biotechnological applications are known to date. 
Nonetheless, the 15β-hydroxyl group attached to 
both prednisolone and prednisone structures 
provides a new reaction site for further 
functionalization, contributing to the development 
of novel glucocorticoids possessing anti-
inflammatory/immunomodulatory activity with a 
potentially reduced risk of side effects. 
Using the CYP106A1-based whole-cell 
system, nearly 50 % of dexamethasone was 
converted in 24 h, yielding four products, P1 to P4, 
which were all successfully isolated and 
characterized. Each of the identified metabolites 
showed identical retention times to the ones 
observed in vitro, eluting at 5.1, 6.9, 8.3 and       
15.8 min, respectively (Fig. 3 B, C). The major 
product, P1 (37 %), and P2 (6 %) were identified 
as 15β-hydroxy- and 6β-hydroxy-derivatives of 
dexamethasone, respectively. The latter one also 
known as the major human metabolite of 
dexamethasone produced by CYP3A4 (Gentile et 
al. 1996; Minagawa et al. 1986; Tomlinson et al. 
1997). Besides the hydroxylated derivatives, two 
minor 11-oxidized compounds were observed and 
characterized as 11-ketodexamethasone (P4, 2 %) 
and 15β-hydroxy-11-ketodexamethasone (P3,       
3 %) (Scheme 2). The 11-keto compound was 
previously identified as a specific glucocorticoid 
receptor agonist, explaining the glucocorticoid 
effect of dexamethasone in tissues expressing the 
11β-hydroxysteroid dehydrogenase type 2 
enzyme, responsible for 11-oxidation in 
mammalian tissues (Rebuffat et al. 2004). 
 
Fig. 3 - HPLC chromatograms of the CYP106A1-
catalyzed dexamethasone conversion. (A) Negative control, 
containing dexamethasone only. (B) In vitro dexamethasone 
conversion, using bovine Adx4-108 (100 µM), bovine AdR (10 
µM) and CYP106A1 (5 µM). (C) In vivo conversion of 
dexamethasone using the CYP106A1-overexpressing             
B. megaterium MS941 strain. 
The in vivo turnover of 11-OH-AD resulted in 
~90 % conversion within 24 h and a single main 
product along with traces of minor side products, 
which were not observed in the in vitro system 
(Fig. 4 C). The major product, P1 (~10.5 min), 
showed identical retention time to that of the in 
vitro reaction (Fig. 4 B). The NMR 
characterization identified P1 as the 11-keto 
derivative, adrenosterone, supporting the 
previously observed 11-oxidase activity of 
CYP106A1 during the transformation of 
corticosterone and cortisol (Kiss et al. 2015) 
(Scheme 3). Adrenosterone is a weak androgen 
hormone found only in trace amounts in 
mammals, but in higher quantities in fish, where it 
 
Scheme 1 – Oxidative transformation of prednisolone catalyzed by CYP106A1. 
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acts as a precursor of 11-ketotestosterone, the 
endogenous androgenic sex hormone (Blasco et al. 
2009; Borg 1994). It is sold as a dietary 
supplement, reducing body fat and increasing 
muscle mass and was also proposed to be a 
selective inhibitor of 11β-hydroxysteroid 
dehydrogenase type I enzyme (Brooker et al. 
2009). 
 
Fig. 4 - HPLC chromatograms of the CYP106A1 
catalyzed 11β-hydroxyandrostenedione conversion. (A) 
Negative control, containing 11-OH-AD only. (B) In vitro 11-
OH-AD conversion, using bovine Adx4-108 (40 µM), bovine 
AdR (4 µM) and CYP106A1 (2 µM). (C) In vivo conversion 
of 11-OH-AD using the CYP106A1-overexpressing                
B. megaterium MS941 strain. 
Steady state kinetic turnover in protiated and 
deuterated solvent systems 
The CYP106A1-mediated conversion of 
prednisolone and dexamethasone resulted in 
multiple products, in contrast to 11-OH-AD, 
where only the 11-keto product formation was 
detected. Thus, the latter reaction was chosen as a 
suitable model for the investigation of KSIE in 
CYP106A1-mediated 11-oxidation. The steady 
state turnover of 11-OH-AD by CYP106A1 was 
investigated with a time-dependent reaction in the 
presence of saturating substrate concentration. To 
study the catalytic activity, an incubation time of 
20 min was chosen, representing the linear phase 
of the reaction (Fig. 5 A). The turnover was 
carried out in a protiated buffer system, in which 
an individual rate of adrenosterone formation of 
0.36 ± 0.04 min-1 was observed. Interestingly, 
upon H2O substitution for D2O, the conversion 
demonstrated a significantly increased catalytic 
rate of 0.81 ± 0.03 min-1, leading to a 2.25-times 
faster product formation upon H/D exchange. 
These rates correspond to an inverse KSIE (kH/kD) 
of 0.44 (Fig. 5 B) suggesting that the 11-oxidation 
reaction is mediated through the unprotonated 
ferric peroxo intermediate, in contrast to 
traditional hydroxylation reactions, which are 
believed to proceed through the classical Groves 
 
Scheme 2 – Oxidative transformation of dexamethasone catalyzed by CYP106A1. 
 
Scheme 3 – 11-oxidation of 11β-hydroxyandrostenedione catalyzed by CYP106A1. 
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rebound mechanism with Cpd I as the reactive 
intermediate (Batabyal et al. 2013; Groves 2006; 
Liu and Ortiz de Montellano 2000; Vidakovic et 
al. 1998). The detected large inverse KSIE could 
be explained by the fact that inhibiting protonation 
of the peroxo-ferric species in deuterated solvents 
facilitates the productive oxidation rather than the 
uncoupling via proton-dependent unproductive 
pathways (peroxide shunt, oxidase shunt). 
Forming the nucleophilic peroxoanion 
intermediate (Fig. 1, (5a)) does not involve any 
protonation event, thus the catalytic activity would 
be expected to be the same in both H2O and D2O 
buffer systems. However, the slower rate of Cpd I 
formation in a deuterated solvent system in 
combination with inhibited unproductive 
pathways could result in the increase of the 
peroxoanion intermediate, along with the product 
formation (Gregory et al. 2013). The latter was 
described for tyrosine hydroxylase (Frantom and 
Fitzpatrick 2003) and putidamonooxin (Twilfer et 
al. 2000), where, as a result of the slower rate of 
uncoupling reactions compared with the 
productive pathway in D2O, a large inverse KSIE 
was observed. Concerning P450 enzymes, the 
involvement of the ferric peroxoanion has only 
been observed for the CYP17-catalyzed C17-C20 
lyase reaction (Gregory et al. 2013), its 
involvement in an oxidase reaction has not been 
demonstrated so far. 
To exclude the role of unproductive pathways 
and the possible H2O2-mediated substrate 
oxidation (reverse peroxide shunt) and to support 
the participation of the ferric peroxo species in the 
CYP106A1-catalyzed 11-oxidation, the in vitro 
conversions were performed with the addition of 
radical scavengers and in the presence of H2O2 or 
cumene hydroperoxide. As scavenging agents 
ascorbate (neutralizing the superoxide radical, 
singlet oxygen and hydroxyl radicals), catalase 
(decomposing hydrogen peroxide to water and 
oxygen) and superoxide dismutase (SOD) 
(scavenger of superoxide anion) were applied, 
individually or in combination. No significant 
decrease in the catalytic rate was observed in 
comparison to the positive control, the 11-OH-AD 
conversion in protiated environment (Fig. 5 C). 
Using H2O2 or cumene hydroperoxide (CHP), no 
product formation was detected. These results 
suggest that the previously observed inverse KSIE 
is not the result of an inhibited uncoupling reaction 
but of the catalysis via a proton-independent 
intermediate. Since steroid 11-dehydrogenation by 
a P450 had never been investigated before, similar 
P450 dependent keto-product formations 
described in the literature have been considered 
for possible parallels. Interestingly, in contrast to 
our observations, the microsomal oxidation of 
cyclohex-2-en-1-ol (Bellucci et al. 1996),                 
the CYP3A11 mediated hydroxy-Δ8-
tetrahydrocannabinol transformation (Matsunaga 
et al. 2001) and the CYP2E1-catalyzed ethanol 
oxidation (Wang et al. 2007) were all proposed to 
proceed through the gem-diol or the combination 
 
Fig. 5 - Investigation of the catalytic rate of 11-oxidation by CYP106A1. (A) Time dependent conversion of 11-OH-AD 
using CYP106A1 (2 µM) and 11-OH-AD (50 µM). (B) Steady-state kinetic solvent isotope effects observed for 11-oxidase 
CYP106A1 catalysis. The numbers inside the bars indicate the catalytic activity, while the error bars represent the standard 
deviation of 5 independent reactions. (C) The effect of radical scavengers on the catalytic rate of 11-OH-AD oxidation. The 
error bars represent the standard deviation of 3 independent measurements.  
*SOD, superoxide-dismutase; RSC, radical scavengers in combination; CHP, cumene hydroperoxide 
 
52 
 
of gem-diol and double hydrogen abstraction 
pathways involving Cpd I (Fig. 1, [6]) as a reactive 
intermediate. However, the observed inverse 
KSIE and the absent role of proton-dependent 
uncoupling pathways in the CYP106A1 catalyzed 
11-oxidation are not reconcilable with a proton-
dependent, Cpd I-mediated mechanism. 
Therefore, we propose that the 11-oxidation 
reaction of 11-OH-AD is mediated by a 
nucleophilic attack of the ferric peroxoanion, as 
illustrated in Scheme 4. To provide additional 
evidence for the involvement of the ferric peroxo 
species, the spectroscopic characterization of the 
reactive intermediate could be a topic of further 
research, as reviewed elsewhere (Krest et al. 2013; 
Luthra et al. 2011; Sligar et al. 2005). 
In conclusion, we present prednisolone, 
dexamethasone and 11-OH-AD as novel 
substrates for the 11-oxidation by CYP106A1. 
The enzyme performed selective 11-oxidation on 
11-OH-AD, resulting in a single 11-keto product, 
while the conversion of prednisolone and 
dexamethasone displayed 6β- and                          
15β-hydroxylated derivatives, as well as the        
11-keto steroids. Since the hydroxy metabolites 
can be developed into functionalized drugs with 
improved properties (e.g.: higher specificity, 
improved pharmacokinetics) (Bernhardt and 
Urlacher 2014), the production of such novel 
derivatives using CYP106A1 is considered a 
promising approach for the pharmaceutical 
industry. In addition, due to the selective 
conversion of 11-OH-AD, the 11-oxidation 
mechanism was also investigated. We observed an 
inverse KSIE (~0.44), suggesting that the             
11-oxidation takes place without the involvement 
of proton uptake, proposing for the first time the 
ferric peroxoanion as a reactive intermediate in a 
P450-mediated oxidation reaction. 
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NMR data of the identified products of: 
Prednisolone: 
 15β-Hydroxyprednisolone 
Its NMR data matched perfectly with those of an 
authentic sample (Schmitz et al., in preparation). 1H 
NMR (CD3OD, 500 MHz): δ 1.06 (m, H-9), 1.11 (s, 
3xH-18), 1.16 (m, H-7a), 1.52 (s, 3xH-19), 1.57 (dd, 
13.8 and 3.3 Hz, H-12a), 1.61 (dd, 11.2 and 6.0 Hz, 
H-14), 1.98 (dd, 15.5 and 7.5 Hz, H-16a), 1.99 (m, 
H-12b), 2.39 (m, H-6a), 2.44 (m, H-7b), 2.52 (m, H-
8), 2.68 (tdd, 13.5, 5.0 and 2.0 Hz, H-6b), 2.73 (dd, 
15.5 and 2.3 Hz, H-16b), 4.24 (d, 19.2 Hz, H-21a), 
4.31 (ddd, 7.5,  6.0 and 2.3 Hz, H-15), 4.39 (q, 3.3 
Hz, H-11), 4.62 (d, 19.2 Hz, H-21b), 6.01 (t, 2.0 Hz, 
H-4), 6.22 (dd, 10.0 and 2.0 Hz, H-2), 7.48 (d, 10.0 
Hz, H-1). 
 
 15β-Hydroxyprednisone 
The NMR spectra of this prednisolone product 
revealed a carbonyl, instead of an alcohol function at 
C-11 (δC 208.01). A further hydroxyl group at 
position 15β could be deduced from the results of the 
2D NMR measurements. 1H NMR (CDCl3, 500 
MHz): δ 0.97 (s, 3xH-18), 1.35 (m, H-7a), 1.48 (s, 
3xH-19), 1.74 (m, H-8), 2.04 (m, H-9), 2.09 (d, 11.7 
Hz, H-12a), 2.29 (dd, 11.6 and 6.0 Hz, H-14), 2.35 
(dd, 15.5 and 7.5 Hz, H-16a), 2.39 (m, H-7b), 2.40 
(m, H-6a), 2.58 (tdd, 13.5, 5.0 and 1.7 Hz, H-6b), 
2.75 (dd, 15.5 and 2.3 Hz, H-16b), 2.80 (d, 11.7 Hz, 
H-12b), 4.29 (d, 20.0 Hz, H-21a), 4.56 (ddd, 7.5,  6.0 
and 2.3 Hz, H-15), 4.66 (d, 20.0 Hz, H-21b), 6.15 (t, 
2.0 Hz, H-4), 6.22 (dd, 12.0 and 2.0 Hz, H-2), 7.68 
(d, 10.2 Hz, H-1). 13C NMR (CDCl3, 125 MHz): δ 
18.40 (CH3, C-18), 18.83 (CH3, C-19), 24.73 (CH, 
C-8), 32.15 (CH2, C-6), 32.80 (CH2, C-7), 42.41 (C, 
C-10), 47.07 (CH, C-16), 50.05 (CH2, C-12), 51.35 
(C, C-13), 53.33 (CH, C-14), 60.90 (CH, C-9), 67.44 
(CH2, C-21), 69.10 (CH, C-15), 87.36 (C, C-17), 
124.74 (CH, C-4), 127.75 (CH, C-2), 154.98 (CH, C-
1), 166.19 (C, C-5), 186.29 (C, C-3), 208.01 (C, C-
11), 210.94 (C, C-20). 
 
 1,2-Dihydro-15β-hydroxyprednisone 
Its 1H NMR spectrum showed some remarkable 
differences to that of the substrate, prednisolone. The 
resonances for the double bond between C-1 and C-
2, as well as for the hydroxyl group at C-11 were 
absent. Signals of four additional methylene protons 
appeared in the spectrum and the doublet resonances 
of H-12a and H-12b showed an α-carbonyl induced 
downfield shift. These observations led to the 
structure of 1,2-dihydro-15β-hydroxyprednisone. 1H 
NMR (CD3OD, 500 MHz): δ  0.84 (s, 3xH-18), 1.34 
(m, H-7a), 1.47 (s, 3xH-19), 1.70 (m, H-1a), 1.99 (d, 
12.0 Hz, H-12a), 2.15 (m, H-9), 2.21 (dd, 15.5 and 
7.5 Hz, H-16a), 2.24 (m, H-2a), 2.31 (m, H-7b), 2.33 
(m, 2H, H-8 and H-14), 2.52 (m, H-2b), 2.55 (m, 2H, 
H-6a and H-6b), 2.72 (m, H-1b), 2.75 (dd, 15.5 and 
2.3 Hz, H-16b), 2.96 (d, 12.0 Hz, H-12b), 4.20 (d, 
19.5 Hz, H-21a), 4.42 (ddd, 7.5,  5.7 and 2.2 Hz, H-
15), 4.60 (d, 19.5 Hz, H-21b), 5.72 (br s, H-4).  
 
Dexamethasone: 
 15β-Hydroxydexamethasone 
Compared to the substrate, dexamethasone, the 
NMR data of the conversion product showed 
resonances for an additional hydroxyl group (δC 
78.60; δH 3.67 dd). Its position at C-15 could be 
deduced by vicinal couplings of the methine proton 
with H-14 (δH 2.08 dd, 12.0 and 6.3 Hz,) and H-16 
(δH 3.02 qd, 7.5 and 3.0 Hz). The β orientation of the 
hydroxyl was confirmed by the NOESY effects of H-
15 to H-16 and H-14, all in a-position. 1H NMR 
(CD3OD, 500 MHz): δ 0.93 (d, 7.5 Hz, 3H, Me-16), 
1.17 (s, 3xH-18), 1.43 (dd, 13.7 and 2.5 Hz, H-12a), 
1.57 (m, H-7a), 1.60 (s, 3xH-19), 2.08 (dd, 12.0 and 
6.3 Hz, H-14), 2.20 (m, H-7b), 2.29 (m, H-12b), 2.40 
(tdd, 14.0, 5.0 and 2.0 Hz, H-6a), 2.73 (m, H-6b), 
2.80 (dtd, 29.5, 12.0 and 4.5 Hz, H-8), 3.02 (qd, 7.5 
and 3.0 Hz, H-16), 3.67 (dd, 6.3 and 3.0 Hz, H-15), 
4.22 (d, 19.2 Hz, H-21a), 4.25 (m, H-11), 4.60 (d, 
19.2 Hz, H-21b), 6.09 (t, 2.0 Hz, H-4), 6.28 (dd, 10.0 
and 2.0 Hz, H-2), 7.41 (d, 10.0 Hz, H-1). 13C NMR 
(CD3OD, 125 MHz): δ 13.12 (CH3, Me-16), 20.21 
(CH3, C-18), 23.67 (d, JCF=6.0 Hz, CH3, C-19), 
27.66 (CH2, C-7), 32.15 (CH2, C-6), 32.27 (d, 
JCF=19.3 Hz, CH, C-8), 38.12 (CH2, C-12), 48.92 (C, 
C-13), 48.95 (CH, C-14), 49.47 (CH, C-16), 50.41 
(d, JCF=22.5 Hz, C, C-10), 67.89 (CH2, C-21), 72.83 
(d, JCF=37.5 Hz, CH, C-11), 78.60 (CH, C-15), 92.01 
(C, C-17), 103.02 (d, JCF=176.0 Hz, C, C-9), 125.09 
(CH, C-4), 129.81 (CH, C-2), 155.96 (CH, C-1), 
171.16 (C, C-5), 189.07 (C, C-3), 211.95 (C, C-20). 
 
 6β-Hydroxydexamethasone 
Selected 1H NMR data of this compound were 
published by Matsuzaki et al. [1]. Our 1H NMR 
results matched these data. 2D NMR measurements 
led to the full assignments of the 1H and 13C NMR 
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spectra. 1H NMR (CD3OD, 500 MHz): δ 0.89 (d, 7.5 
Hz, 3H, Me-16), 1.04 (s, 3xH-18), 1.22 (ddd, 12.0, 
8.0 and 4.0 Hz, H-15d), 1.48 (dd, 13.8 and 2.0 Hz, 
H-12a), 1.76 (m, H-7a), 1.77 (s, 3xH-19), 1.78 (m, 
H-15b), 1.92 (ddd, 14.5, 4.5 and 2.3 Hz, H-7b), 2.23 
(dd, 12.0 and 8.0, H-14), 2.30 (dt, 13.8 and 3.3 Hz, 
H-12b), 2.69 (dtd, 29.5, 12.0 and 4.5 Hz, H-8), 3.09 
(dqd, 11.3, 7.5 and 4.0 Hz, H-16), 4.25 (d, 19.2 Hz, 
H-21a), 4.29 (m, H-11), 4.44 (dd, 3.8 and 2.2 Hz, H-
6), 4.59 (d, 19.2 Hz, H-21b), 6.16 (t, 2.0 Hz, H-4), 
6.26 (dd, 10.0 and 2.0 Hz, H-2), 7.37 (d, 10.0 Hz, H-
1). 13C NMR (CD3OD, 125 MHz): δ 15.34 (CH3, 
Me-16), 17.44 (CH3, C-18), 25.12 (d, JCF=5.5 Hz, 
CH3, C-19), 31.86 (d, JCF=20.0 Hz, CH, C-8), 33.54 
(CH2, C-15), 36.01 (CH2, C-7), 37.05 (CH, C-16), 
37.62 (CH2, C-12), 45.07 (CH, C-14), 49.46 (C, C-
13), 50.33 (d, JCF=22.7 Hz, C, C-10), 68.08 (CH2, C-
21), 72.80 (d, JCF=38.3 Hz, CH, C-11), 73.07 (CH, 
C-6), 92.09 (C, C-17), 102.42 (d, JCF=172.5 Hz, C, 
C-9), 127.39 (CH, C-4), 128.95 (CH, C-2), 157.27 
(CH, C-1), 167.85 (C, C-5), 189.38 (C, C-3), 212.69 
(C, C-20). 
 
 11-Ketodexamethasone 
Due to the low amount of obtained product, only 1H 
NMR and HHCOSY could have been measured for 
this sample. These revealed a C11-keto function as 
the only structural difference from the substrate. 1H 
NMR (CD3OD, 500 MHz): δ 0.74 (s, 3xH-18), 0.91 
(d, 7.5 Hz, 3H, Me-16), 1.30 (m, H-15a), 1.55 (s, 
3xH-19), 1.61 (m, H-7a), 1.78 (q, 12.0 Hz, H-15b), 
1.89 (m, H-7b), 2.08 (dd, 11.7 and 1.5 Hz, H-12a), 
2.73 (m, H-14), 3.09 (m, H-16), 2.45 (m, 2H, H-6a 
and  H-8), 2.70 (m, H-6b), 3.35 (dd, 11.7 and 6.5 Hz, 
H-12b), 4.22 (d, 19.5 Hz, H-21a), 4.55 (d, 19.5 Hz, 
H-21b), 6.15 (t, 2.0 Hz, H-4), 6.23 (dd, 10.3 and 2.0 
Hz, H-2), 7.50 (d, 10.3 Hz, H-1). 
 
 15β-Hydroxy-11-ketodexamethasone 
In contrast to dexamethasone, the NMR data of this 
conversion product missed resonances for the 
hydroxyl group at C-11. However, a supplemental 
carbonyl resonance appeared as a doublet at δC 
206.81 exhibiting a JCF = 27.5 Hz coupling with the 
fluorine atom at C-9. In addition, a hydroxyl group 
at 15β-position could be deduced from the 
comparison of its NMR data with those of 15β-
hydroxydexamethasone and by means of 2D NMR. 
1H NMR (CD3OD, 500 MHz): δ 0.91 (s, 3xH-18), 
0.98 (d, 7.5 Hz, 3H, Me-16), 1.58 (s, 3xH-19), 1.66 
(m, H-7a), 2.04 (dd, 11.7 and 1.5 Hz, H-12a), 2.22 
(m, H-7b), 2.47 (ddd, 14.2, 4.5 and 2.3 Hz, H-6a), 
2.63 (m, H-14), 2.67 (m, H-8), 2.72 (m, H-6b), 3.03 
(qd, 7.5 and 3.0 Hz, H-16), 3.37 (dd, 11.7 and 6.5 Hz, 
H-12b), 3.74 (dd, 6.3 and 3.0 Hz, H-15), 4.21 (d, 19.2 
Hz, H-21a), 4.57 (d, 19.2 Hz, H-21b), 6.16 (t, 2.0 Hz, 
H-4), 6.24 (dd, 10.3 and 2.0 Hz, H-2), 7.52 (d, 10.3 
Hz, H-1).  13C NMR (CD3OD, 125 MHz): δ 13.08 
(CH3, Me-16), 18.30 (CH3, C-18), 22.07 (d, JCF=5.5 
Hz, CH3, C-19), 26.90 (CH2, C-7), 32.38 (CH2, C-6), 
36.73 (d, JCF=21.0 Hz, CH, C-8), 48.34 (CH, C-14), 
48.69 (CH2, C-12), 49.27 (d, JCF=23.0 Hz, C, C-10), 
51.27 (CH, C-16), 52.52 (C, C-13), 68.16 (CH2, C-
21), 77.07 (CH, C-15), 91.04 (C, C-17), 101.59 (d, 
JCF=186.5 Hz, C, C-9), 126.62 (CH, C-4), 129.89 
(CH, C-2), 154.63 (CH, C-1), 167.88 (C, C-5), 
188.42 (C, C-3), 206.81 (d, JCF=27.5 Hz, C, C-11), 
211.70 (C, C-20). 
11β-hydroxyandrostenedione: 
 Adrenosterone                                               
(Androst-4-ene-3,11,17-trione) 
Its 13C NMR data matched those in literature [2, 3]. 
1H NMR (CDCl3, 500 MHz): δ 0.88 (s, 3xH-18), 
1.31 (m, H-7a), 1.49 (s, 3xH-19), 1.65 (m, H-1a), 
1.70 (td, 12.5 and 9.3 Hz, H-15a), 1.90 (ddd, 12.5, 
11.0 and 6.0 Hz, H-14), 1.92 (d, 11.0 Hz, H-9), 2.07 
(m, H-8), 2.11 (m, H-7b), 2.14 (m, H-15b), 2.28 (dt, 
19.5 and 9.2 Hz, H-16a), 2.32 (m, H-2a), 2.33 (m, H-
12a), 2.35 (m, H-6a), 2.46 (m, H-6b), 2.47 (m, H-2b), 
2.50 (d, 13.0 Hz, H-12b), 2.58 (ddd, 19.5, 9.2 and 1.3 
Hz, H-16b), 2.77 (ddd, 13.5, 5.0 and 3.2 Hz, H-1b), 
5.75 (s, H-4). 13C NMR (CDCl3, 125 MHz): δ 14.65 
(CH3, C-18), 17.30 (CH3, C-19), 21.56 (CH2, C-15), 
30.92 (CH2, C-7), 31.97 (CH2, C-6), 33.68 (CH2, C-
2), 34.71 (CH2, C-1), 35.93 (CH2, C-16), 36.80 (CH, 
C-8), 38.30 (C, C-10), 49.83 (CH, C-14), 50.36 (C, 
C-13), 50.40 (CH2, C-12), 63.34 (CH, C-9), 124.82 
(CH, C-4), 167.80 (C, C-5), 199.50 (C, C-3), 207.49 
(C, C-11), 216.77 (C, C-17). 
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Process development for the production of                                        
15β-hydroxycyproterone acetate using Bacillus megaterium 
expressing CYP106A2 as whole-cell biocatalyst 
Flora M Kiss1,†, Marie T Lundemo3,†, Josef Zapp2, John M Woodley3, Rita Bernhardt1* 
Abstract 
Background: CYP106A2 from Bacillus megaterium ATCC 13368 was first identified as a regio- and 
stereoselective 15β-hydroxylase of 3-oxo-Δ4-steroids. Recently, it was shown that besides                              
3-oxo-Δ4-steroids, 3-hydroxy-Δ5-steroids as well as di- and triterpenes can also serve as substrates for 
this biocatalyst. It is highly selective towards the 15β position, but the 6β, 7α/β, 9α, 11α and 15α positions 
have also been described as targets for hydroxylation. Based on the broad substrate spectrum and 
hydroxylating capacity, it is an excellent candidate for the production of human drug metabolites and 
drug precursors. 
Results: In this work, we demonstrate the conversion of a synthetic testosterone derivative, cyproterone 
acetate, by CYP106A2 under in vitro and in vivo conditions. Using a Bacillus megaterium whole-cell 
system overexpressing CYP106A2, sufficient amounts of product for structure elucidation by nuclear 
magnetic resonance spectroscopy were obtained. The product was characterized as                                       
15β-hydroxycyproterone acetate, the main human metabolite. Since the product is of pharmaceutical 
interest, our aim was to intensify the process by increasing the substrate concentration and to scale-up the 
reaction from shake flasks to bioreactors to demonstrate an efficient, yet green and cost-effective 
production. Using a bench-top bioreactor and the recombinant Bacillus megaterium system, both a 
fermentation and a transformation process were successfully implemented. To improve the yield and 
product titers for future industrial application, the main bottlenecks of the reaction were addressed. Using 
2-hydroxypropyl-β-cyclodextrin, an effective bioconversion of 98 % was achieved using 1 mM substrate 
concentration, corresponding to a product formation of 0.43 g/L, at a 400 mL scale. 
Conclusions: Here we describe the successful scale-up of cyproterone acetate conversion from shake 
flasks to bioreactors, using the CYP106A2 enzyme in a whole-cell system. The substrate was converted 
to its main human metabolite, 15β-hydroxycyproterone acetate, a highly interesting drug candidate, due 
to its retained antiandrogen activity but significantly lower progestogen properties than the mother 
compound. Optimization of the process led to an improvement from 55 % to 98 % overall conversion, 
with a product formation of 0.43 g/L, approaching industrial process requirements and a future large-
scale application. 
Keywords: Cytochrome P450, CYP106A2, Bacillus megaterium, Whole-cell biocatalyst, Steroid 
hydroxylase, Cyproterone acetate, Bioreactor, Cyclodextrin 
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Background 
Cytochrome P450 monooxygenases (P450s) are 
hemeproteins that catalyze the oxidation of a wide 
variety of substrates, from endogenous 
compounds, such as steroids, vitamins and fatty 
acids, to xenobiotics and drugs. They have 
attracted interest in research due to their unique 
ability to activate molecular oxygen, introducing 
one atom into the substrate and reducing the 
second one to water [1]. The fact that they are able 
to introduce an oxygen atom into non-activated 
hydrocarbons without extreme conditions, in 
combination with their high regio- and 
stereoselectivity on complex molecules, makes 
their application particularly interesting to the 
pharmaceutical industry. P450s represent a 
suitable alternative over chemical synthesis, 
especially in the hydroxylation of steroidal 
pharmaceuticals, where the chemical methods are 
either time- and labor-intensive, expensive and 
complex or non-existent [2]. Steroid-based drugs 
are one of the largest groups of marketed 
pharmaceuticals [3]. There are about 300 
approved steroid drugs to date and their number is 
constantly growing due to the production of 
diversely functionalized steroid cores, resulting in 
often altered therapeutic activity [4]. Thus, 
steroid-hydroxylating P450s could provide an 
alternative for the production of drug precursors 
and human drug metabolites. 
The bacterial P450, CYP106A2 from Bacillus 
megaterium (B. megaterium) ATCC 13368, is one 
of the few cloned bacterial steroid hydroxylases 
that has been studied in detail and was announced 
to be a suitable biocatalyst for the production of 
hydroxysteroids [5]. CYP106A2, also known as 
15β-hydroxylase, converts mainly                               
3-oxo-Δ4-steroids [6-8] although recent studies 
have shown that it can perform di- and triterpenoid 
hydroxylation [9-11] and the conversion of            
3-hydroxy-Δ5-steroids [12]. Moreover, as a result 
of on-going screening of a natural substrate 
library, the substrate range of this enzyme is 
constantly extended. However, the native 
substrate of CYP106A2, and thus its biological 
function, is still unknown. Its natural electron 
transfer protein is also unknown, yet the activity 
was successfully demonstrated using megaredoxin 
and megaredoxin reductase [7] and it is also 
supported by the bovine adrenal redox partners as 
well as by putidaredoxin and putidaredoxin 
reductase [5,13,14].  
In the past two decades CYP106A2 was 
profoundly investigated as a biocatalyst, applying 
the enzyme in whole-cell systems, efficiently 
using both Escherichia coli (E. coli) [5,13] and          
B. megaterium as expression hosts [9-12]. Whole-
cell systems, in which the P450 is expressed by a 
microbial host, have the advantage of stabilizing 
the enzyme under process conditions and 
providing cofactor regeneration through cellular 
metabolism, avoiding the need for the expensive 
NADPH supply. 
Since the transport of hydrophobic substances 
across the outer membrane of E. coli was found to 
be limiting [5], the attention was shifted to the 
gram-positive B. megaterium as host. This spore-
forming, mainly aerobic bacterium became a long-
term participant of the biotechnological industry, 
due to the fact that even the wild-type strains are 
capable of producing high titers of proteins of 
industrial interest [15,16]. Further attractive 
characteristics include the ability to grow on a 
variety of carbon sources, the GRAS status, high 
plasmid stability and the lack of endotoxin and 
extracellular protease production. These 
characteristics make this organism highly favored 
for industrial practice [17]. 
The endogenous CYP106A2 system in              
B. megaterium ATCC 13368 was used for in vivo 
transformation of the diterpene abietic acid 
producing 12β-hydroxyabietic acid and              
12α- hydroxyabietic acid [10]. As a next step, the 
CYP106A2 gene was overexpressed in 
combination with bovine adrenal redox partners in 
B. megaterium MS941 for the hydroxylation of 
11-keto-β-boswellic acid in the 15α position [9]. 
Another triterpenoid, dipterocarpol, was also 
hydroxylated by CYP106A2 in B. megaterium 
ATCC 13368 resulting in six products at a 1 L 
scale [11]. Recently reported, the regioselective 
hydroxylation of the 3-hydroxy-Δ5 steroid 
dehydroepiandrosterone (DHEA) was achieved by 
CYP106A2 expressed in the natural host                 
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B. megaterium ATCC 13368 and the recombinant 
B. megaterium MS941 [12]. 
In the present work, the conversion of a 
synthetic testosterone derivative, cyproterone 
acetate (CPA, 6-Chloro-1β,2β-dihydro-17-
hydroxy-3’H-cyclopropa(1,2)-pregna-1,4,6-
triene-3,20-dione acetate), was performed using a 
recombinant B. megaterium MS941 system 
overexpressing the CYP106A2 enzyme. The 
synthetic antiandrogen, CPA, was converted to 
15β-hydroxy cyproterone acetate (15β-OH-CPA, 
15β-hydroxy-6-Chloro-1β,2β-dihydro-17-
hydroxy-3′H-cyclopropa(1,2)-pregna-1,4,6-
triene-3,20-dione acetate) (Scheme 1). CPA is a 
synthetic derivative of 17α-hydroxyprogesterone, 
an anti-androgenic compound with additional 
progestogen and antigonadotropic properties 
[18,19]. It has antagonistic properties towards the 
androgen receptor, although it can also act as its 
partial agonist. It is generally used as a treatment 
for metastatic prostate cancer and for the control 
of libido in severe hypersexuality and/or sexual 
deviation in males, but it is also applied for the 
treatment of hirsutism and acne in female patients 
and in oral contraceptive pills. The main human 
metabolite of CPA in both plasma and urine is the 
15β-OH-CPA. It shows only 10 % of the 
progestogenic potency of CPA but retains the anti-
androgen activity [19]. These characteristics 
imply that the metabolite is potentially a better 
option for the treatment of androgen-induced 
problems, particularly in male patients.In 1982, 
the B. megaterium ATCC 13368 strain was 
already proposed for the bioconversion of          
1α,2α-methylene steroids into their 15β-hydroxy 
derivatives, in order to produce new anti-
androgenic steroids with minor progestogen 
activity [20]. According to our latest information, 
1 mg 15β-hydroxy metabolite costs 300 $, while 
250 mg of the original compound costs                  
199 $ (Santa Cruz Biotechnology, 
http://www.scbt.com/, 2014). Although we lack 
detailed information about the production, the 
price difference suggests an expensive procedure.  
In the present work we perform process 
development of the CPA bioconversion in shake 
flasks and lab-scale bioreactors, thus providing an 
improved model for a greener yet cost-effective 
large-scale production of the 15β-hydroxy 
metabolite. The reaction was successfully carried 
out at 400 mL scale, although to further improve 
the conversion rate the bottlenecks of the system 
were identified. Working with P450s applied in 
whole-cell systems, the following difficulties have 
already been recognized [1,21]: 
• NADP(H) depletion 
• low substrate and product solubility 
• 
problematic uptake of the substrate and efflux of 
the product 
• substrate or product inhibition/toxicity. 
To find the bottleneck of our system, we 
addressed each point separately. The cofactor 
limitation was investigated by adding NADPH in 
excess. Issues with solubility, toxicity or 
inhibition, related to substrate or product were 
investigated. Subsequently, substrate feeding 
strategies were evaluated in an attempt to 
overcome these effects. Moreover, the proposed 
transport restriction was addressed by using 
different membrane permeabilization methods 
(freeze-thawing, ultrasonication, acetone 
treatment). 2-hydroxypropyl-β-cyclodextrin        
(HP-β-CD) was also applied to improve the 
process performance since it was previously 
 
Scheme 1 Cyproterone acetate conversion to its main human metabolite 15β-hydroxycyproterone acetate by 
CYP106A2. 
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described to be successful as a solubilizing agent 
and was used for improved substrate transport 
across the cell membrane. By identifying the 
limitations of the system, the aim was to be able to 
improve the economic performance of the process 
by increasing the reaction yield at higher substrate 
concentrations. 
Results 
Purification and spectral characterization of 
CYP106A2 
The CYP106A2 protein was expressed and 
purified using a recombinant E. coli C43 (DE3) 
strain. The UV–vis absorbance spectra recorded 
from 250 to 700 nm showed the characteristic 
absorbance peaks at 356, 417, 534 and 567 nm in 
the oxidized form. In the case of the reduced and 
carbon monoxide-bound form, the peak at 450 nm 
was observed, with no peak indicating inactive 
P450 at 420 nm. 
In vitro conversion, reaction kinetics and 
inhibition studies 
Using difference spectroscopy, the binding of 
CPA to CYP106A2’s active site was studied in 
vitro. CPA did not induce any spectral shift, 
indicating that the steroid does not contribute to 
the replacement of the axial water molecule, 
hindering the determination of the dissociation 
constant. The catalytic activity of CYP106A2 
towards CPA was first tested in vitro. The activity 
was reconstituted using bovine adrenal redox 
partners (Adx4–108 and AdR) proven to be highly 
efficient electron suppliers for CYP106A2 
[14,22]. The CYP106A2-dependent conversion of 
CPA was analyzed by high-performance liquid 
chromatography (HPLC) and resulted in one main 
product. Using 0.5 μM CYP106A2 and 400 μM 
substrate, the conversion reached 48.2 ± 2.8 % in 
60 minutes (Figure 1). 
The in vitro conversions were also performed 
with increasing substrate concentrations (50 μM-
1.2 mM) to study the potential inhibitory effect of 
the substrate. Using 200 μM or higher substrate 
concentrations, the product concentration never 
exceeded 200 μM. These results suggest that the 
enzyme is inhibited above a certain product 
concentration, regardless of the amount of 
substrate, since the reaction stops after 150 to 200 
μM product was formed (Figure 2). 
 
Figure 1 HPLC chromatogram of the in vitro conversion 
of cyproterone acetate by CYP106A2. The reaction was 
performed in 50 mM potassium phosphate buffer containing 
20 % glycerol (pH 7.4) at 30 °C, using 0.5 μM CYP106A2, 
10 μM Adx4–108 and 1 μM AdR. The reaction was stopped and 
extracted twice by ethyl acetate directly after the addition of 
the substrate (grey dotted line, 0 h) and after 1 h (black line, 
1 h). Cyproterone acetate (400 μM) was converted to one 
main product (P1). 
 
Figure 2 In vitro conversion of cyproterone acetate using 
increasing substrate concentrations. The reaction was 
performed using substrate concentrations, in a range of 50 μM 
to 1.2 mM for 60 min. Each bar represents the mean value of 
three independent measurements, with the corresponding 
standard deviation indicated by the error bars. 
As a next step, the Michaelis-Menten 
parameters for the CYP106A2-dependent CPA 
conversion were determined. The catalytic activity 
of the CPA conversion showed a Vmax of           
61.65 ± 2.56 nmol product per nmol CYP106A2 
per minute and a Km of 103.14 ± 11.99 μM (Figure 
3). 
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Figure 3 Determination of the kinetic parameters for the 
cyproterone acetate conversion catalyzed by CYP106A2. 
The reaction kinetics were performed in 50 mM potassium 
phosphate buffer containing 20 % glycerol (pH 7.4) at 30 °C 
for 2 min using 0.5 μM CYP106A2, 10 μM Adx4–108 and           
1 μM AdR. Cyproterone acetate was used in a concentration 
range of 0 to 400 μM. The data shown are the result of four 
independent measurements (R2>0.98). 
To investigate potential product inhibition, in 
vitro product inhibition experiments were 
performed using a fixed amount of substrate with 
increasing initial product concentrations (purified 
by preparative HPLC). The results confirmed the 
assumption that the product used in 200 μM or 
higher concentrations strongly inhibits the 
reaction. Using 200 μM 15β-OH-CPA, we could 
observe only a 25 ± 1.9 % conversion, which was 
roughly half of the product formation that was 
observed in the control sample (47 ± 4.3 %) 
containing only the substrate (400 μM). When 
increasing the product concentration to 1200 μM 
the conversion drastically decreased to 5 ± 0.12 %, 
one tenth of the control conversion (Figure 4). 
In vivo conversion, product localization and 
catalyst reusability 
Following the successful conversion of CPA by 
the CYP106A2-overexpressing B. megaterium 
strain (Figure 5), the product of the reaction was 
purified on preparative HPLC and its structure was 
identified by nuclear magnetic resonance (NMR) 
spectroscopy. The resulting main product (P1), 
15β-OH-CPA, was used in the above-mentioned 
in vitro as well as in the in vivo product inhibition 
studies. The whole-cell catalyst was further 
characterized by examining the substrate and 
product localization. Both substrate and product 
were shown to be attached to the cell pellet 
fraction (data not shown). Adding more cells after 
4 h of conversion did not improve the reaction 
yield, most likely since all remaining substrate 
was already inside or attached to the original cells 
(Figure 6). However, the addition of 3 times more 
cells (150 g/L wet cell weight (WCW)) and 2 
times more substrate (1 mM) only doubled the 
product concentration thereby giving a lower 
biocatalyst yield. 
 
Figure 4 In vitro conversion of cyproterone acetate using 
increasing initial product concentrations. The reactions 
were performed using 400 μM substrate concentration and 
initial product concentrations ranging from 0 to 1200 μM for 
60 min. The data represents the mean of three independent 
measurements with the corresponding standard deviation 
shown by the error bars. 
 
Figure 5 HPLC chromatogram of the cyproterone acetate 
conversion using B. megaterium MS941 overexpressing 
the CYP106A2 enzyme. The reaction was performed with 
resting cells in 100 mM potassium phosphate buffer (pH 7.4) 
at 30 °C, 150 rpm. Cyproterone acetate (400 μM) was added 
to the cells in DMSO solution (2 % v/v). Samples were 
collected directly at the point of substrate addition (grey 
dotted line) and after 2 h (black line). The substrate was 
converted to one main product (P1). 
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Figure 6 Effect of whole-cell catalyst addition, with and 
without additional substrate, on 15β-hydroxycyproterone 
acetate production. Reactions were performed in shake 
flasks with 1 mM cyproterone acetate and an initial catalyst 
concentration of 50 g/L WCW. After 4 h, additional 150 g/L 
WCW was added to the reaction represented with , both 
catalyst and substrate (1 mM) were added to the reaction 
represented with  and buffer was added to the control () 
to compensate for the change in volume. 
In a further attempt to improve the biocatalyst 
yield, the reusability of the whole-cell system was 
investigated to decrease the cost contribution of 
the catalyst and increase the economic potential of 
a resting cell process. Removal of the product by 
solvent extraction between batches was explored. 
Washing with buffer did not have any effect on the 
product in the cell pellet fraction. Exposing the 
cells to the organic solvent ethyl acetate 
completely destroyed the activity of the cells. 
Furthermore, washing with decanol removed the 
product from the cells, but at the same time 
damaged the catalyst resulting in around 30 % 
relative conversion compared to the first batch 
(Figure 7). 
Transport and cofactor dependence 
The potential limitations of the whole-cell system 
in terms of substrate transport across the cell 
membrane and cofactor regeneration were ruled 
out as seen in Figure 8. The reactions were 
performed with resting whole-cells in shake flasks 
and NADPH was added in 1 mM (stoichiometric 
to substrate) and 2 mM final concentrations. The 
influence of cofactor addition and the cell 
permeabilization methods (sonication, acetone 
treatment or freeze-thawing) on the reaction rate 
was investigated. The initial rates measured in 
these experiments did not show any significant 
difference (data not shown). In addition, Figure 8 
shows that no significant difference was observed 
in the final product concentration either, 
regardless of permeabilization treatment or 
external addition of cofactor. The cofactor is 
assumed to pass the cell membrane and enter the 
cell, similarily to observations in E. coli where this 
was monitored by a decreasing absorbance of the 
supernatant at 340 nm (unpublished work, results 
not shown). The results demonstrate that the 
cofactor regeneration of the host B. megaterium 
MS941 is sufficient to support the observed 
biocatalytic reaction rates and that the natural 
redox partners are sufficiently expressed to 
transport electrons from the cofactor to the active 
site of the overexpressed P450. The substrate 
transport that has been shown to limit a 
CYP106A2-catalyzed steroid transformation in   
E. coli [5] was not limiting the reaction studied 
here in B. megaterium, according to the tested 
permeabilization methods, emphasizing the 
suitability of this whole-cell catalyst. 
 
Figure 7 Cell recycling by product extraction using 
decanol.  represents the control and  the cells washed 
with decanol after 4 h. Reactions were performed with resting 
cells in shake flasks, using 1 mM cyproterone acetate and an 
initial catalyst concentration of 100 g/L WCW. 1 mM 
substrate was added when starting each reaction but only to 
the washed cells at 4 h. 
In vivo substrate and product inhibition 
The influence of increasing substrate and product 
concentrations on the reaction performance was 
also investigated in vivo with the recombinant       
B. megaterium MS941 strain overexpressing 
CYP106A2. The substrate inhibition studies were 
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performed within a concentration range of 50 μM 
to 1 mM. When using up to 200 μM substrate 
concentration, complete conversion of the 
substrate took place already within 2 h, while at 
higher substrate concentrations the conversion 
stopped at an approximate product concentration 
of 300 μM (70 % conversion in the case of 400 μM 
and 27 % in the case of 1000 μM CPA) (Figure 9), 
showing a similar trend as the in vitro 
experiments. 
 
Figure 8 Effect of different cell permeabilization methods 
and cofactor addition on 15β-hydroxycyproterone acetate 
production. White bars represent the results without cofactor 
addition, grey bars have 1 mM NADPH and the black bar 
have 2 mM NADPH added. All reactions were run using          
1 mM cyproterone acetate, 2 % DMSO and 100 g/L WCW 
cells from the same fermentation batch. Error bars are 1σ. 
Product removal strategies 
To remove the product and push the reaction 
equilibrium in the forward direction, thereby 
enhancing the reaction performance, the use of 
two water-immiscible solvents, diisononylphtalate 
(C26H42O4) and hexadecane (C16H34) (selected to 
be compatible with the whole-cell catalyst and 
with oxygen requiring reactions) was investigated. 
However, solubilization of the substrate in these 
solvents, prior to addition to the aqueous phase 
containing the whole-cell catalyst, did not improve 
the reaction performance. The hydrophobicity of 
the substrate hinders the partitioning to the 
aqueous phase and thereby hampers the catalytic 
reaction (results not shown). The negative results 
could also be explained by analytical difficulties 
and problems with homogenous sampling in a 
solid–liquid 2-phase system. 
 
Figure 9 In vivo conversions performed in shake flasks 
with increasing substrate concentrations using resting 
cells. The reactions were performed in 100 mM potassium 
phosphate buffer (pH 7.4) at 30 °C, 150 rpm, with a substrate 
concentration ranging from 50 μM to 1 mM. 
Another approach to maintain a low 
concentration of the dissolved product in the 
aqueous phase is to avoid the use of a miscible co-
solvent and instead apply solid substrate. This 
approach requires that the rate of dissolution of the 
substrate into the aqueous phase is faster than the 
reaction rate so that it does not limit the observed 
reaction. However, this method was not successful 
either, most likely due to the low solubility and 
rate of dissolution of the substrate. 
A third approach was to pre-solubilize the 
substrate in an aqueous solution of HP-β-CD 
((C6H9O5)7(C3H7O)4.5), in order to take advantage 
of its multiple effects. Cyclodextrin (CD), 
especially the derivatized forms, have been shown 
to be useful in enhancing steroid conversions by 
e.g. increasing the cell-wall permeability, 
stimulating cell growth and efficiently solubilizing 
hydrophobic substrates [2]. The complexation of 
β-CD with substrate and/or product also leads to 
lower amounts of free dissolved species and 
thereby lower inhibitory effects of either substrate 
or product on the catalyst, as suggested previously 
for steroid biotransformations [23,24]. Using CD-
solubilized CPA, the transformations were 
performed first in shake flasks with 1 mM final 
concentration of the substrate. As a control, the 
conversion was also performed with the substrate 
dissolved in dimethyl sulfoxide (DMSO). The 
CPA was added from the 45 % CD solution, not 
exceeding 5 % of the reaction volume. During the 
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conversion, 250 μl reaction samples were taken at 
the indicated time points and the product/substrate 
ratio was analyzed by HPLC. Despite the slow 
initial rate, a higher conversion was reached 
within 4 h using CD as solubilizing agent, 
compared to the control. After 24 h, the conversion 
with CD showed 38 ± 0.05 % product formation, 
while the control could only reach 27 ± 4.6 % 
(Figure 10). Given the improved conversion, the 
same strategy was applied in the bioreactor 
(Figure 11). 98 % conversion of 1 mM substrate 
was achieved on a 400 mL scale compared to a 
final conversion of  55 % for the control without 
CD. 
 
Figure 10 In vivo cyproterone acetate conversion in shake 
flasks, using 2-hydroxypropyl-β-cyclodextrin and DMSO 
for substrate solubilization. The reactions were carried out 
with resting cells, in 100 mM potassium phosphate buffer (pH 
7.4) at 30 °C, 150 rpm. The substrate was pre-dissolved either 
in a 45 % CD solution mixed overnight () or in DMSO () 
with a final concentration of 1 mM.  
Influence of reaction mixing 
In this study, catalyst-dependent parameters, 
believed to be independent of the used scale, were 
investigated in shake flasks. Shake flask 
experiments are commonly used in research 
laboratories, providing a simple and fast tool to 
demonstrate the proof of concept. However, for 
process development and scale-up studies, a more 
controlled environment and a more easily scalable 
configuration is preferred. When comparing batch 
transformations between bioreactor and shake 
flasks under identical conditions, the former 
showed faster initial rates (Figure 12). This result 
indicates that increased mixing enhances the 
reaction rate, most likely due to increased mass 
transfer of poorly water-soluble substrate but also 
due to the increased aeration. These results also 
suggest that for processes targeting scale-up and 
industrial implementation, process development 
should be performed with the intended final 
reactor configuration, in this case a stirred tank 
reactor instead of shake flasks. This especially 
concerns reactions involving species with low 
water solubility and gaseous components           
(e.g. oxygen). 
 
Figure 11 In vivo cyproterone acetate conversion in 
bioreactor, using 2-hydroxypropyl-β-cyclodextrin and 
DMSO for substrate solubilization. The reactions were 
carried out in 400 mL final volume with resting cells 
resuspended in 100 mM potassium phosphate buffer (pH 7.4) 
at 30 °C. The substrate was either pre-dissolved, in a 45 % 
CD solution mixed overnight () or in DMSO () with a 
final concentration of 1 mM. 
Catalyst stability 
The stability of a biocatalyst is crucial for the 
economic potential of a biocatalytic process. In 
this study we examined the storage stability, due 
to practical reasons, and more importantly, the 
stability under process conditions, under which the 
relevant information is collected. The dry cell 
weight and the correctly folded P450 were 
monitored during the process and it was found that 
the cells remained intact but the stability of the 
CYP106A2 was limited. One third of the correctly 
folded P450 is degraded after 4 h of the reaction 
and more than 50 % is lost after 24 h (Figure 13). 
The storage stability of the catalyst was 
determined by running resting cell 
biotransformations with cells previously 
resuspended in buffer and stored gently shaken at 
4 °C. No significant loss in reaction performance 
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was found over 7 days of storage (data not shown). 
The stability of the catalyst could potentially also 
be affected by the mode of operation. However, no 
significant difference was seen between growing 
and resting cells in terms of conversion,         
whole-cell stability or P450 stability. 
 
Figure 12 Comparison of 1 mM cyproterone acetate 
transformation in bioreactor and shake flask. The 
reactions were carried out using the same batch of cells, in a 
resting cell format (100 g/L WCW), and the substrate was 
added dissolved in DMSO. The initial rate of the reaction 
performed in the bioreactor () showed a higher initial rate 
compared to the reaction performed in shake flasks (), 
although the reaction in the shake flask resulted in a higher 
final conversion. 
 
Figure 13 Stability of the whole-cell catalyst under process 
conditions. Reaction performed with resting cells in the 
bioreactor at 1 mM cyproterone acetate concentration and a 
cell density of 100 g/L WCW. Samples were collected at the 
indicated time points. The dry cell weight () and the P450 
content () were measured. 
Discussion 
Even though in the past decade significant 
progress was made to develop efficient 
biocatalysts for steroid transformations, there is 
still a great demand for greener and cost-efficient 
routes for valuable steroid production [2]. 
Microbial steroid transformations, using 
heterologously expressed cytochrome P450 
enzymes are considered to be a promising 
approach, since the regio- and stereospecific 
hydroxylations are known to be challenging for 
synthetic steroid chemistry, suffering from low 
predictability and specificity [1,25]. However, in 
most cases the reactions performed at analytical 
scale are not directly applicable for industrial 
practice. For an industrial process, the economic 
feasibility needs to be considered. For guidance, at 
the current stage of process development, targets 
for economic metrics such as space-time yield (for 
a growing cell process), final product 
concentration and biocatalyst yield (for a resting 
cell process) can be used. For high-value products 
or pharmaceuticals, such as the 15β-OH-CPA, 
target values for product concentration of 20 g/L, 
a space-time yield of 2 g/L/h (for a growing            
cell process) and a biocatalyst yield of                        
10 g product/g dry cell weight (DCW) (for a 
resting-cell process) can be used as reference [21]. 
These targets can only be achieved using higher 
substrate concentrations, and problems associated 
with higher concentrations such as low solubility 
of the substrate, potential substrate or product 
inhibition and toxicity most likely will arise. 
In a previous study, Hannemann and co-
workers converted 11-deoxycorticosterone             
to 15β-hydroxy-11-deoxycorticosterone using 
CYP106A2, functionally expressed with bovine 
adrenal redox partners in a growing whole-cell     
E. coli host. According to our calculations, the 
molar substrate concentration applied in this study 
(0.5 mM) could result in a maximal final product 
concentration of 0.17 g/L. The space-time yield 
was reported to be 0.33 g/L/d, however, it has to 
be taken into account that the substrate was not 
fully converted after 24 h [13]. Nevertheless, the 
focus of the study was to design a whole-cell 
catalyst and demonstrate the applicability of a 
screening assay. The whole-cell system was then 
further improved by the coexpression of a cofactor 
regeneration system and was used for the           
15β-hydroxylation of progesterone and 
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testosterone [5]. This system was shown to be 
limited by substrate transport across the cell 
membrane and solubility of the substrate was 
shown to be crucial for the reaction performance. 
The productivity concerning testosterone 
hydroxylation was reported to be 5.5 g/L/d using 
0.5 mM initial substrate concentration and a 
lyophilized cell extract on a 20 mL scale, however, 
this value was extrapolated from a 30 min 
reaction. Taking into account the 0.5 mM initial 
substrate concentration the 96 % conversion could 
only lead to a final product concentration of      
0.15 g/L. In the same study experiments with 
growing cells showed only 25 % selectivity 
towards the 15β position, considerably lower than 
resting cells (≥80 %). More recently, DHEA was 
regioselectively hydroxylated to 7β-OH-DHEA 
by CYP106A2 expressed in B. megaterium [12]. 
A benchmark 0.44 g/L total final product 
concentration was obtained upon addition of       
1.5 mM substrate in a repeated batch mode, 
yielding 6 different products in 12 h, which is the 
highest reported concentration of the studies 
published so far. The selectivity towards the        
7β-position was improved from 0.7 to 0.9 by 
changing the host from B. megaterium strain 
ATCC 13368 to MS941. The bottlenecks of the 
reaction were discussed but never investigated. 
In our study a systematic approach was taken 
to identify catalyst- and reaction-related 
limitations to enable an efficient process with 
defined targets based on economic guidance. By 
addressing the identified limitations we managed 
to evaluate and improve the process performance. 
This is a novel approach compared to previous 
studies on steroid hydroxylation by CYP106A2. 
We investigated the regio- and stereoselective 
15β-oxidation of CPA, in shake flasks and 
laboratory scale bioreactors. CYP106A2 was 
overexpressed in B. megaterium MS941 and 
proved to be a robust catalyst for the synthetic 
biotransformation of CPA. The B. megaterium 
host offers a protected environment for the 
enzyme, enhancing its stability, besides the 
cofactor regeneration provided by the cellular 
metabolism, which, according to our studies, was 
shown to be sufficient to not limit catalysis. The 
substrate transport across the membrane of the     
B. megaterium whole-cell catalyst turned out not 
to be a limiting factor either, as was described in 
the case of steroid hydroxylation by E. coli [5]. In 
contrast, the low overall solubility of the reactants, 
the limited stability of the P450, in combination 
with product inhibition, are suggested to be the 
main bottlenecks of this system. 
The low solubility of substrate is a common 
challenge to many P450-catalyzed reactions. In 
the case of CPA the solubility is reported to be 
0.64 mg/L [26] and 34 mg/L for the hydroxylated 
product [27]. However, this should be put in 
perspective to the aimed final product 
concentration of 20 g/L. Low steroid solubility is 
usually solved by the application of a water 
immiscible co-solvent but this approach has 
limitations at higher concentrations when the co-
solvent can damage the biocatalyst [28]. This can 
partly be circumvented by the application of CDs. 
These cyclic oligosaccharides are used in e.g. drug 
delivery [29] and have also been applied in P450-
catalyzed reactions, mainly as a solubilizing agent 
and to improve substrate transport across the cell 
membrane, however at limited substrate 
concentrations (50 mg/L) [23]. The effects of    
HP-β-CD on steroid dehydrogenation of the gram-
positive bacteria Arthrobacter simplex was 
investigated by Shen and coworkers [30]. Cells 
pretreated with HP-β-CD showed double the 
initial rate and reached final conversion 1 h faster 
compared to the non-treated cells, although in the 
end both reached the same concentration. This was 
shown to be the result of the cell membrane 
permeabilization by altered lipid and protein 
profiles of the membrane. CDs have also been 
applied in other fermentation and 
biotransformation processes to avoid toxic and 
inhibitory effects of the substrate or product, as 
summarized by Singh et al. [31]. In this work, 
using HP-β-CD, we were able to achieve 98 % 
conversion of 1 mM CPA in a regio- and 
stereoselective manner within 8 h, resulting in 
0.43 g/L product. This matches the literature 
benchmark for steroid conversion by CYP106A2 
[12], yet the 8 h conversion time applied here 
improves the space-time yield by 31 %. This new 
approach of bottleneck identification, takes P450-
catalyzed reactions one step further towards 
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higher product titers and economic viability. In 
our system, the time-dependent product inhibition 
was shown to limit final achievable product 
concentrations at higher substrate concentrations, 
thereby decreasing the reaction yield. By 
overcoming this problem, the main effect of CD 
was believed to be the complexation of the product 
in the lipophilic central cavity, thereby pulling it 
out of the hydrophilic environment present in the 
cell and pushing the equilibrium towards the 
product formation. 
Conclusion 
Ultimately, with the help of HP-β-CD, we could 
achieve a nearly complete conversion and a 
product formation of 0.43 g/L at a 400 mL scale, 
getting closer to industrial process requirements 
and a future large-scale application. However, in 
order to fully exploit the potential of the CD 
process, further optimization studies should be 
performed. Using CD to circumvent the identified 
bottlenecks of solubility and product inhibition, 
the stability of the P450 is still a challenge for an 
economically feasible process. Considering that 
the stability of the enzyme will make cell recycling 
difficult, and that no significant differences could 
be found between a growing and resting cell 
process, the preferred mode of operation for 
further process development would be growing 
cells. As stated above, the targets for an 
economically feasible growing cell process are a 
final product concentration of 20 g/L and a space-
time yield of 2 g/L/h [21]. Although we could 
demonstrate a successful process development 
towards the suggested values by addressing the 
limitations, there is still room for improvement. 
Materials and methods 
Reagents and chemicals 
All used chemicals were from standard sources 
and of highest grade available. Solvents of 
analytical grade were used for HPLC, while 
solvents used for large-scale extraction were of 
reagent grade. CPA was obtained from 
BIOTREND Chemikalien GmbH, Köln, Germany 
(≥98 % (HPLC)). 
Bacterial strains and plasmids 
The in vivo conversions were performed using a 
recombinant B. megaterium MS941 strain, a 
variant of DSM319, lacking the major 
extracellular protease gene nprM [32]. The host 
organism was transformed with the plasmid 
pSMF2.1C (CYP106A2 gene introduced within 
the SpeI/MluI sites) by a polyethylene glycol-
mediated technique using protoplasts [9,16]. As 
control, the wild type B. megaterium MS941 strain 
was used (lacking the pSMF2.1 plasmid, but 
naturally containing cytochrome P450 genes) to 
confirm that the reaction is catalyzed by the 
CYP106A2 enzyme. The wild type strain did not 
display any activity towards the substrate (data not 
shown) and no P450 was detected using CO 
difference spectroscopy [33], indicating that the 
P450 expression and catalytic activity reported is 
assigned to the overexpressed CYP106A2. 
Protein expression, purification and spectral 
characterization 
The expression and purification of the CYP106A2 
protein was performed as described previously 
[6,34]. For the reconstituted in vitro system, a 
truncated form of bovine adrenodoxin (Adx4–108) 
was used in combination with bovine 
adrenodoxin-reductase (AdR), their expression 
and purification was completed as described 
elsewhere [35,36]. The characteristics of the 
purified CYP106A2 were analyzed by UV-visible 
absorbance spectroscopy. The spectrum was 
recorded in a range of 200 to 700 nm with a double 
beam spectrophotometer (UV-1800, UV-2101 PC, 
Shimadzu Corporation, Kyoto, Japan) and 
analyzed constantly during the purification 
process, to determine the Q value (A417/A280), 
which was in all cases above 1.5, suggesting a high 
amount of correctly folded, active P450s. The 
samples taken from the bacterial cultures during 
cultivation or conversion were spun down and the 
pellet kept frozen at -20 °C until measurement 
when the samples were resuspended in 100 mM 
potassium phosphate buffer, pH 7.4. The 
concentration of the purified protein and the 
protein expressed in the whole-cell system was 
determined by CO difference spectroscopy 
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according to the method of Omura and Sato [33], 
using an extinction coefficient of 91 mM−1 cm−1. 
Substrate binding assay 
The substrate binding spectrum was investigated 
using a double-beam spectrophotometer (UV-
2101PC, Shimadzu, Japan) and tandem quartz 
cuvettes. The analysis took place in 800 μL total 
volume. One chamber of each cuvette contained 
10 μM solution of CYP106A2 in 50 mM 
potassium phosphate buffer pH 7.4, while the 
other chamber was filled with buffer. CPA was 
dissolved in DMSO at a stock concentration of    
10 mM. The enzyme was titrated with the 
substrate in a concentration range of 5 to 150 μM. 
After each titration step the spectrum was recorded 
in a range of 350 to 500 nm. 
In vitro conversions and enzyme kinetics 
The in vitro conversion of CPA was carried out 
with a reconstituted system in a final volume of 
250 μL at 30 °C for 30 min in 50 mM potassium 
phosphate buffer (pH 7.4), containing 20 % (v/v) 
glycerol. The reconstituted system contained 
bovine AdR (1 μM), a truncated form of Adx4–108 
(10 μM), CYP106A2 (0.5 μM), a NADPH-
regenerating system [MgCl2 (1 mM),          
glucose-6-phosphate (5 mM), glucose-6-
phosphate dehydrogenase (1 U), and NADPH   
(0.1 μM)], and CPA (200 μM). The reaction was 
started by adding NADPH (1 mM) and incubated 
at 30 °C. The assay was stopped by the addition of 
250 μL of ethyl acetate, mixed vigorously, and 
extracted twice. The combined organic phases 
were evaporated and the residues were dissolved 
in the HPLC mobile phase (60:40% ACN:H2O) 
and subjected to analysis. 
Reaction kinetics of CPA and CYP106A2 were 
performed for 2 min as described above, using 
bovine AdR (0.5 μM), bovine Adx4–108 (5 μM) and 
CYP106A2 (0.25 μM). The substrate 
concentration varied from 20 to 250 μM. Product 
amounts were determined by plotting the amount 
of product formed (nmol product/nmol P450/min) 
against the substrate concentration (μM). Each 
reaction was performed six times, the data 
represents the mean of these independent results. 
Data were fitted by hyperbolic regression with the 
help of Origin (OriginLab Corporation, 
Massachusetts, USA). 
The substrate inhibition studies were 
performed using a 20 mM CPA stock solution 
dissolved in DMSO and added in a final 
concentration of 200 to 1200 μM. Studying the 
product inhibition, the substrate was added in a 
final concentration of 400 μM, while the purified 
product concentration ranged from 0 to 1200 μM. 
The reactions took place for 60 min, then the 
samples were extracted and subjected to HPLC 
analysis as described before. 
Heterologous expression in shake flasks 
Pre-cultures were inoculated from a -80 °C 
glycerol stock, using 25 mL complex TB medium 
(24 g/L yeast extract, 12 g/L soytone, 2.31 g/L 
KH2PO4 and 12.5 g/L K2HPO4) supplemented 
with 10 mg/L tetracycline and incubated 
overnight, at 150 rpm, 30 °C. The main culture, 
containing 250 mL complex medium 
(supplemented with the corresponding amount of 
tetracycline) was inoculated with 1 % of the 
culture volume from the pre-culture. The main 
culture was incubated until an OD578 = 0.5, when 
5 g/L xylose solution was added to induce 
expression. After 24 h expression, the cells were 
harvested (4500 x g, 4 °C, 15 min), the cell pellet 
was washed and resuspended in 100 mM 
potassium phosphate buffer (pH 7.4). 
Heterologous expression at fermenter scale 
The fermentation process was adapted from 
Korneli and coworkers [37]. A -80 °C glycerol 
stock was used to inoculate the first pre-culture 
with LB medium which was used to inoculate a 
second pre-culture with batch medium (3.52 g/L 
KH2PO4; 6.62 g/L Na2HPO4*2H2O; 0.3 g/L 
MgSO4*7 H2O; 25 g/L (NH4)2SO4; 1 g/L yeast 
extract and trace elements as described [37]). The 
first pre-culture was incubated for 8 h in a 100 mL 
shake flask with 10 mL LB medium at 150 rpm, 
37 °C. 100 mL batch medium supplemented with 
5 g/L fructose was used for the cultivation of the 
second pre-culture in a 1 L flask, inoculated from 
the first pre-culture to an OD600 of 0.1. After 12 h 
of cultivation, it served as inoculum for the 
fermenter. The batch medium in the fermenter was 
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supplemented with 15 g/L fructose. The feed 
medium consisted of 150 g/L fructose; 5 g/L         
D-xylose; 9.9 g/L KH2PO4; 14.98 g/L Na2HPO4;    
0.3 g/L MgSO4*7H2O, 25 g/L (NH4)2SO4. All 
media preparations were supplemented with          
10 mg/L tetracycline. The fed-batch fermentation 
process was carried out in a 1 L Infors Multifors 
fermentation vessel (Infors HT, Bottmingen, 
Switzerland). Initial conditions were set to 37 °C; 
pH 7.0; aeration 0.5 Lpm and pO2 setpoint 20 % 
controlled by stirrer. The fermenter was inoculated 
to a final OD600 of 0.7 and induced at an OD600 of 
10 with 5 g/L xylose. The induction at a higher 
OD600 in the fermenter, compared to shake flask, 
is due to the higher possible final cell density 
utilizing a fed-batch process. At the time of 
induction, the temperature was decreased to 30 °C, 
agitation was increased to 1 Lpm and a linear feed 
was initiated. The pH was controlled during the 
process with 5 M NaOH and 1 M H3PO4. Cells 
were harvested by centrifugation and washed by 
resuspension in 100 mM potassium phosphate 
buffer, pH 7.4. 20 mM fructose was added to the 
cells for direct use in biotransformation or stored 
at 4 °C, gently shaking, at a cell density of 200 g/L 
WCW. 
Bioconversion in shake flasks 
The small scale conversion of CPA was performed 
with resting cells in a 15 mL culture volume using 
100 mL baffled shake flasks. The catalyst 
concentration was 100 g/L WCW, unless 
otherwise stated. To obtain sufficient amount of 
product (mg) for NMR structure characterization, 
the conversion was scaled up to 50 mL, using    
300 mL baffled shake flasks. CPA was added in 
200 μM final concentration from a 20 mM DMSO 
stock solution. The use of DMSO did not exceed 
2 % of the culture volume. Every 4 h, 2 M fructose 
solution was added as carbon source in a final 
concentration of 20 mM. 250 μL samples were 
taken at indicated time points to monitor the 
conversion. The samples were extracted twice 
using 250 μL ethyl acetate, the organic phases 
collected and evaporated to dryness for the 
subsequent analysis by reverse-phase HPLC. In 
the case of product isolation, the reaction was 
stopped and the steroids were extracted twice by 
ethyl acetate. The organic phase was dried over 
anhydrous MgSO4 and concentrated to dryness in 
a rotavapor (Büchi R-114). The yellowish residue 
was dissolved in the mobile phase of the HPLC 
and filtered through a sterile syringe filter 
(Rotilabo syringe filter, 0.22 μm, Carl Roth 
GmbH, Karlsruhe, Germany). The product 
purification was completed by preparative HPLC, 
according to its retention time. The collected 
fractions were evaporated to dryness and analyzed 
by NMR spectroscopy. The in vivo substrate and 
product inhibition was studied in shake flasks, 
using resting cells, as described for the in vitro 
studies. 
HPLC analysis 
The HPLC analysis was performed either on a 
Jasco system consisting of a Pu-980 HPLC pump, 
an AS-950 sampler, a UV-975 UV/Vis detector, 
and an LG-980–02 gradient unit (Jasco, Gross-
Umstadt, Germany) or on a Dionex UltiMate 3000 
HPLC equipped with a Photodiode Array Detector 
(Dionex, Thermo Scientific, Sunnyvale, CA, 
USA). A reversed-phase ec MN Nucleodor C18    
(3 μM, 4.0x125 mm) column (Macherey-Nagel, 
Betlehem, PA, USA) was used and kept at an oven 
temperature of 40 °C. An isocratic gradient of 
acetonitrile:water in a ratio of 60:40 was applied 
using a flow rate of 0.8 mL/min. UV detection of 
the substrate and product was accomplished at  
282 nm. Product isolation was performed using 
preparative reversed-phase HPLC (ec MN 
Nucleodur C18 VP (5 μM, 8x250 mm), Macherey-
Nagel, Betlehem, PA, USA) with a flow rate of  
2.5 mL/min. The results are presented as 
conversion %, calculated from the product area 
divided by the sum of substrate and product areas. 
Regarding the product inhibition experiments, 
when product was added initially to the system, 
the data is presented as relative conversion 
(subtracting the initially added product) or 
calculated back to concentrations from 
conversions. 
NMR characterization of the main metabolite 
The NMR spectrum was recorded in CDCl3 with a 
Bruker DRX 500 NMR spectrometer at 300 K. 
The chemical shifts were relative to TMS using the 
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standard δ notation in parts per million. The 1D 
NMR (1H and 13C NMR, DEPT135) and the 2D 
NMR spectra (gs-HH-COSY, gs-NOESY, gs-
HSQCED, and gs-HMBC) were recorded using 
the BRUKER pulse program library. All 
assignments were based on extensive NMR 
spectral evidence. 
The product (P1) was identified as                  
15β-hydroxycyproterone acetate (15β-OH-CPA) 
(3.4 mg). In comparison to cyproterone acetate the 
NMR spectra of its conversion product showed 
signals for an additional secondary hydroxyl 
group (δH 4.50 ddd, J = 7.5, 6.0 and 2.0 Hz; δC 
68.86). Its position at C-15 could be deduced by 
vicinal couplings of the methin proton with H-14 
(δH 1.93 dd, J = 12.0 and 6.0 Hz), H-16α (δH 2.47 
dd, J = 16.8 and 7.5 Hz) and H-16β (δH 3.03 dd, J 
= 16.8 and 2.0 Hz) in the HHCOSY and with C-
13 (δC 47.00) and C-17 (δC 96.11) in HMBC. The 
β orientation of the hydroxyl was obvious by the 
NOESY effects of H-15 to H-16α and to H-9 (δH 
1.53 m) and H-14, both in α position. In addition, 
the coupling constants found for H-15α resembled 
those for other closely related steroids, e.g.        
15β-hydroxy-11-deoxycortisol [8]. Selected 1H 
NMR data of 15β-hydroxycyproterone acetate 
could be found in the literature [38] and matched 
with our values. 1H NMR (CDCl3, 500 MHz): δ 
0.89 dt (6.3 and 4.7 Hz, cPr-Ha), 1.01 s (3xH-18), 
1.27 s (3xH-19), 1.29 ddd (9.0, 7.8 and 4.7 Hz, 
cPr-Hb), 1.53 m (H-9), 1.62 m (2H, H-11β and H-
12β), 1.74 td (7.8 and 6.3 Hz, H-1), 1.93 dd (12.0 
and 6.0 Hz, H-14), 1.98 m (H-11α), 2.03 m (H-2), 
2.04 m (H-1 2α), 2.09 s (3x OCOCH3), 2.10 s 
(3xH-21), 2.47 dd (16.8 and 7.5 Hz, H-16α), 2.73 
td (12.0 and 2.3 Hz, H-8), 3.03 dd (16.8 and 2.0 
Hz, H-16β), 4.50 ddd (7.5, 6.0 and 2.0 Hz, H-15), 
6.20 brs (H-4), 6.44 d (2.3 Hz, H-7). 13C NMR 
(CDCl3, 125 MHz): δ 12.30 (CH2, cPr), 16.95 
(CH3, C-18), 20.74 (CH2, C-11), 21.11 (C, 
OCOCH3), 22.86 (CH3, C-19), 25.24 (CH, C-2), 
26.12 (CH, C-1), 26.35 (CH3, C-21), 31.96 (CH2, 
C-12), 34.44 (CH, C-8), 38.84 (C, C-10), 43.13 
(CH2, C-16), 47.00 (C, C-13), 47.98 (CH, C-9), 
52.80 (CH, C-14), 68.86 (CH, C-15), 96.11 (C, C-
17), 120.47 (CH, C-4), 130.45 (C, C-6), 136.30 
(CH, C-7), 152.32 (C, C-5), 170.51 (C, OCOCH3), 
197.98 (C, C-3), 202.84 (C, C-20). 
Transport and cofactor dependence 
Transport limitation was examined by different 
cell membrane permeabilization methods prior to 
the biocatalytic reaction. Both mechanical and 
chemical methods were applied (freeze-thawing, 
acetone treatment and ultra-sonication). Frozen 
cells were spun down and the pellet was kept at 
−20 °C overnight. Acetone-treated cells were 
incubated with 5 % acetone for 2 min while 
vortexing and mechanical disruption was 
performed by sonication for 2 min (amplitude      
60 %, 0.5 s cycles) (UP400 S; Hielscher 
Ultrasonic GmbH, Teltow, Germany). Following 
the permeabilization treatment (acetone and 
sonication) cells were spun down and the pellet 
resuspended in 100 mM potassium phosphate 
buffer pH 7.4. Cofactor was added to the untreated 
control samples and to the permeabilized ones, 
once and twice stoichiometric amounts relative to 
substrate concentration. 
Storage stability 
To examine the storage stability of the whole-cell 
catalyst, the transformation was performed with 
resting cells after 1, 3 and 7 days of storage. The 
cells were stored at 4 °C, gently shaking at a cell 
density of 200 g/L WCW in 100 mM potassium 
phosphate buffer, pH 7.4. 20 mM fructose was 
added as carbon source at the time of harvest, after 
1 and 3 days of storage and also at the start of the 
reactions. 
Cyclodextrin 
As an alternative substrate feeding strategy, the 
substrate was pre-dissolved in a 45 % (w/v) 
solution of HP-β-CD in sterile-filtered MilliQ 
water and stirred overnight using a magnetic 
stirrer. 
Optical density and dry cell weight 
determination 
To estimate the cell concentration, the optical 
density at 600 nm (OD600) was monitored and the 
gravimetric dry cell weight (g/L DCW) was 
determined. Samples collected for dry cell weight 
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measurement were spun down, the supernatant 
was discarded and the pellet was kept at −20 °C 
until further analysis. Thereafter the pellets were 
thawed and resuspended in the original sample 
volume using 100 mM potassium phosphate 
buffer, pH 7.4. Dry cell weight was measured in 
triplicates by filtering the samples through a pre-
weighed 0.22 μm PES membrane filter (Frisenette, 
Knebel, Denmark) applying vacuum. The filters 
were washed with buffer, dried in a microwave 
oven and weighed after equilibrating to room 
temperature in a desiccator. 
Bioconversion in bioreactor 
Biocatalysis in bioreactors was performed in the 
same vessels as the fermentation (Infors Multifors, 
Infors HT, Bottmingen, Switzerland) in a working 
volume of 400 mL. Set points applied were: 30 °C, 
aeration 1 Lpm, pO2 30 % controlled by agitation, 
pH 7.2 controlled with 5 M NaOH and 1 M H3PO4. 
2 M stock solution of fructose was added at time 
point 0, 4 and 8 h in a final concentration of           
20 mM. CPA was dissolved in DMSO and added 
in a final concentration of 1 mM, the DMSO 
content not exceeding 2 % of the total volume. For 
an accurate comparison of growing and resting 
cells half of the fermentation volume was removed 
after 16 h and this fraction was harvested by 
centrifugation, washed and resuspended in          
100 mM potassium phosphate buffer, pH 7.4. 
Resuspended cells were transferred to a 
bioreactor, parallel to the still growing cells. 
Fructose and xylose were continuously fed, for 
both resting and growing cells, at half the 
volumetric rate compared to the fermentation due 
to half the volume. 
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3. Discussion and outlook 
Cytochrome P450 monooxygenases are considered as unique biocatalysts due to their ability to 
introduce atomic oxygen into non-activated hydrocarbons. They are amongst the most potent enzymes to 
exploit as industrial biocatalysts, capable of performing regio- and stereo-selective hydroxylations of 
complex molecules such as steroids [29]. Today, there are more than 300 approved steroid drugs, making 
them the second largest marketed medical product group after antibiotics [115, 116]. The pharmaceutical 
activity of steroidal drugs is strongly influenced by their functional groups, for instance a selectively 
introduced hydroxyl group could result in distinct physiological functions [107]. Selective regio-
/stereochemistry is challenging to achieve by classical chemical approaches making P450s even more 
interesting for the pharmaceutical industry. Bacterial P450s are of particular interest, since, being soluble 
enzymes, they display higher expression levels, stability and often higher substrate specificity compared 
to their eukaryotic counterparts [13]. The biosynthesis of novel steroid drugs and drug precursors by 
bacterial species is a well-established tool in the pharmaceutical industry. Despite the fact that 
microorganisms are widely used for steroid modifications, the responsible enzyme catalyzing the reaction 
is usually not identified and/or characterized [106, 107]. The increasing number of sequenced bacterial 
genomes enables the continuous identification of novel P450s, providing a variety of uncharacterized 
catalysts with potential value for metabolite production, such as the CYP106A1 from the B. megaterium 
strain DSM 319 [81, 92]. The in depth analysis of the bacterial P450s described in this work contributes 
to the exploration of their so far unknown potentials, providing a detailed characterization of the 
CYP106A subfamily towards their future application as industrial biocatalysts for steroid hydroxylation. 
Our approach started off with a comparison of the well-studied CYP106A2 enzyme and its 
subfamily member CYP106A1, sharing 63 % sequence identity (Chapter 2.1). Although CYP106A1 
was recently identified by Brill et al. (2014) [81] and was shown to successfully convert steroids by Lee 
et al. (2014) [82], its potential value for steroid transformations was not thoroughly investigated. We 
focused on the differences between the subfamily members with respect to substrate binding, enzyme 
activity and product pattern, using a library of 23 steroids, from which 13 novel substrates were identified 
for CYP106A1 and 7 for CYP106A2. Difference spectroscopy was used to reveal the binding properties 
of all tested steroids towards the enzymes. Out of 23, only 4 (β-estradiol, estrone, pregnenolone and     
17α-hydroxypregnenolone) did not display a type I shift, all with similar structural characteristics, an 
aromatic A-ring or a double bond between C5 and C6. However, due to the opposing results (type I shift) 
with another 3-hydroxy-Δ5 steroid, dehydroepiandrostenedione, we could not draw an explicit conclusion 
about such structures. Despite the lack of spin shift induction, pregnenolone and                                             
17α-hydroxypregnenolone were converted by both enzymes, coinciding with previous results and 
supporting that type I binding is an indication but not a necessity for conversion [100, 121-123]. The lack 
of spin-shift induction could be explained by the absence of a hydrogen bond acceptor in the case of the 
pregnenolone structure, which results in weaker binding to the heme iron and only partial displacement 
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of the water as sixth ligand. Regarding the aforementioned estrogens, neither type I shift nor a conversion 
were detected; most probably due to the lower flexibility of the aromatic A-ring interfering with the 
binding of the substrate [100]. 3-oxo-Δ4-steroids were the first and for long the only known substrates 
described for CYP106A2. However, in our study we came across two exceptions,                                             
19-hydroxyandrostenedione and adrenosterone, which despite the 3-oxo-Δ4-moiety were not subjects for 
conversion. Since these steroids have a high structural similarity to the known substrate, androstenedione, 
the additional hydroxyl group at C19 or the keto-function at C11 may account for the unsuccessful 
conversion. 
Subsequently, the substrates were narrowed down to those 6 (androstenedione, corticosterone, 
11-deoxycorticosterone (DOC), 11-deoxycortisol (RSS), cortisol and cortisone) whose conversion 
revealed differences between the enzymes concerning the product pattern or activity. Binding studies 
demonstrated similar steroid affinities to both subfamily members as reflected by their dissociation 
constants (KD). The strongest binding was observed for DOC (68 ± 2 µM with CYP106A1 and                    
50 ± 1 µM with CYP106A2) and androstenedione (77 ± 2 µM and 81 ± 10 µM, respectively) with both 
enzymes, while functionalized substrates at C11 or C17 showed fairly weak interactions. 
Previously established whole-cell biocatalysts [81, 88] were applied for the biotransformations 
on a preparative scale, leading to a sufficient amount of products for structure elucidation by NMR. 
Concerning C21-steroids such as, DOC, RSS and cortisone, both subfamily members favored the         
15β-hydroxylation. However, the CYP106A1 conversions were shown to be less selective in all cases 
producing additional mono- and dihydroxysteroids at 6β, 7β and 7β,15β positions. Such distinct behavior 
was also observed regarding androstenedione, where CYP106A2 formed the 15β-hydroxy compound as 
main product, while CYP106A1 produced only the 6β and 7β-hydroxy derivatives. In the literature, 6 
and 7-substituted 1,4,6-androstatriene-3,17-diones have been described as suitable inhibitors of 
CYP19A1, the enzyme responsible for the development of post-menopausal breast cancer [124, 125]. 
The 6β and 7β-hydroxyandrostenediones produced by CYP106A1 could serve as precursors for further 
functionalization, the hydroxyl function being an easily accessible reaction site, thus, an important feature 
for drug design and development. 
Even though most steroid hydroxylations took place at the B- and D-rings, the transformation of 
11β-hydroxysteroids produced unexpected results: CYP106A1 performed the 11-dehydrogenation of 
both cortisol and corticosterone, whereas CYP106A2 demonstrated the same with corticosterone (yet still 
producing the 15β-hydroxy derivative as main metabolite). Besides the unprecedented CYP106A             
11-oxidase activity, the transformation of cortisol to cortisone is also remarkable, since both steroid 
hormones have important roles as pharmaceutical agents: cortisone being widely used as a short-term 
pain killer and anti-inflammatory drug and cortisol applied as an immunosuppressive drug against severe 
allergic reactions. The production of cortisol at an industrial scale started in the 1940s, when it was proved 
to be an efficient treatment for symptoms of rheumatoid arthritis. Over the decades its production was 
reduced from a complex 31-step to an 11-step chemical synthesis in combination with microbial 
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bioconversion. Today, the industrial production of cortisone starts from stigmasterol through the           
11α-hydroxylation of progesterone with Rhizopus nigricans, followed by the chemical modification to 
cortisol and then to cortisone. Another possibility is the chemical conversion of diosgenin to cortexolone, 
which is 11β-hydroxylated by Curvularia lunata to cortisol [35, 117]. However in each strategy the last 
reaction step leading to cortisone is still accomplished by synthetic chemistry. Even though microbial                      
11-oxidations were described from the 1950s, involving e.g. Cunninghamella blakesleeana, Trichoteum 
roseum and Absidia regnieri, none of these microbes were implemented for the last step of the industrial 
cortisone production [126]. We propose that the identified CYP106A 11-oxidase activity could serve as 
an alternative to the chemical reaction step. However, concerning the low selectivity of the reaction, 
additional protein engineering and strain optimization must be applied to enhance the 11-keto formation. 
To facilitate this, the homology model based on the CYP106A2 crystal structure [102] or the CYP106A1 
crystal structure itself has to be attained. This could serve to define the substrate-interacting amino acids 
and provide a better understanding of the connection between high spin-shift induction and conversion 
of certain substrates. Additionally, based on our results, the steroid-hydroxylase and 11-oxidase function 
of the CYP106A subfamily could be further exploited by screening a steroid library including only high-
value pharmaceuticals to target the efficient production of their hydroxy derivatives used as drugs or 
human drug metabolites. 
In summary, the substrate array of the CYP106A subfamily was extended, revealing 13 new 
steroid substrates for CYP106A1 and 7 for CYP106A2. The latter was shown to be more selective 
towards the 15β-hydroxylation, whereas CYP106A1 produced hydroxy-metabolites at positions 6β, 7β, 
9α and 15β. In addition, a previously unknown 11-oxidase activity of the CYP106A subfamily was 
observed during the conversion of 11β-hydroxysteroids. The selectively introduced hydroxyl groups in 
the steroid backbone makes these derivatives valuable as drug precursors or drug metabolites, stressing 
the advantage of the CYP106A subfamily over chemical approaches for the production of fine chemicals 
and pharmaceuticals. 
 
The 11-oxidase activity observed for the CYP106A subfamily is uncommon for P450 catalysis.  
Such an 11-oxidation reaction was only suggested to occur for one other P450, CYP11B1, transforming 
cortisol to cortisone, yet, the mechanism was never investigated [127]. In Chapter 2.2 we aimed to obtain 
a better understanding of the 11-dehydrogenation mechanism focusing on the CYP106A1 enzyme. 
Although CYP106A1 catalyzed the 11-oxidation of both corticosterone and cortisol, due to the multiple 
product formation observed in both transformations, none of these were considered suitable to study the 
kinetic solvent isotope effect (KSIE) on the reaction. Therefore, analogous substrates were probed with 
hydroxyl function at C-11 (prednisolone, dexamethasone and 11β-hydroxyandrostenedione                        
(11-OH-AD)) to identify a suitable model reaction resulting in single product formation. The steroid 
conversions were carried out first in vitro then in vivo using resting whole-cells. Single product formation 
was only observed for 11-OH-AD, yet, all obtained product structures were elucidated in order to broaden 
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our understanding of the CYP106A1-mediated steroid transformations and to obtain functionalized 
glucocorticoids of potential pharmaceutical importance. The main products of dexamethasone and 
prednisolone were identified as the 15β-hydroxy compounds. Nevertheless, the 11-keto formation was 
also detected in both cases. Additionally, the formation of the main human metabolite,                                   
6β-hydroxydexamethasone, was also observed, while in the case of prednisolone a 1(2)-double bond 
hydrogenation took place, speculated to be the outcome of an uncharacterized enzyme present in the        
B. megaterium MS941 strain. 
The conversion of 11-OH-AD yielded a single 11-keto product, adrenosterone, hence this 
reaction was chosen to further investigate the mechanism using KSIE. The conversion was performed, 
first in protiated, then in deuterated buffer system, displaying a 2.25 times faster product formation upon 
H/D exchange. This corresponds to an inverse KSIE (kH/kD) of 0.44, suggesting the involvement of the 
ferric peroxoanion in the 11-oxidation. Since the P450-mediated 11-oxidation of steroids was studied 
here for the first time, similar alcohol-oxidations by P450s described in literature have been considered 
for possible equivalents. For this purpose, the microsomal cyclohex-2-en-1-ol oxidation [128], the 
CYP3A11-dependent hydroxy-Δ8-tetrahydrocannabinol conversion [129] and the CYP2E1 mediated 
ethanol oxidation [130] were reviewed. In all these cases the gem-diol and the combination of gem-diol 
and double hydrogen abstraction pathways were suggested for the mechanism, propounding Cpd I as 
reactive intermediate. These propositions are analogous to standard P450-mediated hydroxylations, 
which are believed to proceed through the Cpd I-mediated H-rebound mechanism [131-133]. However, 
the involvement of Cpd I seems not to be reconcilable with our observations concerning the 11-oxidation, 
which suggests the involvement of the ferric peroxoanion. 
To exclude the influence of the unproductive pathways and the potential H2O2-mediated substrate 
oxidation (reverse peroxide shunt), the in vitro conversions were performed with the addition of radical 
scavengers and in the presence of H2O2 or cumene hydroperoxide. The presence of radical scavengers 
did not alter the catalytic rate compared to the rate observed in the protiated system, while with H2O2 or 
cumene hydroperoxide no conversion was detected. These results exclude the influence of a slower 
uncoupling reaction rate in deuterated buffer on the KSIE, thus suggesting that the catalysis takes place 
with the help of the ferric peroxo intermediate via a nucleophilic attack at C11 hydroxyl function. 
To sum up, in Chapter 2.2, we present three novel substrates (prednisolone, dexamethasone and 
11-OH-AD) for the 11-oxidation by CYP106A1. Single 11-keto product formation was found for            
11-OH-AD, while prednisolone and dexamethasone displayed 6β- and 15β-hydroxylated derivatives, 
besides the 11-keto product. Since hydroxysteroids are well-suited precursors for further steroid 
functionalization, the production of such derivatives using CYP106A1 is considered to be a promising 
approach for the pharmaceutical industry. The selective conversion of 11-OH-AD was chosen to further 
investigate the 11-oxidation mechanism. An inverse KSIE was observed in the catalytic activity, 
indicating for the first time the ferric peroxoanion as reactive intermediate in a P450-mediated oxidation.  
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The involvement of the ferric peroxo species was based on the experimental results obtained 
from the KSIE in this study. However, further evidence could be provided by spectroscopic 
characterization (e.g.: electron paramagnetic resonance, X-ray, raman resonance etc.) of the reactive 
intermediate, also serving as an interesting topic for future research [134, 135]. As for further follow-up 
experiments, a broader library of 11-hydroxysteroid analogues could be screened, targeting only 
substrates with known and valuable 11-keto metabolites. Besides, by obtaining the CYP106A1 homology 
model/crystal structure, computational substrate docking studies may help to define amino acids which 
potentially influence enzyme activity/specificity. Consequently, via the production of rationally designed 
mutants, the selectivity of the 11-oxidation could be improved. In lack of mechanistic and structural data, 
the mutants could be produced by directed evolution. To provide a rapid preliminary screening method 
of the forthcoming CYP106A1 mutants, suitable for the analysis of the cortisol-cortisone turnover, a 
fluorimetric assay developed by Appel et al. (2005) [136] has been established (Appendix 5.1).  
 
Finally, with the aim of establishing a model for potential industrial scale P450-biocatalysis, the 
CYP106A2 based B. megaterium MS941 system was applied for the conversion of cyproterone acetate 
(CPA) in a collaborative project with the Technical University of Denmark (Chapter 2.3). CPA is a 
synthetic derivative of 17α-hydroxyprogesterone, an anti-androgen with additional progestogen and 
antigonadotropic properties. It has been long used in the treatment of prostate cancer to control severe 
hypersexuality in males, as well as for the treatment of hirsutism and acne in females and as a component 
of oral contraceptive pills (Diane 35 or Bella Hexal 35 in Germany) [137-140]. 
The synthetic antiandrogen was first transformed under in vitro conditions using purified 
CYP106A2 enzyme, followed by the in vivo conversion with a recombinant B. megaterium whole-cell 
system, in which CYP106A2 was overexpressed with the autologous redox partners present in the MS941 
strain. The single conversion product was then purified using reverse phase HPLC and the subsequent 
NMR characterization confirmed the structure of 15β-hydroxycyproterone acetate (15β-OH-CPA), also 
known as the main human metabolite. The product retained anti-androgen activity but only 10 % 
progestogen potency of CPA, which makes it a potentially better option for the treatment of solely 
androgen-induced problems, particularly in males [141]. To evaluate the potentially altered 
pharmaceutical effect of 15β-OH-CPA, the cell growth and drug sensitivity of the human prostate 
carcinoma cell line, LNCaP, was investigated using an XTT cell proliferation assay (Appendix 5.2). 
Besides its potential pharmaceutical value, another motivation for its alternative process 
development was the significant price difference between the substrate and the product, the latter being 
375 fold more expensive (Santa Cruz Biotechnology, http://www.scbt.com/, 2015). This suggests a rather 
pricy process, however, detailed information about the production is not available. Considering the 
product’s pharmaceutical importance and presumed costly current production, our goal was to perform a 
scale-up of the selective 15β-oxidation of CPA from shake flasks to laboratory scale bioreactors. To 
improve the process performance, working towards a future large-scale production of 15β-OH-CPA, we 
80 
 
identified and addressed the limitations associated with the catalyst and the reaction. To recognize the 
bottlenecks we reviewed and analyzed the already described difficulties associated with P450 whole-cell 
applications [29, 40]:  
 Transcellular transport limitation 
 Cofactor (NADP(H)) limitation 
 Substrate/product inhibition and/or toxicity 
 Poor substrate/product solubility 
B. megaterium MS941 has proven to be a stable host organism providing a protective 
environment for the CYP106A2 enzyme. Following the conversion of CPA, both, substrate and product, 
were found to be in the cell pellet fraction, either inside or attached to the cell membrane. The increase 
of the biocatalyst concentration during the reaction time did not improve the yield, possibly due to the 
fast substrate uptake into the cells. The recycling of the catalyst was also examined, on one hand to 
improve the biocatalyst yield and on the other hand to decrease the cost contribution of the catalyst. The 
removal of the attached product was attempted by washing the cells either with buffer or organic solvents 
(ethyl acetate and decanol). Washing with buffer showed no effect on product elimination, while the 
organic solvents damaged the catalyst resulting in no or limited further activity.  
The transport limitation across the cell membrane was probed using different membrane 
permeabilization methods (freeze-thawing, ultrasonication, acetone treatment) in combination with 
stoichiometric amounts of cofactor addition. Neither the permeabilization nor the cofactor addition had 
any influence on the conversion rates compared with the untreated control cells, which lead to the 
conclusion that the B. megaterium cells show no hindrance of transcellular transport and that the cellular 
cofactor regeneration is sufficient not to limit catalysis. 
The inhibitory effects of substrate and product were investigated under in vitro and in vivo 
conditions. The increasing substrate concentration had no effect on the initial rate. However, the reactions 
seemed to stop, following an approximate 300 µM substrate consumption, consistent with the results of 
the product inhibition studies, indicating hindered catalytic activity above a product concentration of    
200 µM. The stability of the biocatalyst, an important factor in assessing the economic feasibility of the 
bioprocess, was examined under process conditions as well as throughout the storage of the cells. 
Monitoring the cell dry weight and the P450 concentration during the transformation, a significant loss 
in the correctly folded P450 concentration was observed after 4 h of conversion, while the Bacillus cells 
seemed to remain undamaged. During 7 days of storage, no substantial loss in activity was found 
compared to conversion made with freshly harvested cells. 
Concluding our preliminary studies, the main bottlenecks of the reaction were identified as: 
 limited P450 stability (under process conditions) 
 low overall solubility of the reactants 
 product inhibition 
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To identify the best mode of operation for the process, we performed the biotransformation using both, 
resting and growing cells, keeping in mind that the instability of the CYP106A2 enzyme might be a 
limiting factor in the process. Interestingly, our results showed no significant difference between growing 
and resting cells in terms of conversion rate, whole-cell or P450 stability. The latter lead to the conclusion, 
that the preferred operation mode, being economically favorable, time- and labor-saving, is the use of 
growing cells. 
The poor solubility of the reactants was addressed by alternative substrate feeding strategies, by 
adding the solid substrate to the system, dissolving the substrate in water-immiscible solvents 
(diisononylphtalate and hexadecane) or aqueous CD solution. The solid feeding of the substrate did not 
succeed, most likely due to the low dissolution rate of the substrate. The use of water-immiscible organic 
solvents did not improve the reaction performance either, owing to the strong hydrophobic character of 
the solvents hampering the substrate partitioning to the aqueous phase, thus limiting the catalytic reaction. 
Our ultimate approach was the application of the aqueous solution of a CD derivative, 2-HP-β-CD. 
Functionalized CD derivatives were already described in the literature to enhance steroid conversion by 
solubilizing hydrophobic substrates, increasing the cell-wall permeability, transcellular transport and 
supporting cell growth [106]. Besides resolving solubility issues, CDs were shown to have an effect on 
the potential substrate and/or product inhibition by forming a complex with the respective compound, 
thus lowering its local concentration [55, 142]. The 2-HP-β-CD derivative was selected due to its highly 
efficient steroid solubilizing capacity [143], its relatively low influence on cell growth, no denaturing 
effect on proteins, no enzyme inhibition and reasonable price [144, 145]. 
The transformation of CPA was performed first in shake flasks and subsequently in the 
bioreactor, applying CD as solubilizing agent, parallel to the organic solvent DMSO, used for the control 
reactions. The shake flask conversions using CD showed only a moderate (~10 %) improvement in the 
relative conversion compared to the DMSO control. Interestingly, applying the same strategy in the 
bioreactor resulted in an almost complete (~98 %) substrate conversion on a 400 mL scale, representing 
a 43 % improvement of the relative conversion compared to the control reaction. The undoubtable 
improvement achieved in the bioreactor also highlights the added value of the reactor configuration 
providing a controlled environment and easily scalable system. The increased mixing and aeration could 
contribute to the enhancement of the reaction rate resulting in improved mass transfer of the poorly 
soluble substrate. Based on these observations, we stress the advantage of process development in the 
final reactor configuration, in our case, using a small-scale stirred tank reactor instead of shake flasks.  
To conclude, in Chapter 2.3 we were able to present the successful process development of   
15β-hydroxycyproterone acetate production based on a systematic strategy involving the identification 
and a step by step analysis of the reaction bottlenecks. As a result, we were able to attain an almost 
complete substrate conversion resulting in a 0.43 g/L product concentration at a 400 mL scale using          
2-HP-β-CD as solubilizing agent. Although these results provide a stable basis for a possible industrial-
scale application of CYP106A2, to achieve the recommended target values for an economically feasible 
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industrial production (final product concentration of 20 g/L and space-time yield of 2 g/L/h) there is still 
room for further optimization [40]. Future challenges could include the investigation of further, 
chemically modified CD derivatives such as methyl-CD, permethyl-β-CD or other hydroxypropyl-CDs 
which could increase the concentration of steroids in aqueous medium to 20 g/L or higher [146, 147]. 
Optimizing the transformation using the best possible CD candidate would allow us to reach higher 
substrate concentrations, resulting in enhanced reaction yields and ultimately to get closer to the above 
stated economic targets. 
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4. List of abbreviations 
11-OH-AD 11β-hydroxyandrostenedione 
15-OH-CPA 15β-hydroxycyproterone acetate 
2-HP-β-CD 2-hydroxypropyl-β-cyclodextrin 
B. megaterium Bacillus megaterium 
CD Cyclodextrin 
CPA Cyproterone acetate 
Cpd 0 Compound 0 
Cpd I Compound I 
CPR Cytochrome P450 reductase 
CTS Charcoal treated/stripped serum 
DHT Dihydrotestosterone 
DMSO Dimethyl sulfoxide 
DOC 11-deoxycorticosterone 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
FAD Flavin adenine dinucleotide 
FBS Fetal bovine serum 
FMN Flavin mononucleotide 
HPLC High performance Liquid chromatography 
KD Dissociation constant 
KSIE Kinetic solvent isotope effect 
NAD(P)H Nicotinamide adenine dinucleotide (phosphate) 
NMR Nuclear magnetic resonance 
P450 Cytochrome P450 
RSS 11-deoxycortisol/Reichstein’s substance S 
S. cerevisiae Saccharomyces cerevisiae 
SRS Substrate recognition site 
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5. Appendix 
5.1. Investigating the applicability of a fluorescence assay for the analysis of cortisol-cortisone 
turnover by CYP106A1 
To provide a suitable analysis for the cortisol-cortisone turnover and a rapid preliminary 
screening method of the forthcoming CYP106A1 mutants with altered 11-oxidase activity, a fluorimetric 
assay developed by Appel et al. (2005) [136] has been implemented. The assay is based on the formation 
of a fluorescent charged resonance complex when cortisol is incubated with the mixture of sulfuric acid 
and acetic acid. The strong fluorescence of cortisol was attributed to the carbonium ion formation at C11 
and the C3 keto group protonation upon sulfuric acid addition. In the case of 11-deoxycortisol, only a 
minor fluorescence was detected, resulting from the C3 keto group protonation, since the structure lacks 
a functional group at C11. 
Based on these results, our intention was to find out, whether any difference could be detected in 
the fluorescence behavior of cortisol and cortisone, which could form the basis of the 11-oxidation 
analysis. The steroids were incubated in isobutyl methyl ketone in a black, acid-resistant 96-well 
microplate with an acid mixture (90:10 sulfuric / acetic acid) for fluorescence development. The 
excitation (300-520 nm) and emission spectra (510-700 nm) of the steroids were measured with constant 
emission (λem 530 nm) and excitation wavelengths (λex 490 nm), respectively, to detect the different 
fluorescent behavior of cortisol and its CYP106A1-dependent product, cortisone.  
Cortisone showed a significantly lower relative fluorescence intensity (R.F.U.) than cortisol 
(Figure A1). Such behavior can be explained by the presence of the 11-oxo-function of cortisone, which 
alters the intensity and characteristics of the resulting fluorescence spectra.  
 
Figure A1 - Excitation (A) and emission (B) spectra of the fluorescent cortisol (blue) and cortisone 
(green) complexes formed in the acidic medium in comparison to the steroid-free control (red). The 
spectra were recorded with a constant emission wavelength of 530 nm and an excitation wavelength of 
490 nm, respectively. 
The differences between the substrate and product allow the detection of the changes in 
conversion efficiency. This makes this assay suitable for the screening of mutants with improved             
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11-oxidation activity reflected by their decreasing fluorescence. Although the assay does not diminish 
the potential selection of false positive mutants, it still serves as a fast and reliable first filter for the 
evaluation of mutants followed by a more precise HPLC analysis. 
5.2. XTT-based cell proliferation assay using the LNCaP cell line, cyproterone acetate and its 
product 
To get an insight into the possibly altered effect of the 15β-OH-CPA on tumor cells, the cell 
growth and drug sensitivity of the human prostate carcinoma cell line, LNCaP, were probed using an 
XTT cell proliferation assay kit (Sigma-Aldrich, Germany). The LNCaP cells have been isolated from a 
metastatic lesion of human prostate cancer and have been applied for long as an experimental model to 
assess new hormonal therapies [148]. The cell line has been considered to be androgen-dependent and 
shown to be inhibited by antiandrogens in vitro [149].  
The effect of CPA, 15β-OH-CPA and dihydrotestosterone (DHT), an androgen hormone with 
high androgen receptor affinity found in the prostate, was tested on the LNCaP cells. The cell proliferation 
was investigated in 96-well tissue culture plates. Half of the cells were cultivated in RPMI 1640 medium 
containing 5 % fetal bovine serum (FBS), while the other half was fed with the same medium 
supplemented with 5 % charcoal-treated serum (CTS), depleted of steroid hormones. 48 h after seeding 
and attachment of the cells, the medium was replaced containing increasing concentrations (0.01 nM to 
10 µM) of the corresponding steroid dissolved in DMSO. The untreated control was supplemented only 
with DMSO. The cells were incubated for 7 days prior to the XTT assay. 
The DHT treatment correlated with the earlier results from Horoszewicz et al. [148], which have 
shown that DHT stimulates cell proliferation in CTS-containing media but shows a dose-dependent 
suppression of cell proliferation in media with FBS. Surprisingly, CPA and 15β-OH-CPA had no 
significant effect on the cell proliferation in either of the used media compared to the control. However, 
since the absorbance readings of the assay were too low in all the cases, a clear conclusion about the 
differences was not possible. Despite increasing the cell numbers per well and prolonging incubation 
time with the XTT reagent, no improvement was achieved. Therefore, further studies are necessary to 
evaluate possible differences in the action of CPA and its product, 15β-OH-CPA, which was proposed to 
have great potential as an alternative antiandrogen drug. 
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